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Obesity has developed into a worldwide pandemic, affecting individuals 
regardless of their socio-economic status, gender or age. It is associated with 
development of multiple co-morbidities including type 2 diabetes mellitus, which 
have been shown to be underpinned by inflammation. Indeed, excessive 
adiposity has been shown to be associated with a large dysregulation of immune 
cell function, including altered phenotype of mucosal-associated invariant T 
(MAIT) cells. MAIT cells from people with obesity were shown to have enhanced 
IL-17 production, accompanied by impaired IFNγ expression. As of now, very little 
is known about the control of MAIT cell function, therefore more research is 
required to understand their biology in order to identify the altered process, which 
leads to their dysfunction in obesity. Immunometabolism of MAIT cells became 
the focus of this thesis as previous data indicated it as a key biological process 
that controls immune cell function. Here we confirmed previously published data, 
showing that MAIT cells are potent producers of IFNγ and IL-17 cytokines and 
that MAIT cells can proliferate and expand upon stimulation. In addition, we 
reported that MAIT cells enhance glycolysis upon activation, which in turn is 
controlled by the influx of amino acids into the cells via LAT1 amino acid 
transporters. Glycolytic metabolism was required for successful IFNγ production 
as well as proliferation and expansion of MAIT cells. People with obesity have 
impaired IFNγ expression and MAIT cell expansion that was accompanied by 
impaired glycolytic metabolism. Collectively our data indicates that MAIT cells 
effector functions are in part controlled by the intrinsic metabolic pathways 
including the glycolytic metabolism. Defect in glycolysis or glycolysis-associated 















1.1.1. Obesity Overview  
Obesity is a chronic progressive disease, which has evolved into a global 
pandemic (Bray et al., 2017; WHO, 2020a). Between 1975 to 2016 the number 
of individuals living with obesity has almost tripled. As of 2016 it is estimated that 
650 million adults are living with obesity worldwide (WHO, 2020a). Initially, 
obesity affected only high-income countries, but it has quickly spread to the 
middle-income and low-income countries with the number of cases of obesity 
having increased in the vast majority of countries worldwide between 1975 and 
2014 (Collaboration(NCD-RisC), 2016). 
 
Obesity is described as an excessive accumulation of adipose tissue (AT) which 
is disproportionate to the height of an individual (CDC, 2020). Diagnosis of the 
disease in adults is most commonly based on the calculation of Body Mass Index 
(BMI), due to the lack of more precise and freely available diagnostic tools 
(Rothman, 2008; Shah and Braverman, 2012; WHO, 2020a). BMI is calculated 
by dividing the weight of the individual in kilograms by their height in meters 
squared. This equation allows for a crude estimation of an individual’s nutritional 
status, proportion of AT and classification into one of the following categories as 
set out by World Health Organisation (WHO): underweight BMI of <18.5 kg/m2, 
normal weight as 18.5-24.9 kg/m2, pre-obesity/overweight as 25-29.9 kg/m2 and 
obesity as a BMI >30 kg/m2 (WHO, 2020a). This equation is inherently flawed, as 
it doesn’t take into consideration other factors, which would aid the assessment 
of the severity of obesity and its impact on the individual’s health, such as 
localisation of the AT deposits, muscle density or sex (Bray et al., 2018; Rothman, 
2008). BMI measurement can be supported by the measurement of the waist 
circumference, which correlates with the amount of visceral AT and increased 
risk of development of cardiovascular disease (CVD) risk, type 2 diabetes mellitus 
(T2DM) and overall mortality (Cerhan et al., 2014; Jeon et al., 2019; Mamtani et 
al., 2013; Nazare et al., 2015; Siren et al., 2012). Initially, the primary cause of 
obesity was identified as an energy imbalance, where calorie intake exceeded 
the calorie expenditure (WHO, 2020a). Since then, multiple studies have 
highlighted the complexity and heterogenicity of this disease, depicting how 
multiple factors affect disease development (González-Muniesa et al., 2017; 
Swinburn et al., 2011). Susceptibility of an individual to weight gain is largely 
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influenced by their environment, behaviour, socio-economic status and biological 
factors. Calorie intake is greatly affected by food availability and accessibility, as 
well as the marketing strategies employed by the food companies, which promote 
snacking and consumption of highly processed, calorie dense foods (González-
Muniesa et al., 2017; Swinburn et al., 2011). On the other hand, calorie 
expenditure has been reduced as a result of improvement of the public transport 
systems and sedentary lifestyle, resulting in a much-decreased amount of time 
which is dedicated to physical activity (González-Muniesa et al., 2017; Swinburn 
et al., 2011). Weight gain is also affected by biological factors such as sleep 
deprivation, location of AT or genes (Goodarzi, 2018; Swinburn et al., 2011; 
Vishvanath and Gupta, 2019). In recent years, mutations in fat mass and obesity 
associated (FTO) gene and genes coding for proteins involved in the leptin-
melanocortin pathway such as leptin, leptin receptor and melanocortin 4 receptor, 
have been identified in people with obesity (Pigeyre et al., 2016). The contribution 
of the genetic variation to the development of obesity yet remains to be fully 
elucidated.  
 
The rate of obesity in Ireland is growing at an alarming rate. Pineda et al. have 
estimated that without appropriate interventions, by 2025 Ireland will become the 
country with the highest rate of obesity in Europe (Pineda et al., 2018). This is in 
line with an earlier study by Keaver et al., which estimated that by 2030 as many 
as 89% of Irish men and 85% of Irish women will be living with overweight or 
obesity (Keaver et al., 2013). Healthy Ireland Survey revealed that 37% of Irish 
adults are overweight and a further 23% are living with obesity (Department of 
Health and MRBI IPSOS, 2015). It also revealed bad behavioural habits in regard 
to calorie intake by adults. Out of those surveyed, 65% reported to consume 
snack food or sugar drinks daily, whereas little under half of the participants met 
the minimum level of recommended physical activity of 150 minutes per week 
(Department of Health and MRBI IPSOS, 2015). Although obesity has significant 
implications on a person's health, the economic consequences cannot be 
overlooked. It has been estimated that the direct and indirect costs of obesity in 
Ireland in 2009 accounted for €1.13 billion (Perry et al., 2012). Keaver et al. 
projected that by 2030 this bill will be greatly exceeded, as the direct healthcare 
cost of obesity alone in Ireland will reach staggering €5.4 billion (Keaver et al., 
2013). Although obesity was initially considered an adult disease, a substantial 
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increase of cases in the paediatric population has been observed worldwide 
(WHO, 2020a). As reported by the Childhood Obesity Surveillance Initiative, at 
least 1 in 5 Irish primary school children were living with overweight or obesity 
(Bel-Serrat et al., 2017). The Children’s Sport participation and Physical Activity 
study showed only 17% of primary and 10% of post-primary school children met 
the national guidelines for physical activity (Woods et al., 2018). If paired with bad 
eating habits, this may contribute to the increasing rates of obesity in children. It 
is now well established that childhood obesity strongly tracks into adulthood 
(Evensen et al., 2016; Gordon-Larsen et al., 2004; Wang et al., 2008; Ward et 
al., 2017). Study by Simmonds et al. estimated that 55% of children with obesity 
will become obese adolescents, and 80% of obese adolescents will become 
obese adults, highlighting the need for early interventions (Simmonds et al., 
2016). As obesity is affecting children at a very young age, obesity-associated 
co-morbidities such as T2DM, begin to manifest much earlier than previously 
observed, often still in childhood or adolescence (Mayer-Davis et al., 2017). 
Unfortunately, treatment options of obesity are still limited and include lifestyle 
interventions, pharmacological treatments and bariatric surgery (Bray et al., 
2018). None of these methods are fully successful, as studies have shown that 
following each of these treatment regimes, weight can be regained (Felsenreich 
et al., 2016; Franz et al., 2007). Undisputedly, prevention of obesity starting in 
early childhood years and development of safe and non-invasive treatments are 
desperately needed.  
 
1.1.2. Obesity associated co-morbidities 
Obesity is associated with an extensive list of co-morbidities, ranging from T2DM, 
CVD, development of multiple types of cancers and mental health problems 
(Figure 1.1) (Avgerinos et al., 2019; Daousi et al., 2006; Mannan et al., 2016; 









Figure 1.1. Obesity associated co-morbidities. Obesity contributes to 
development of multiple diseases such as T2DM, CVD and multiple types of 
cancers (Doheny, 2015).  
 
Individuals who are living with overweight or obesity are at a major risk of 
developing T2DM, in fact up to 90% of cases are weight related (Daousi et al., 
2006; Iglay et al., 2016; Public Health England, 2014). T2DM is characterised by 
a defect in insulin secretion and/or impaired insulin sensitivity of tissues, which 
ultimately leads to chronic hyperglycaemia (DeFronzo et al., 2015). Although 
pathogenesis of T2DM in obesity is still not fully elucidated, it is known to be 
underpinned by low-grade inflammation. White adipose tissue (WAT) has been 
identified as the main source of pro-inflammatory mediators in obesity. It was 
shown to release high amounts of molecules such as tumour necrosis factor 
(TNF)-a, interleukin (IL)-1b, IL-6, leptin and monocyte chemoattractant protein-1 
(MCP-1). This leads to the recruitment of inflammatory immune cells, which 
contribute to the establishment of the pro-inflammatory environment and insulin 
resistance in the AT (Longo et al., 2019; Mantzoros et al., 2011; Zatterale et al., 
2020; Zorena et al., 2020).  
 
TNF-a is one of the best studied cytokines in the establishment of T2DM and was 
shown to be implicated in the onset of insulin resistance by inducing a defect in 
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insulin signalling (Aguirre et al., 2000; Hotamisligil et al., 1995, 1993). Despite the 
promising data, clinical trials which focused on the neutralisation of TNF-a in 
individuals with T2DM, no improvement in insulin sensitivity after treatment was 
reported (Bernstein et al., 2006; Dominguez et al., 2005; Ofei et al., 1996). 
Although other inflammatory cytokines have been also implicated in the 
development of T2DM and insulin resistance (McArdle et al., 2013), the role of 
immune cells and immune derived factors in this disease is yet to be fully 
understood. 
 
Obesity is also a significant risk factor associated with the development of CVD 
(Khan et al., 2018). Excessive weight was shown to alter not only the function of 
the cardiovascular system, but also the structure of the heart. Individuals with 
obesity displayed a larger left ventricular mass and worse systolic function, both 
of which are likely to contribute to the development of hypertension (Bello et al., 
2016; Kotchen, 2010; Wu et al., 2019). Failure to regulate blood pressure leads 
to further complications, such as coronary heart disease, heart failure, stroke and 
renal disease (Landsberg et al., 2013). Dyslipidaemia, often diagnosed alongside 
obesity, is strongly linked to atherosclerosis (Duncan et al., 2019; Klop et al., 
2013). Excessive exposure to high levels of low-density lipoprotein cholesterol is 
the main risk factor associated with development of atherosclerosis in humans, 
as it has been shown to initiate atherogenesis. Over time the plaques deposited 
on the arterial wall, increase in size, accumulating more lipids. This eventually 
leads to a substantial restriction of the blood flow and increases a risk of plaque 
rupture, which can cause acute thrombosis and myocardial infarction. 
Development of atherosclerosis is accompanied by an inflammatory response in 
immune cells (Libby et al., 2019). This highlights the common denominator 
between the pathogenesis of CVD and T2DM in the context of obesity – altered 
immune response and pro-inflammatory environment.  
 
It is acknowledged that obesity is positively correlated with the development of 
certain cancers such as colorectal, ovarian, gallbladder, kidney, post-
menopausal breast and liver (Bhaskaran et al., 2014; Lauby-Secretan et al., 
2016). Recently, it was reported that excessive body weight is attributed to 3.9% 
of all cancers worldwide (Sung et al., 2018). The contribution of excess adiposity 
to cancer development is complex, as multiple types of cancer and multiple 
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factors are involved (Bhaskaran et al., 2014; Sung et al., 2018). Chronic 
inflammation, which persists in obesity, favours tumour development, through the 
disruption of tissue homeostasis and dysregulation of immune cell function (Y. S. 
Lee et al., 2018; Quail and Dannenberg, 2019). Although inappropriate activation 
of the immune system is closely related to obesity, excessive adiposity is also 
associated with a loss of immune cell function. People with obesity have a defect 
in natural killer cell mediated killing of the tumour cells in vitro (Michelet et al., 
2018; Tobin et al., 2017). In addition, chronic stimulation of T cells in obese AT 
induces expression of exhaustion markers such as programmed cell death 
protein-1 (PD-1) and leads to dampened anti-tumour responses. However, using 
PD-1 checkpoint inhibitors, anti-tumour activity in subjects with obesity can be 
restored (Canter et al., 2018; Z. Wang et al., 2019). Once again, this illustrates 
how the immune system dysregulation caused by obesity underpins the 
development of another co-morbidity.  
 
Although obesity has a detrimental effect on the body, the impact of obesity on 
mental health is often overlooked. It has been reported that more than half of 
adults with obesity admitted to experience stigmatisation by their co-workers, 
whereas children with obesity have over 60% higher chance of being bullied 
(WHO, 2017). Mistreatment of individuals due to their weight can lead to the 
development of mental health diseases. A study by van Vuuren et al. found that 
adolescents who are overweight displayed more suicidal thought tendencies than 
their lean counterparts (Van Vuuren et al., 2019). A meta-analysis which looked 
at the relationship between weight stigma and mental health, reported a medium 
or large correlation between weight-related stigma and symptoms of depression, 
anxiety and psychological distress (Emmer et al., 2020; Luppino et al., 2010). 
Discrimination and prejudice of the individuals with excessive weight is 
undisputable, although in 2016 almost 4 in 10 adults were living with overweight 
and 1 in 8 were living with obesity, indicating a high prevalence of this condition 
in society (WHO, 2020a). Hence, appropriate actions must be taken to end the 






1.2 Immune system in health and obesity  
1.2.1 Immune system and inflammation 
The aim of the immune system is to provide the host with protection from invading 
microorganisms and injury. Upon pathogen entry or tissue damage, an 
inflammatory response is initiated, led by the innate immune system which 
include cells like monocytes, neutrophils and dendritic cells (Figure 1.2) (Delves 
et al., 2011). This results in the production of pro-inflammatory cytokines and 
chemokines and recruitment of other leukocytes in order to contain the infection 
(Coico and Sunshine, 2015; Delves et al., 2011). The innate immune response is 
supported by the more specialised adaptive arm of the immune system, which 
assists in the eradication of the infection and aims to provide long-term protection 
from the pathogen via memory (Figure 1.2) (Coico and Sunshine, 2015; Delves 
et al., 2011). The adaptive immune system is composed of T lymphocytes, which 
are classified as cytotoxic CD8+ cells and cytokine producing helper CD4+ cells, 
and B lymphocytes, which support the immune response by producing antigen 
specific antibodies.  
Figure 1.2 Response of the immune system to infection with pathogen. 
Upon infection, the innate immune system is activated upon recognition of 
pathogen associated molecular patterns and damage associated molecular 
patterns by antigen presenting cells (APC). This is followed by the engagement 
of the adaptive immune system in order to successfully restore homeostasis and 
provide long-term protection to the host thorough formation of immunological 
memory(Khader et al., 2019) . 
 
Activation of the adaptive arm of the immune system leads to clonal expansion 
of the cell population and the formation of effector cells, providing a more specific 
memory response upon re-challenge with the pathogen and therefore a better 
protection to the host (Coico and Sunshine, 2015; Delves et al., 2011).  
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As research in the area of immunology is quickly advancing, it becomes clear that 
the initial classification of cells into the innate and adaptive immune system 
requires reconsideration. In recent years more subtypes of immune cells have 
been discovered and termed as unconventional T cells, which include cells such 
as mucosal associated invariant T (MAIT) cells, gd cells and invariant natural killer 
T (iNKT) cells (Figure 1.3) (Godfrey et al., 2015). These T cells have been 
classified as “unconventional” as they are not restricted by major 
histocompatibility complex (MHC) molecules like classical T cells. However, they 
still in part rely on the antigen presentation and recognition by their T cell receptor 
(TCR), but in addition these cells can be activated through cytokine stimuli alone 
(Godfrey et al., 2015). Furthermore, they don’t recognise protein antigens. MAIT 
cells recognise vitamin B metabolites in the context of MHC class I related protein 
1 (MR1) complex, gd cells recognise lipid antigens and phosphoantigens 
presented by CD1c & CD1d molecules, whereas iNKT cells respond to lipid 
antigens in the context of CD1d (Godfrey et al., 2015). This provides the immune 
system with another rapid response to pathogens, bridging the innate and 
adaptive systems. 
Figure 1.3 Cells of the immune system. Immune cells can be divided into innate 
and adaptive immune systems, however some cells such as MAIT cells, don’t fit 
into either of these categories possess feature of both systems. (Adapted from 
Bonam et al., 2017).  
 
Inflammation is deemed to be beneficial to the host in many circumstances. Acute 
inflammation is a short-lived response, which is followed by resolution to achieve 
tissue homeostasis (Coico and Sunshine, 2015). Acute inflammation can become 
chronic if the agent, which stimulates the immune response cannot be removed 
(Chen et al., 2018). Sustained low-grade inflammation underpins the 
Innate immune system Adaptive immune system
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development of multiple inflammatory diseases such as T2DM, rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE) (Guo et al., 2018; Moulton 
et al., 2017; Wu and Ballantyne, 2020). However, the cause of many of these 
diseases remains to be elucidated. Identifying the primary triggers of an 
inappropriate immune response would aid the development of successful 
treatments. Currently, our understanding of inflammatory diseases is insufficient, 
and we are limited to the treatment of symptoms. Current therapies aim to 
dampen down the immune response by using immunomodulatory drugs such as 
anti-TNF-a and anti-IL-17A, however they don’t eradicate the triggers of such 
diseases (Bissonnette et al., 2018; Kimball et al., 2016; Thaçi et al., 2015; Wang 
et al., 2016). Advancing research to understand the pathophysiology of the 
immune response during inflammation and identifying the antigens, which 
stimulate the cells, will aid in developing successful treatments.  
 
1.2.2 Adipose tissue associated inflammation and immune cell 
dysregulation in obesity 
Obesity is associated with a systemic, low-grade chronic inflammation 
(Hotamisligil, 2017; Y. S. Lee et al., 2018). It has been well established that this 
inappropriate activation of the immune system strongly contributes to the 
development of insulin resistance and T2DM (Zatterale et al., 2020). The origin 
and cause of this inflammation is still to be fully elucidated and researchers are 
currently investigating multiple sites including liver, pancreas, muscles. However, 
studies have strongly focused on the AT as the primary site of inflammation (Y. 
S. Lee et al., 2018).  
 
For decades, AT has been considered merely as an energy storing tissue. As 
research progressed, it has been demonstrated that AT is capable of producing 
and releasing a variety of factors such as adipokines and hormones and is 
enriched in immune cells, which ultimately lead to the re-classification of AT as 
an endocrine organ (Ouchi et al., 2011; Rodríguez et al., 2015). Nonetheless, AT 
plays a very important role in energy homeostasis in a lean individual. It provides 
long-term storage of excess nutrients, which are released during demand for 
energy (Ouchi et al., 2011). From the point of view of evolution, this is a very good 
process of saving nutrients for periods of starvation, where they can be easily 
accessed and used for survival. Today in the westernised world, this process is 
11 
not as crucial, due to the wide availability of food, which often requires very little 
effort to obtain. Instead, this very process is now leading to over-storing of energy, 
contributing to the development of diseases. AT adapts to the excess of nutrients 
by undergoing structural remodelling and expansion. Hypertrophy and 
hyperplasia of the adipocytes occurs. This leads to increased oxygen demand 
and therefore the induction of angiogenesis which was shown to be supported by 
the resident adipose tissue macrophages (ATM) (Figure 1.4) (Cho et al., 2007; 
Sun et al., 2011; White and Ravussin, 2019). Expansion of the AT is associated 
with an increase in immune cell infiltration, release of pro-inflammatory factors 
from the adipocytes and leukocytes leading to inflammation (Figure 1.4). Chronic 
over-nutrition causes those changes to be sustained for a long-time causing 
hypoxia, fibrosis and sustained inflammation, leading to AT dysfunction (Zatterale 
et al., 2020). 
Figure 1.4. Changes in adipose tissue in obesity. Obesity leads to hypertrophy 
and hyperplasia of adipocytes and recruitment of immune cells, resulting in 
chronic inflammation (Wu and Ballantyne, 2020).  
 
In obesity, adipocytes alter their secretory profile and produce higher levels of 
leptin but downregulate the production of adiponectin (Considine et al., 1996; 
Hanley et al., 2007; Ryan et al., 2003). In addition to the role of these hormones 
in maintaining energy homeostasis in humans, both impact the function of 
immune cells. Leptin was shown to have pro-inflammatory properties. It can 
stimulate macrophages to produce pro-inflammatory cytokines such as IL-6 and 
TNF-α (Acedo et al., 2013), promote chemotaxis of neutrophils (Montecucco et 
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al., 2006), and enhance the differentiation of T cells into Th1 and Th17 subsets 
(Gerriets et al., 2016; Reis et al., 2015; Rodríguez et al., 2007). On the other 
hand, adiponectin can upregulate the secretion of IL-10 from macrophages, 
suppress M1 type in favour of M2 polarisation and decrease production of 
interferon γ (IFNγ) and IL-17A by CD4+ T cells (Ohashi et al., 2010; Surendar et 
al., 2019; Wolf et al., 2004). Taking into consideration the opposing effects of 
leptin and adiponectin, it can be hypothesised that the imbalance of these 
hormones observed in obesity, contributes to the inflammatory state. In addition, 
production of AT tissue derived TNF-a was found to be increased in obesity (Cao 
et al., 2008; Hotamisligil et al., 1993). As TNF-a was shown to have a negative 
impact on insulin sensitivity, this further suggests that changes in the AT and the 
pro-inflammatory environment induced by obesity is contributing to development 
of T2DM (Aguirre et al., 2000; Hotamisligil et al., 1995, 1993).  
 
Alterations in the function of AT is not the only change observed in obesity. 
Infiltration of immune cells plays one of the key roles in initiating and maintaining 
low-grade inflammation. Both arms of the immune system are implicated, 
however macrophages have received a lot of attention as they are enriched in 
the AT of people and mice with obesity (Harman-Boehm et al., 2007; Weisberg 
et al., 2003). In mice, macrophages were shown to make up 40-50% of immune 
cells in obese AT vs 5-10% observed in the AT of lean mice (Weisberg et al., 
2003). Macrophages can be broadly classified as pro-inflammatory M1 or anti-
inflammatory M2. In obesity, AT is largely enriched in the M1 subtype of 
macrophages which produce pro-inflammatory cytokines such as IL-6, TNF-a, IL-
1b (Figure 1.4) (Lumeng et al., 2007). Their recruitment is likely driven by 
secretion of chemokines by AT such as of MCP-1, and death of adipocytes, which 
must be removed to maintain tissue homeostasis and resolve inflammation. 
(Guilherme et al., 2008; Vishvanath and Gupta, 2019). The association between 
inflammatory macrophages and insulin resistance in obesity is well established 
(Catrysse and van Loo, 2018). They are primary producers of TNF-α, and it has 
been shown that the depletion of these cells normalizes insulin sensitivity 
(Patsouris et al., 2008). As more evidence is mounting, it is now becoming clearer 
that macrophages in the AT cannot be strictly identified as M1 or M2 (Kratz et al., 
2014), but rather their phenotype is more flexible and lies on a spectrum, which 
changes our approach in investigating the role of macrophages in the AT. The 
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adaptive arm of the immune system is also implicated in creating this pro-
inflammatory environment. CD3 expressing lymphocytes are the second most 
abundant cells in obese AT after the macrophages. Of those lymphocytes, an 
increase in both CD8 and CD4 expressing T cells is observed (Y. S. Lee et al., 
2018). Although the sequence in which the cells arrive in the AT is still to be 
elucidated, some evidence suggests that the accumulation of CD8+ T cells 
precedes the increase in ATM (Nishimura et al., 2009). T cells contribute to the 
AT inflammation by releasing Th1 and Th17 type cytokines such as IFNγ and IL-
17, which can induce recruitment of M1 macrophages to the tissue (Fabbrini et 
al., 2013; Winer et al., 2009). These changes were found to be accompanied by 
a decrease in T reg cells, which are known for their anti-inflammatory functions, 
suggesting further loss of control over inflammation (Winer et al., 2009). Other 
immune cells have been also identified to be altered in obese AT. MAIT cells 
were shown to accumulate in human AT in obesity and display a type 17 
phenotype characterised by predominant production of IL-17 cytokines rather 
type 1 phenotype which in turn is identified by IFNγ production. This suggests 
that MAIT cells are involved in maintaining the inflammatory environment in AT 
(Carolan et al., 2015; Magalhaes et al., 2015). Similarly, IL-17 producing gd T 
cells were also found to be enriched in AT of obese mice and were shown to 
regulate T reg populations in this tissue (Kohlgruber et al., 2018). On the other 
hand, populations of innate lymphoid cells 2 (ILC2) and iNKT cells in obese AT 
is diminished (Brestoff et al., 2015; Lynch et al., 2012). As ILC2 and iNKT cells 
support M2 profile of macrophages and contribute to the anti-inflammatory profile 
of AT, it suggests that a reduction in their frequencies may favour pro-
inflammatory environment in obese AT (Lynch et al., 2015; Molofsky et al., 2013).  
 
The primary trigger of inflammation in obese AT is yet to be discovered, however 
some hypotheses have been put forward. Increased circulation of free fatty acids 
(FFA) in obesity is likely caused by the eruption of the adipocytes during AT 
expansion (Arner and Rydén, 2015; Ni et al., 2015). FFA have been shown to 
initiate the pro-inflammatory immune response by binding to toll like receptor 4 
on adipocytes and macrophages and activate nuclear factor-kappa light chain 
enhanced of activated B cells (NFκB) and c-Jun N-terminal kinase (JNK) 
signalling (Shi et al., 2006). In addition, FFA were shown to contribute to hypoxia, 
by uncoupling of mitochondrial oxidative metabolism in adipocytes. This leads to 
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deprivation of oxygen in the cell, enhancement in hypoxia inducible factor-1a 
(HIF-1a) expression and activation of the pro-inflammatory pathways within the 
adipocyte (Lee et al., 2014). Increased gut permeability has been also reported 
in obesity, which has been suggested to be one of the multiple triggers of 
systemic chronic inflammation in this disease (Toubal et al., 2020). In fact, an 
increase in lipopolysaccharide circulation in individuals with obesity has been 
reported and correlated with development of T2DM (De La Serre et al., 2010; 
Trøseid et al., 2013). The onset of obesity is multifactorial therefore, the trigger 
of its associated inflammation is hypothesised to be affected by multiple events. 
Identification of the triggers of the disease as well as the sequence of immune 
cell infiltration into the AT and factors involved in initiation of the immune 
response will aid in further examination of the causes of development of diabetes 
and other inflammation associated diseases in obesity, hopefully leading to a 
successful treatment.  
 
1.3 Mucosal Associated Invariant T cells 
1.3.1 Mucosal Associated Invariant T cells overview  
MAIT cells are a type of unconventional adaptive T cells, which display innate 
properties and they don’t strictly belong to the innate or adaptive category. Initially 
they have been identified to be enriched at mucosal tissues, hence their name, 
however it is now well established they are abundant at multiple sites including 
liver, AT and lungs (Dusseaux et al., 2011; Lezmi et al., 2019; Tobin et al., 2017). 
They can be also readily identified in the peripheral blood, where they 
compromise 1-10% of T cells (Le Bourhis et al., 2010).  
 
MAIT cells are defined by the semi-invariant, highly conserved, ab TCR, which is 
accompanied by high expression of CD161 molecules. MAIT cell TCR is 
composed of TRAV1-2 (Va7.2) and TRAJ33/12/20 (Ja33/12/20) alpha chains 
paired with a limited number of beta chains (Lepore et al., 2014; Porcelli et al., 
1993; Tilloy et al., 1999). In contrast to classical T cells, MAIT cells were shown 
to be restricted by MR1, rather than MHC-I or MHC-II antigen presenting 
complexes (Treiner et al., 2003). The antigen presented by MR1 to MAIT cells 
has been unidentified for many years. The first clue of the potential origin of the 
antigens was uncovered by Gold et al. and Le Bourhis et al. who showed that 
MAIT cells respond to a wide array of gram- positive and gram-negative bacteria 
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as well as some strains of yeast (Gold et al., 2010; Le Bourhis et al., 2010). It 
wasn’t until 2012, when the landmark study Kjer-Nielsen et al. identified the 
antigen of MAIT cells as metabolites of vitamin B2 and B9, which are produced by 
multiple strains of microorganisms, utilising the riboflavin synthesis pathway 
(Kjer-Nielsen et al., 2012). This antigen is very unique to microorganisms, as 
humans don’t synthesise vitamin B, providing the host with an advantage in 
detecting these pathogens. The most potent antigen which activates MAIT cells 
is synthesised from a 5-amino-6-D-ribityaminouracil (5-ARU), an intermediate 
produced during riboflavin synthesis and methylglyoxal (MG), a metabolite 
produced during glycolysis, which together form 5-(2-oxopropulideneamino)-6-D-
ribitylaminouracil (5-OP-RU) (Corbett et al., 2014).  
 
MAIT cells development begins in the thymus, where they undergo thymic 
selection. In contrast to T cells, which are selected by binding to thymic epithelial 
cells, MAIT cells bind to double positive (CD4+/CD8+) cortical thymocytes, which 
express MR1 molecule (Seach et al., 2013). The process of thymic selection of 
MAIT cells still remains largely unexplored. It is yet to be established whether 
MR1 is loaded with any antigen, and if so whether it is low or high affinity and 
where it originates from. Future studies should also investigate whether thymic 
negative selection applies to MAIT cells and how and if overreactive MAIT cells 
are removed. Following the successful positive selection, MAIT cells undergo a 
three-step maturation process which begins in the thymus. A study by Koay et al. 
has significantly contributed to our current understanding of MAIT cell maturation 
in human and mice. They classified the different stages of development based 
on surface markers. Stage 1 of MAIT cell were defined as CD27- CD161-, stage 
2 as CD27+ CD161- and stage 3 by CD27lo/-, CD161+ and co-expression of IL-
18R (Koay et al., 2016).  
The mouse study showed that progression through the three stages is depended 
on the MR1 expression, as addition of anti-MR1 antibody successfully inhibited 
this process. The progress from stage 2 to stage 3 was described to be of 
particular importance in functional development of MAIT cells. Promyelocytic 
leukaemia zinc finger (PLZF), a transcription factor shared by the cells of the 
innate immune system, was found to be absolutely necessary for MAIT cell 
maturation from stage 2 to stage 3 and development of their functional 
competence. PLZF-null mice completely lacked stage 3 MAIT cell population and 
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residual stage 1 and stage 2 cells failed to produce cytokine upon stimulation in 
contrast to stage 3 MAIT cells from wild type (WT) mouse (Koay et al., 2016). 
Expression of PLZF, T-box protein expressed in T cells (T-bet) and RAR-related 
orphan receptor gamma γT (RORγT) transcription factors increased upon MAIT 
cell maturation to stage 3. In human MAIT cells, T-bet and RORγT were co-
expressed in contrast to murine MAIT cell development, where these two 
transcription factors were mutually exclusive (Koay et al., 2016). To assess the 
functional capacity of stage 3 MAIT cells, Koay et al. stimulated samples obtained 
from matched blood and thymus and measured their cytokine production. More 
than 80% of stage 3 MAIT cells from peripheral blood produced IFNγ and TNF-
a, in comparisons to <25% of stage 3 MAIT cells derived from the thymus. The 
superiority of peripheral blood stage 3 MAIT cells in cytokine expression, 
indicates that MAIT cells leaving the thymus are somewhat functionally 
competent, with further maturation of the cells occur extrathymically (Koay et al., 
2016). A more recent study by Koay et al. focused on the transcriptional profile 
of MAIT cells during the three stages of development and maturation, using 
single-cell RNA sequencing in mice and humans (Koay et al., 2019). This study 
confirmed previous data that murine MAIT cells at stage three cells show a more 
mature prolife and express more Zbtb16 (PLZF), Rorc (RORγT), and IL18r (IL-
18 receptor) but less Ccr7 than stage 1 cells. In addition, upregulation of other 
genes was identified at stage 3 such as GzmB (Granzyme B), IL7R (CD127) and 
chemokine receptors Ccr6, Ccr2, Cxcr6 which bind C-C Motif Chemokine Ligand 
(CCL) 20, CCL2 and CCL16 respectively. The increase in the chemokine 
receptors was confirmed on the protein level by flow cytometry (Koay et al., 
2019). Upon closer investigation of the stage 3 MAIT cells, this study was able to 
differentiate between type 1 and type 17 MAIT cells and found a significant 
difference in the expression of genes between those two subtypes of cells.  
 
Mature MAIT cells can be identified in the peripheral blood and display a memory 
phenotype identified by the lack of the expression of CC-chemokine receptor 
(CCR)7, CD62L and CD45RA (Dusseaux et al., 2011; Gold et al., 2013). They 
are largely CD8+, with a small proportion being double negative of CD4+ 
(Gherardin et al., 2018b; Kurioka et al., 2017; Walker et al., 2012). As discussed 
in more detail in chapter four, MAIT cells can be activated via engagement of their 
TCR with MR1 bound to an antigen or via cytokine stimulation alone (Le Bourhis 
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et al., 2010; Leng et al., 2019; Van Wilgenburg et al., 2016). MAIT cells express 
a wide range of cytokine receptors including IL-2R, IL-12R, IL-15R or IL-18R, 
suggesting their activation can be induced by a various cocktails of cytokines in 
the absence of TCR antigens (Sattler et al., 2015; Wallington et al., 2018; 
Wilgenburg et al., 2018). Indeed, MAIT cells were shown to respond with 
enhanced IFNγ production when stimulated with a combination of cytokines 
namely IL-12 and IL-18 or IL12 and IL-15, whereas stimulation with single 
cytokines did not induce cytokine production or led to their very weak expression 
(Ussher et al., 2014; Van Wilgenburg et al., 2016). This shows plasticity of MAIT 
cells in responding to a potential threat, as cytokine stimulation alone, allows the 
cells to become activated in the absence of TCR antigens. This response may 
be very beneficial during viral infections or infections with bacteria which do not 
produce riboflavin; however, the non-specific MAIT cell activation may be harmful 
and contribute to the development of autoimmune and inflammatory diseases. 
Activation of MAIT cells induces rapid secretion of pro-inflammatory cytokines 
such as IFNγ, TNF-a and IL-17 and chemokines CCL3 and CCL4 which support 
recruitment of other immune cells to the site of inflammation and their activation 
(Hinks et al., 2019; Lamichhane et al., 2019). In addition, MAIT cells were shown 
to produce other effector molecules such as granzyme B and perforin, indicating 
their role in direct killing of cells infected with a pathogen (Dusseaux et al., 2011; 
Lamichhane et al., 2019; Wilgenburg et al., 2018). Indeed, MAIT cells were 
shown to kill bacterially infected cells in in vitro studies (Kurioka et al., 2015; Le 
Bourhis et al., 2010), however their role seems to extend beyond infections. MAIT 
cells exposed to MR1 expressing cancer cells lines were shown to induce killing 
of the cancer cells, indicating their role in cancer surveillance (Gherardin et al., 
2018a; Won et al., 2016).  
 
Although MAIT cells have been discovered relatively recently, their pleotropic 
functions and highly conserved TCR indicate a key role in the immune protection 
of the host. More research into MAIT cell biology and function is required to fully 
understand the role they play in bridging the innate and adaptive immune system. 
 
1.3.2 MAIT cells in infection  
MAIT cells mount an immune response to bacterial and yeast riboflavin 
biosynthesis metabolites in the context of MR1 molecules expressed by antigen 
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presenting cells. Study by Le Bourhis et al. in 2010 was one of the first to highlight 
the important contribution of MAIT cells to the immune response against microbial 
infections (Le Bourhis et al., 2010). This study showed MAIT cells respond to 
APC infected with E. coli in an MR-1 dependent manner (Le Bourhis et al., 2010). 
The response of MAIT cells to multiple bacteria strains has since been 
investigated in much more detail. Meierovics et al. reported MAIT cell activation 
and cytokine production during infection with Francisella Tularensis, which was 
dependent on MR1 and IL-12 signals (Meierovics et al., 2013). MAIT cells were 
also found to be implicated during infections with bacteria from the 
mycobacterium family. Initially, MAIT cells were shown to be reduced in the 
peripheral blood of patients with active infection with Mycobacterium tuberculosis 
and exhibited defective IFNγ production in comparison to the healthy controls 
(Jiang et al., 2016; Kwon et al., 2015). In contrast, Suliman et al. and Paquin-
Proulx et al. reported no significant difference in the frequencies of MAIT cells or 
their IFNγ production between individuals with active infection versus healthy 
controls (Paquin-Proulx et al., 2018; Suliman et al., 2020). This indicates that the 
role of MAIT cells in tuberculosis infection may differ between the stages of 
infection, and more research is required to clearly establish their involvement in 
the response against this pathogen. Additionally, MAIT cells are capable of 
responding to multiple other bacteria via TCR-MR1 engagement such as 
Klebsiella pneumoniae and Staphylococcus aureus as well as yeast strains 
including Candida albicans (Le Bourhis et al., 2010). Although the majority of 
these studies identified MAIT cells as a major subtype of T cells mediating 
beneficial immune response, the opposite has been observed with Helicobacter 
pylori in mice. During H. pylori infection in WT mice, MAIT cells accumulated in 
the mucosa of the stomach and contributed to gastritis, whereas changes in 
gastric pathology were ameliorated in MR1 deficient mice, suggesting a 
pathogenic role of MAIT cells in this infection (D’Souza et al., 2018).  
 
While the involvement of MAIT cells in mounting an effective immune response 
against bacterial infection wasn’t surprising, as their primary antigen was 
identified to be a bacterial metabolite, MAIT cells were also shown to respond 
during viral infections. Early reduction in MAIT cell frequency has been shown in 
the peripheral blood of individuals infected with human immunodeficiency virus 
(HIV) and Hepatitis C virus (HCV) and this decrease was reported to be 
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irreversible in adults despite successful antiviral treatment during the chronic 
stage of the disease (Barathan et al., 2016; Cosgrove et al., 2013; Eberhard et 
al., 2014; Spaan et al., 2016). A study of HIV by Lal et al. showed that MAIT cells 
were highly activated at the peak of viremia, which was followed by an expansion 
of the population and enhancement of its effector functions. Decreases in the 
MAIT cell frequencies and impairment of function were observed at about one-
year post infection, suggesting that early treatment of HIV patients, could help to 
rescue MAIT cell population and preserve their effector functions for a longer time 
(Lal et al., 2020). On the other hand, MAIT cells from peripheral blood of 
individuals with HCV infection displayed an activated phenotype measured by the 
CD69 expression and a significant increase in the expression of markers such as 
human leukocyte antigen- DR (HLA-DR) and PD-1, suggesting their exhausted 
phenotype (Barathan et al., 2016; Hengst et al., 2016). MAIT cells are also 
involved during influenza virus infection. Studies by Van Wilgenburg et al. and 
Loh et al. have demonstrated a decrease in the frequency of circulating MAIT 
cells and upregulation of IFNγ and granzyme B during the infection (Loh et al., 
2016; Van Wilgenburg et al., 2016). The direct role of MAIT cells in response to 
influenza was demonstrated in MR1 deficient mice, which upon infection with 
H1N1 showed a higher mortality rate than controls. Adoptive transfer of MAIT 
cells into the MR1 deficient mice, extended the lifespan of infected mice, 
suggesting a non-redundant role of MAIT cells in influenza infections (Wilgenburg 
et al., 2018). All these studies demonstrate that MAIT cells are implicated in 
multiple bacterial and viral infections, making them an interesting target for 
vaccine development. However, more studies are required to establish their exact 
role, as discussed, they have a beneficial role in multiple infection, but like in the 
case of H. pylori they might cause excessive inflammation and contribute to 
development of pathologies.  
 
1.3.3 MAIT cells in inflammatory and autoimmune diseases 
The role of MAIT cells in autoimmune and inflammatory diseases is still under 
investigation, however an alteration in peripheral blood MAIT cell frequencies and 
function has been observed in a range of diseases including, RA or inflammatory 







Figure 1.5 MAIT cells in inflammatory and autoimmune diseases. MAIT cell 
phenotype and function is altered in multiple inflammatory and autoimmune 
diseases, where they largely present with an IL-17 phenotype (Pisarska et al., 
2020). 
 
Despite multiple studies, the role of MAIT cells in multiple sclerosis (MS) remains 
controversial. One of the primary T cells implicated in MS are Th17 cells, 
however, MAIT cells were shown to contribute to IL-17 production in MS 
(Abrahamsson et al., 2013; Willing et al., 2018). In addition, they were also shown 
to overexpress migratory molecules, suggesting their ability to migrate across the 
blood brain barrier (Salou et al., 2016). Indeed, MAIT cells were found to 
accumulate in central nervous system lesions supporting the hypothesis that they 
may be implicated in the pathology of the disease (Illés et al., 2004; Salou et al., 
2016; Willing et al., 2014). It is not clear whether the frequency of MAIT cells ih 
MS is altered due to conflicting reports. Willing et al. and Miyazaki et al. have 
shown a decrease in the frequencies of MAIT cells in the peripheral blood of MS 
subjects (Miyazaki et al., 2011; Willing et al., 2014), whereas other studies have 
shown an increase or no difference in MAIT frequencies in the peripheral blood 
of MS individuals (Ammitzbøll et al., 2020; Annibali et al., 2011; Salou et al., 2016; 
Sugimoto et al., 2016). In search for the cause of RA, the role of MAIT cells has 
been also evaluated. In comparison to the healthy controls, MAIT cell frequencies 
in the peripheral blood of RA patients vary between studies, with some reporting 
a decrease or no change (Cho et al., 2014; Gracey et al., 2016; Koppejan et al., 
2019). However, an increase in MAIT cell frequencies has been identified in the 
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synovial fluid versus blood of individuals with RA, suggesting their migration to 
the inflamed tissue (Cho et al., 2014; Gracey et al., 2016). Indeed, TNF-α and IL-
1β found at high concentrations in the synovial fluid of RA patients were shown 
to trigger MAIT cell migration into the tissue through the induction of migration-
associated molecules on the endothelium (Kim et al., 2017). The negative effect 
of MAIT cells on the disease development was confirmed in a mouse model of 
arthritis, in which MR1 deficient mice developed less severe disease. 
Repopulation of MR1 deficient mice with MAIT cells caused an exacerbation of 
the disease (Chiba et al., 2012).  
 
Similarly to RA, MAIT cell frequency is reduced in the peripheral blood of SLE 
patients (Chiba et al., 2017; Cho et al., 2014), which display impaired IFNγ 
production (Cho et al., 2014). A direct relationship between MAIT cells and 
development of SLE has been depicted in a mouse study of SLE, which reported 
that MR1 knockout mice had lower levels of autoantibodies than controls, 
whereas co-incubation of MAIT cells & B cells from a murine lupus mouse model, 
showed an enhancement in the production of antibodies which are a hallmark of 
the disease (Murayama et al., 2019).  
 
MAIT cells are known to be involved in multiple inflammatory diseases such as 
IBD. The pathophysiology of the disease is not fully understood; however, 
immune system dysfunction strongly underpins the development of this disorder 
(Neurath, 2019). IBD individuals with ulcerative colitis or Crohn’s Disease 
displayed a very similar phenotype of MAIT cells observed in RA. Patients with 
IBD had reduced frequency of peripheral blood MAIT cells which largely 
displayed IL-17 phenotype, with only Hiejima et al. reporting no difference in IL-
17A production (Haga et al., 2016; Hiejima et al., 2015; Serriari et al., 2014; 
Tominaga et al., 2017). In addition, IBD patients presented with enhanced 
accumulation of MAIT cells in the inflamed mucosa (Haga et al., 2016; Serriari et 
al., 2014; Tominaga et al., 2017). Together with MS, RA and IBD reports, this 
further suggests that MAIT cells may be actively recruited from the blood to the 
site of inflammation. Studies of immune cells in the skin revealed that MAIT cells 
form a small population of the resident immune cells in the normal healthy skin 
(Li et al., 2017; Teunissen et al., 2014). However, investigation of the skin of 
individuals with psoriasis or dermatitis herpetiformis reported the presence of IL-
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17 producing MAIT cells in the inflamed skin areas (Teunissen et al., 2014), 
suggesting that during inflammation, MAIT cells are likely to contribute to the pro-
inflammatory environment.  
 
MAIT cell frequency in the peripheral blood, lungs tissue and bronchioalveolar 
lavage of adults with asthma was shown to be reduced in comparison to the 
healthy controls and correlated with the disease severity and administration of 
inhaled corticosteroids (Hinks et al., 2015). It is unknown whether the reduction 
of MAIT cell frequency was directly related to the disease pathology or inhaled 
corticosteroids treatment, however, this reduction in MAIT cell frequency may 
contribute to an increased susceptibility of infection in this cohort. A study of 
children with asthma by Lezmi et al. identified a higher frequency of IL-17 
producing MAIT cells, in children who had one or more severe exacerbations 
during a twelve-month period versus children who did not. In addition, the 
frequency of IL-17 producing MAIT cells positively correlated with the number of 
exacerbations of the disease (Lezmi et al., 2018). More recently, Lezmi et al. 
obtained similar results in a study of children with severe asthma, showing an 
enhancement in the frequency of IL-17A producing MAIT cells in their 
bronchoalveolar lavage samples, which positively correlated with the number of 
exacerbation (Lezmi et al., 2019). Recently it was identified that chronic 
stimulation of MAIT cells can result in IL-13 production (Kelly et al., 2019). This 
suggests Th2 cells in asthma may not be the only source of the allergy associated 
cytokines which contribute to the severity of disease.  
 
Majority of the diseases discussed here can be characterised by a reduction in 
the frequencies of MAIT cells in the peripheral blood and their enhanced IL-17 
phenotype, suggesting their migration to the site of inflammation and aggravation 
of the pro-inflammatory response. More research is required to identify the trigger 
which alters the phenotype of MAIT cells and to find targets to ameliorate their 
pro-inflammatory response.  
 
1.3.4 MAIT cells in diabetes and obesity 
Type 1 and type 2 diabetes mellitus are considered chronic inflammatory 
diseases, which involve an array of immune cells, primarily B and T lymphocytes 
(DeFronzo et al., 2015; Katsarou et al., 2017). Like in the vast number of 
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autoimmune diseases, the primary factors which contribute to the onset of the 
disease are yet to be identified. The microbiome was shown to play an important 
role in development of type 1 diabetes mellitus (T1DM) (Alkanani et al., 2015; 
Wen et al., 2008). As MAIT cells are associated with gut mucosal sites and are 
in close interactions with the microbiota, this suggests their possible involvement 
in the pathogenesis of T1DM.  
 
Analysis of juvenile T1DM revealed no difference in the proportion of MAIT cells 
in peripheral blood between diabetic or control subjects, however T1DM 
individuals had a significantly larger subset of CD27- MAIT cells in comparison to 
the controls. In addition, CD27- MAIT cells from healthy donors produced more 
IL-17A than CD27+ MAIT cells (Harms et al., 2015). The same group also 
reported a reduction in MAIT cell frequency in seroconverted patients (without 
T1DM yet) in comparison to the control group (Harms et al., 2018). Rouxel et al. 
reported a similar finding whereby MAIT cell frequencies were reduced in the 
peripheral blood of children with recent-onset T1DM versus healthy children. 
MAIT cells from children who recently developed T1DM expressed exhaustion 
markers of inflammation such as PD-1 and they produced less IFNγ, but more IL-
17 and granzyme B upon challenge in vitro in comparison to controls (Rouxel et 
al., 2017). In addition, experiments performed with purified donor MAIT cells 
and b-cell lines demonstrated the ability of MAIT cells to kill them (Rouxel et al., 
2017). In a mouse model of T1DM, non-obese diabetic (NOD) mice had an 
increased migration of MAIT cells into the pancreas during development of 
T1DM, accompanied by an increase in the production of IFNγ and Granzyme B. 
Interestingly, NOD mice showed changes in the gut during the progression of 
diabetes. MR1-/- NOD mice displayed a deterioration of gut integrity, favouring 
translocation of bacteria and possibly ultimately promoting T1DM development 
(Rouxel et al., 2017). On the other hand, Kuric et al. noted no difference in MAIT 
cell frequency in areas of insulitis or its proximity in patients with early onset of 
T1DM as compared to pancreas of healthy donors. They reported low expression 
of Va7.2 MAIT cell TCR mRNA levels in the pancreas of both healthy and 
diseased donors (Kuric et al., 2018). These results contradict the previous 
findings, which suggested a strong role of MAIT cell in the development of T1DM. 
More research is required to assess the level of involvement of MAIT cells in the 
development of T1DM. 
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MAIT cells may also be involved in the development of T2DM, however this area 
is not very well researched. A reduction in MAIT cell frequencies have been 
reported in individuals with T2DM (Magalhaes et al., 2015; Zhang et al., 2019). 
Resting peripheral blood MAIT cells from individuals with T2DM exhibited a more 
activated phenotype as assessed per CD25 expression and upon stimulation 
expressed higher levels of IL-2, granzyme B and IL-17. In addition, MAIT cells in 
the AT of individuals with T2DM displayed enhanced IL-17 production, 
suggesting their contribution to AT inflammation (Magalhaes et al., 2015). More 
recent study, by Zhang et al. assessed the expression of OX40 by MAIT cells in 
T2DM. OX40 is a co-stimulatory molecule expressed by T cells, whose 
engagement leads to their activation and differentiation. This study reported 
significantly higher frequency of OX40+ MAIT cells from individuals with T2DM, 
which was negatively correlated with MAIT cell frequencies. In addition, 
engagement of OX40 leads to the induction of apoptosis by MAIT cells, 
suggesting that over-expression of OX40 may be leading to the diminished 
frequencies observed in subjects with T2DM (Zhang et al., 2019). The knowledge 
of MAIT cell activation and function in T2DM remains very limited, therefore more 
studies are required to identify their role in the development of the disease.  
 
Development of T2DM is closely associated with obesity, and in fact MAIT cells 
from people with obesity displayed very similar phenotype. A significant reduction 
in MAIT cell frequencies has been recorded in peripheral blood of people with 
obesity or obesity and T2DM (Carolan et al., 2015; Magalhaes et al., 2015). As 
described in detail in the introduction to chapter 4, these MAIT cells displayed an 
activated phenotype, with an enhanced IL-17 production and a defect in 
expression of IFNγ in comparison to the lean controls (Carolan et al., 2015; 
Magalhaes et al., 2015). Although it has been established that MAIT cells are 
highly dysfunctional in obesity, currently it remains unknown what causes such 
profound alterations in their frequencies and function. As MAIT cells have been 
discovered relatively recently, more basic research is required to establish what 
mechanisms control their activation. This will establish which of the pathways are 
dysfunctional in MAIT cells from individuals with obesity and hence identify 





For a long time, the function and metabolism of immune cells have been 
investigated separately, overlooking the strong connection between these two 
areas. Immunologists have gained more insight into how metabolism of an 
organism can influence immune cells during the early studies of nutrient 
deprivation, obesity and obesity related diseases such as T2DM. Although it may 
seem obvious now, the disruption to nutrient availability and metabolism of such 
nutrients by immune cells is critical to their function, it hasn’t been that evident for 
many years. One of the first clues that indicated the importance of metabolism in 
immune cell functions was reported as early as 1950s (Oren et al., 1963; 
Pachman, 1967; Sbarra AJ and Karnovsky M. L., 1959) however, research in the 
area didn’t escalate until about 10 years ago. This is when immunometabolism 
emerged as a new exciting area of immunology.  
 
Cell metabolism is very complex and involves multiple pathways, which are 
closely linked. A defect in one of those pathways may have further downstream 
consequences on whole cell metabolism and function. The aim of these pathways 
is to provide energy and biosynthetic intermediates which are required for the cell 
survival, activation and proliferation (Dimeloe et al., 2017; Munford and Dimeloe, 
2019; O’Neill et al., 2016). It has been described that the metabolism of T cells 
varies greatly depending on their activation state. In naïve T cells in the quiescent 
state or during memory formation, their energy production is largely supported by 
the Kreb’s cycle and mitochondrial oxidative phosphorylation (OxPhos), which 
are known to generate large amounts energy through adenosine triphosphate 
(ATP) production (Munford and Dimeloe, 2019; O’Neill et al., 2016).  
 
Upon stimulation, T cells undergo metabolic reprogramming and rapid 
upregulation of glycolysis. This is known as the Warburg effect, which was first 
discovered by Otto Warburg in 1920s in cancer cells (Warburg, 1925). Although 
OxPhos is upregulated in activated T cells, glycolysis becomes the dominant 
pathway (Palmer et al., 2015; Sena et al., 2013). Glucose is one of the primary 
fuels required for cell function. It is obtained from the extracellular environment of 
immune cells and its uptake is facilitated by glucose transporters such as GLUT1 
(Jacobs et al., 2008; Macintyre et al., 2014). Glycolysis breaks down a molecule 
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of glucose into pyruvate in a series of enzymatically controlled steps. It is 
considered to be an inefficient source of energy production as it only yields two 
net ATP energy molecules per one molecule of glucose, however it provides 
multiple intermediates, which can feed into other metabolic pathways. In this way, 
glycolysis contributes to the synthesis of nucleotides by feeding into the pentose 
phosphate pathway (PPP) as well as the synthesis of fatty acids by feeding into 
the Krebs’s cycle or synthesis of amino acids by fuelling the serine synthesis 
pathway (Munford and Dimeloe, 2019; O’Neill et al., 2016). This shows that the 
upregulation of glycolysis upon activation is more beneficial to the cell, as it 
provides it with enough energy, but also yields biosynthetic precursors required 
for its proliferation and exertion of its functions. Upregulation of glycolysis can 
also happen more swiftly than the upregulation of OxPhos, providing the cell with 
the advantage of faster response to stimuli (O’Neill et al., 2016). The importance 
of glucose and glycolysis in T cell activation was demonstrated by multiple 
studies. Mice deficient in the GLUT1 receptor on their T cells demonstrated 
reduced proliferation capacity and impaired glycolysis upon stimulation 
(Macintyre et al., 2014). Incubation of T cells in media in which glucose was 
substituted for galactose, resulted in a defect in their IFNγ production (Chang et 
al., 2013). Stimulation of human T cells demonstrated an increase in glycolysis 
during the period of 24-72 hours as measured by extracellular acidification rate 
(ECAR), whereas incubation of T cells with 2-deoxy-d-glucose (2DG), inhibitor of 
hexokinase 2, the first enzyme of glycolysis, significantly reduced IFNγ 
production (Renner et al., 2015).  
 
Glycolysis is dependent on mammalian target of rapamycin complex 1 
(mTORC1) and complex 2 (mTORC2) activation, although the action of mTORC2 
is less understood (Saxton and Sabatini, 2017). Mammalian target of rapamycin 
(mTOR) plays a central role in T cell metabolism and has multiple functions. It is 
upregulated upon T cell activation and acts as a nutrient sensor in the cells. It 
integrates the signals of nutrient status and antigen signalling to orchestrate the 
activation of appropriate pathways. It detects levels of amino acids such as 
leucine, promotes lipid synthesis, as well as RNA transcription (Salmond, 2018; 
Saxton and Sabatini, 2017). Multiple studies have demonstrated the role of 
mTOR activation in glycolytic metabolism. Inhibition of mTOR activation with 
rapamycin was shown to impair their expression of glucose transporters GLUT1 
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and GLUT3 by cytotoxic T lymphocytes and impair glucose uptake (Hukelmann 
et al., 2016). mTORC1 signalling implicated in aerobic glycolysis is still not very 
clear, however it is thought to be controlled by the regulation of Myc and HIF1α 
transcription factors (Finlay et al., 2012; Wang et al., 2011). As mentioned earlier, 
mTOR is sensitive to amino acid levels. In the past few years, studies have 
focused on elucidating the role of amino acids in T cell metabolism. It was found 
that upon activation, cells not only increase the flux of glucose, but the uptake of 
amino acids is higher (Carr et al., 2010; Nakaya et al., 2014). Stimulation of the 
cells leads to an increase in the expression of amino acid transporters (Carr et 
al., 2010; Sinclair et al., 2013). The most well studied amino acid transporter in 
lymphocytes to date is the L-type amino acid transporter 1 (LAT1). LAT1 is a 
heterodimer of CD98 and solute carrier (SLC)7A5. It is an antiporter which 
transports extracellular leucine into the cell in exchange of intracellular glutamine 
(Hsu and Dzhagalov, 2019). It is known to be upregulated on T cells upon 
stimulation via TCR/CD28 and is controlled by the expression of Myc (Hayashi et 
al., 2013; Sinclair et al., 2013). It can transport several amino acids, however it 
plays a major role in transporting leucine, as leucine is required for mTORC1 
activity (Saxton et al., 2016; Sinclair et al., 2013). The role of LAT1 was strongly 
highlighted in a study by Cantrell lab, which showed the deletion of SLC7A5 in 
mouse T cells leads to the impairment of cell proliferation and differentiation into 
CD4 and CD8 cells (Sinclair et al., 2013). Similar results were obtained by 
Hayashi et al. where LAT1 expression on human T cells was disrupted by small 
interfering RNA (siRNA). They have reported a reduction in the uptake of amino 
acids and impaired cytokine production by T cells (Hayashi et al., 2013). There is 
mounting evidence highlighting a role for glutamine in T cell activation and 
proliferation (Carr et al., 2010; Johnson et al., 2018; Sener et al., 2016). 
Glutamine is involved in multiple metabolic aspects of the cell. It is transported 
into the cell via multiple transporters belonging to the solute carrier family 
including SLC1A5, SLC3A2, SLC7A5 and SLC38A1, however many more 
glutamine transporters exist (Carr et al., 2010; Nakaya et al., 2014; Wang et al., 
2011). Upon entry into the cell, glutamine can be converted to α-ketoglutarate 
and fed into the Kreb’s cycle or it can fuel acetyl Coenzyme A (Acetyl Co-A) 
production. It can also be used in the generation of glutathione, a natural anti-
oxidative or enter the serine biosynthesis pathway (Altman et al., 2016). 
Glutamine was shown to be utilised by cells upon activation and proliferation 
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(Carr et al., 2010; Wang et al., 2011). Deprivation of this amino acid during 
stimulation of naïve CD4 T cells resulted in T reg differentiation, despite Th1 
cytokine signal. It was shown that α-ketoglutarate, a metabolite derived from 
glutamine metabolism, acts as a CD4 T cell differentiation controller, as addition 
of α-ketoglutarate analogue to the cultured lead to Th1 differentiation (Klysz et 
al., 2015). This was further confirmed by Johnson et al. who found that the 
inhibition of glutaminase, an enzyme which converts glutamine to glutamate, 
promoted T cell differentiation into Th1 type, while impairing Th17 differentiation, 
indicating Th17 cells are dependent on glutaminase and glutamine influx during 
cell activation (Johnson et al., 2018). These studies highlight the importance of 
amino acids, not only as building blocks required for cell function, but as a 
signalling molecule which together with the external stimulation signals largely 
impact the cell function. 
 
Identifying this close relationship between immune cell function and metabolism 
opened a new avenue in targeting immune cells in inflammatory diseases. As 
mentioned before, inhibition of glycolysis with 2DG has profound effects on T cell 
function and leads to the impairment of its activation. The effects of the inhibitor 
have been further explored and studied by Yin et al. in a mouse model of SLE. 
Combined treatment of the SLE mice with 2DG, the glycolysis inhibitor and 
metformin which was shown to impair OxPhos by inhibiting the complex I of 
electron transport chain, resulted in the downregulation of metabolism in T 
effector cells, with no effect in the control mice (Owen et al., 2000; Wheaton et 
al., 2014; Yin et al., 2015). However, since then, the mode of action of metformin 
has been under review (Wang et al., 2019). Yin et. al also found a decrease in 
the production of anti-nuclear antibodies and anti-double stranded DNA IgG, 
leading to remittance of the SLE phenotype (Yin et al., 2015). Liu et al. 
investigated the effect of 2DG in a mouse model of Guillain-Barre syndrome, an 
inflammatory demyelinating disease of the peripheral nervous system. They 
found that the administration of 2DG prevented progression of the disease and 
inhibited its initiation (Liu et al., 2018). Treatment with 2DG was also applied to 
the NOD mouse model of an autoinflammatory diabetes and resulted in an 
increase in b cell granularity and a reduction in T cells reactive to diabetes 
antigen, the islet-specific glucose-6-phosphate catalytic subunit-related protein 
(IGRP) (Garyu et al., 2016). As GLUT1 plays a very important role in immune cell 
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function, inhibition of GLUT1 mediated transport of glucose is another potential 
target in treatment of inflammatory diseases. Inhibition of GLUT1 with WZB117 
inhibitor in early-stage memory T cells derived from patients with T1DM inhibited 
the expansion of this cell subset (Vignali et al., 2018). The investigations of using 
glycolysis inhibitors to treat autoimmune diseases are in very early days. mTOR 
inhibitors such as Sirolimus are currently approved for use in the clinics to prevent 
organ transplant rejection (Nguyen et al., 2019). A recent clinical trial of Sirolimus 
in active SLE over 12 months found an expansion in Treg and CD8 memory T 
cell populations in the treated patients and improved disease activity (Lai et al., 
2018). Administration of rapamycin in a murine model of EAE has also shown 
promising results. The treatment increased the percentage of Treg cells in the 
rapamycin treated group versus untreated. The percentage of Th17 cells, which 
are considered to be highly pathogenic in MS and EAE, were found to be 
decreased in the rapamycin treated group as well as infiltration of IL-17 
expressing cells in the spinal cord of the EAE mice was reduced in comparison 
to the controls (Li et al., 2019). These studies show a potential in controlling 
inappropriate immune cell activation, as is observed in diabetes and obesity. 
Although these results are very promising, these approaches must be considered 
very carefully, not only immune cells use glycolysis and mTOR to exert their 
functions. The side effects of these drugs could be very widespread, causing 
increased susceptibility to infections and cancer development, due to the 
dampening of the immune system. The effect of these inhibitors must also be 
considered on cells in other tissues and organs, as widespread inhibition of such 
vital life pathways like glycolysis, may impair the function of whole organs.  
 
Metabolism has been shown to be an integral part of the immune cell function; 
however, upon undertaking this thesis no data has been published on the 
metabolism of MAIT cells. In this thesis we aimed to identify the metabolic 
requirements of these cells by investigating the role of glycolysis and glycolysis 
related pathways in MAIT cell activation. We further examined how these 
pathways are involved in supporting cytokine production, proliferation and 
expansion of these cells. It has been established in the literature that people with 
obesity present with a severe impairment of MAIT cell function in comparison to 
the control population (Carolan et al., 2015; Magalhaes et al., 2015). Therefore, 
this study also aimed to investigate the metabolism of MAIT cells from people 
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with obesity and compare it to control individuals in order to determine whether 
there are any differences, which may be negatively affecting MAIT cell function. 
Identification of any alterations could open new avenues of targeted treatments 
















Ethical approval for this study and collection of samples from people with obesity 
and healthy controls was granted by Medical Research Ethics Committee from 
St. Vincent’s University Hospital Dublin. Local ethics were also obtained from 
Maynooth University Research Ethics committee.  
 
 
2.2.  Study Design 
This was a cross-sectional investigative comparative study. Control blood 
samples were obtained from St. Vincent’s University Hospital Dublin and Irish 
Blood Transfusion Service. People with obesity were recruited from the Weight 
Management Clinic in Loughlinstown (part of the St. Vincent’s Healthcare group). 
All recruited control individuals (apart from blood samples obtained from IBTS) 
and people with obesity were recruited into the study after giving informed and 
written consent. The variation in the number of samples obtained from the control 
individuals and people in obesity occurs due to the variability in sample 
availability and sample quality for each of the groups. As control samples were 
more accessible and of better quality, than samples from people with obesity, 
more individuals have been included in the control groups for each experiment.   
  
33 
2.3. Isolation of human peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMC) were isolated using gradient density 
centrifugation from venous blood samples collected from control lean individuals 
or people with obesity into lithium heparin coated tubes (vacutainer, BD 
Bioscience); or from donated buffy coats from the Irish Blood Transfusion 
Service. The blood was diluted 1:1 with sterile phosphate buffered saline (PBS, 
Sigma Aldrich) for venous blood samples and 1:5 for buffy coats and carefully 
layered on top of 15mls of LymphoprepTM medium (StemCell Technologies) in a 
50mls tube (Sarstedt) (Figure 2.1). The blood preparation was centrifugated at 
1800 rpm for 20 minutes, with low acceleration and break turned off as shown in 
Figure 2.1. After centrifugation, the buffy layer was removed into a new sterile 
tube and washed twice in 20mls of PBS at 1800 rpm for 8 minutes with high 
acceleration and deacceleration. Depending on the pellet size, cells were 
resuspended in a volume of complete RPMI (cRPMI) 1640 1X (GIBCO, 
ThermoFisher Scientific) containing 2%v/v HEPES buffer solution 1M (GIBCO), 
10% v/v heat inactivated foetal calf serum (FCS) (GIBCO), 1X antibiotic-
antimycotic (100untis/mL of penicillin, 100µg/mL of streptomycin, 250ng/mL 
Gibco Amphotericin B) (GIBCO) 1mM Sodium Pyruvate and non-essential amino 
acids diluted to 1X(GIBCO)) and the cells were counted as per section 2.4 and 
Figure 2.2.  
Figure 2.1 Isolation of peripheral blood mononuclear cells. A diagram 
showing layering of the blood and compartmentalisation of the blood cells after 
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2.4. Cell enumeration 
The cells were stained using trypan blue solution (GE Healthcare) using 1:10 or 
1:20 dilution and 10µl of the stained cell suspension was applied to a 
haemocytometer counting chamber. Using a dye exclusion test, cells which didn’t 
take up the dye (white in colour) were considered to be viable and only those 
cells were counted in the middle square of the haemocytometer as shown in 
figure 2.2. To calculate the number of the cells in suspension per 1mL the 




The cells were resuspended at 2´106 cells/mL in cRPMI for further analysis.  
Figure 2.2 PBMC counting. Trypan blue stained PBMC were applied to the 
haemocytometer and counted as per diagram. Image created with BioRender. 
 
 
2.5.  MAIT cell proliferation and expansion 
2.5.1. Cell Trace Violet Staining 
MAIT cell proliferation was measured with CellTraceTM Violet (CTV) cell 
proliferation kit for use on flow cytometer (ThermoFisher Scientific). The required 
number of freshly isolated PBMC was pelleted by centrifugation at 1800rpm for 8 
minutes and the supernatant was completely removed. CTV solution was 
prepared immediately prior to use, by adding 20μL of dimethyl sulfoxide (DMSO) 
to the supplied vial with the stain, to obtain 5mM stock. Next, the dye was diluted 






into pre-warmed PBS. The cells were gently resuspended and stained at 106 cells 
per mL of the PBS-dye solution. Cells were incubated for 20 min at room 
temperature, protected from light with circular agitation. Next, five times the 
original staining volume of cRPMI was added to the tubes and incubated for 5 
minutes at room temperature, which allowed for the removal of any unbound dye. 
The cells were pelleted at 1800rpm for 8 minutes and resuspended in warm 
cRPMI culture media at 2x106 cells per ml and re-counted. Cells were incubated 
for at least 10 minutes to allow acetate hydrolysis of the dye, before proceeding 
with the experimental set up.  
 
2.5.2. TCR only induced MAIT cell expansion & proliferation over 5 days 
PBMC were stained with CTV as per section 2.5.1 for assessment of MAIT cell 
proliferation, or PBMC remained unstained for measurement of MAIT cells 
expansion. A sample of 0.25-0.5x106 cells was set aside to stain for flow 
cytometry to measure MAIT cell frequency or CTV uptake prior to proliferation or 
expansion. Next, PBMC were plated at 1x106/mL in a 48 well flat bottom plate, in 
a total volume of 1mL of cRPMI. Cells were stimulated with 1μg/mL of 5-ARU 
(synthesised by and received from Professor Gurdynal Besra) and 100μM of MG 
(Sigma) for 18 hours. On day 1 (18 hours after stimulation), 50μL of the media 
was removed from all the wells and replaced with 50μL of fresh complete media. 
Replacement of 50μL of the media was carried out, to ensure consistency 
between these experiments and experiments of MAIT cell expansion and 
proliferation, which were supplemented with IL-2 on day 1 in 50µL volume (please 
see section 2.5.4). On day 4, 500μL of media was removed and replaced with 
500μL of fresh complete media. On day five, each well was resuspended by 
pipetting and 100μL of cells were removed and stained for flow cytometry as per 
section 2.10.5 MAIT cell frequencies were determined as the percentage of CD3+ 
cells whereas CTV was on MAIT the cell population using geometric mean. 
 
2.5.3. TCR and IL-2 induced MAIT cell expansion & proliferation over 5 days 
CTV stained (proliferation) or unstained (expansion) PBMC were plated at 
1x106/mL in a 48 well flat bottom plate, in a total volume of 1mL of cRPMI. Cells 
were stimulated with 1μg/mL of 5-ARU and 100μM of MG for 18 hours in the 
presence or absence of the following inhibitors: 2DG (10mM) (Sigma), rapamycin 
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(20nM) (Sigma), oligomycin (2μM) (Sigma), antimycin A (4μM) (Sigma) or CB-
839 (10μM) (Sigma). To assess the effect of 2-amino-2-norbornanecarboxylic 
acid (BCH) (50mM) (Sigma) on MAIT cell proliferation and expansion, the same 
experimental procedure was followed, except the complete media was diluted 
with Hanks balanced salt solution (HBSS)(Gibco) in 1:2 ratio. On day 1 (18 hours 
after stimulation), 750μL of the media was removed from all the wells and 
replaced with 750μL of fresh complete media supplemented with low dose of IL-
2 (6.75ng/mL). On day 4, 500μL of media was removed and replaced with 500μL 
of fresh complete media supplemented with high dose of IL-2 (33.33ng/mL). On 
day 5, 18 hours post high dose IL-2, 100μL was removed from each well and 
stained for flow cytometry as per section 2.10.6 (Figure 2.3). MAIT cell 
frequencies and CTV uptake and dilution were assessed prior to expansion and 
on day 5 as described in section 2.5.2. To assess the effect of nutrient restriction 
on MAIT cell proliferation and expansion, the cells were stained 
(proliferation)/unstained (expansion) and the same protocol was followed as 
described above, with the exception that for the duration of the experiment cells 
were kept in their respective nutrient restricted media. i.e., 10mM, 5mM and 1mM 
glucose or 10mM galactose. 
Figure 2.3 Plan of MAIT cell proliferation experiment. Schematic showing the 
experimental set up to investigate the effect of metabolic inhibitors on MAIT cell 
proliferation. Image created with BioRender. 
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2.5.4. TCR & IL-2 induced MAIT cell expansion over 7 days 
PBMC were plated at 1x106/mL in a 48 well flat bottom plate, in a total volume of 
1mL of cRPMI. A sample of 0.25-0.5x106 cells was stained for flow cytometry 
prior to expansion of MAIT cells. Cells were stimulated with 1μg/mL of 5-ARU and 
100μM of MG for 18 hours. On day 1 (18 hours after stimulation), 50μL of the 
media was removed from all the wells and replaced with 50μL of fresh cRPMI 
supplemented with low dose IL-2 media (6.75ng/mL). On day 4, 500μL of media 
was removed and replaced with 500μL of fresh cRPMI supplemented with high 
dose IL-2 media (33.3ng/mL). On day 7, each well was resuspended by pipetting 
and a sample of cells was removed for counting. Next 100μL of cells were 
removed and stained for flow cytometry as per section 2.10.6. Based on cell 
counts and MAIT cell percentage in samples pre- and post-expansion, absolute 
numbers of MAIT cells in the culture were calculated. Fold expansion was 
calculated by dividing the number of MAIT cells present in the culture on day 7 
by the number of MAIT cells prior to stimulation.  
 
2.5.5. TCR & IL-2 induced MAIT cell expansion – 28 days 
PBMC were plated at 2x106 cells in a 24 flat well plate in a total volume of 2mL 
of cRPMI. Cells were stimulated with 1μg/mL of 5-ARU and 100μM of MG for 18 
hours. Following the stimulation, on day 1, low dose of IL-2 at 6.75ng/mL was 
added into each well, followed by a high dose of IL-2 at 33.3ng/mL on day 
4,7,11,14,18 and 21. During the high dosage feeding, 1mL of supernatant was 
removed and replaced with fresh media containing the high dose of IL-2. 
Expansion of MAIT cells was checked prior to expansion and on day 
4,7,11,14,18,21 and 28 by flow cytometry as per table 2.10.5.  
 
2.5.6. MAIT cell expansion for Seahorse, ELISA and real time RT-qPCR 
PBMC were plated at 2x106 cells in a 24 flat well plate in a total volume of 2mL 
cRPMI. Cells were stimulated with 1μg/mL of 5-ARU and 100μM of MG for 18 
hours. Following the stimulation, on day 1 low dose of IL-2 at 6.75ng/mL was 
added into each well, followed by a high dose of IL-2 at 33.3ng/mL on day 4,7,11 
and 14. Expanded MAIT cells were harvested between day 13 and 18 and the 
culture was purified using magnetic isolation as per section 2.6.1 and 2.6.2  
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2.6.  Preparation of expanded MAIT cells for experiments  
2.6.1. MAIT cell magnetic labelling 
Expanded MAIT cells were removed from the culture between day 13 and 18 for 
purification. The cells were counted as previously described in section 2.2 and 
the desired number of cells were removed for isolation. The cells were centrifuged 
at 300g for 10 min (as all centrifugation steps in this protocol) to remove all media 
and then spun in Auto MACS running buffer (BSA/EDTA/0.9%Azide/PBS) 
(Miltenyi Biotec) using 2mL of the buffer per 107 of cells. The supernatant was 
completely removed, and the cells were resuspended in 100µL of MACS buffer 
per 107 of cells. 10µL of APC anti-human TCR Va7.2 conjugated antibody 
(BioLegend) was added per 107 of cells, mixed well and incubated for 10 min in 
the fridge. The cells were washed with MACS buffer as above and after removing 
the supernatant, the cells were resuspended in 80µL of MACS buffer per 107 of 
cells and 20µL of Anti-APC Microbeads (Miltenyi Biotec) were added per 107 of 
cells. Cells were incubated for further 15min in the fridge, washed as above and 
resuspended in 500µL of MACS buffer. 
 
2.6.2. MAIT magnetic separation 
To isolate the labelled MAIT cells, LS columns (Miltenyi Biotec) and a magnetic 
separator (Miltenyi Biotec) were used. The LS columns were carefully placed into 
the magnet holders and prepared by rinsing with 3mL of MACS buffer. Next 
500µL of the labelled cell suspension was applied to the column, which was then 
rinsed three times with 3mL of MACS buffer. The fraction of unlabelled cells was 
collected and discarded. To recover the labelled cells of interest, the column was 
removed from the separator and placed over a suitable tube. 5mL of MACS buffer 
as added into the column reservoir and immediately flushed out with the plunger 
supplied with the column. The cells were spun out of the MACS buffer via 
centrifugation at 300g for 10mins, resuspended in full media and counted. The 
purity of the isolated cells was determined by extracellular staining as per section 






2.7. MAIT cell molecular analysis 
2.7.1. mRNA expression experimental set up  
MAIT cells were expanded, harvested and purified as per sections 2.5.5, 2.6.1 
and 2.6.2. Isolated MAIT cells were plated at 3x106 per well in a 24 flat bottom 
plates in a total volume of 1mL of cRPMI and rested overnight. Next, cells were 
stimulated for 4 hours with TCR microbeads (DynabeadsTM Human T activator 
CD3/CD28, prepared as per manufacturer’s instructions) (ThermoFisher 
Scientific) in 1:1 ratio of beads to the number of cells and with IL-12/IL-18 at 
50ng/mL each (BioLegend) (Figure 2.4) in a total volume of 1.5mL. At the end of 
the stimulation period, the cells were removed into 2ml sterile tubes (Sarstedt) 
and centrifuged at 400g for 10 minutes. The supernatant was removed, the 
pellets were resuspended in 500μL of RNA LaterTM Stabilisation solution 
(Invitrogen) and stored at 4oC overnight, before freezing at -20oC for long term 
storage.  
 
For assessment of the effect of BCH inhibition on MAIT cell activation on the 
molecular level, expanded and purified MAIT cells rested overnight in a flask. The 
following day, cells were recounted, resuspended in cRPMI and plated at 3x106 
per well in a 24 flat bottom plates. BCH (50mM) or HBSS was added to 
appropriate wells for 1 hour prior to MAIT cell activation, ensuring that the media 
is diluted 1:1 with HBSS for the duration of the experiment. After 1 hour, MAIT 
cells were stimulated with TCR Dynabeads and cytokines (IL12/18 at 50ng/ml) in 




Figure 2.4 Diagram showing experimental plan for analysis of MAIT cell 
mRNA expression. Experimental set up used to investigate the expression of 
mRNA by MAIT cells upon stimulation. Image created with BioRender. 
 
 
2.7.2. mRNA isolation 
Isolation of mRNA from MAIT cells was performed using E.Z.N.A Total RNA kit I 
(Omegabio-tek). Manufacturer’s protocol was followed. Briefly, HiBind RNA Mini 
Column were inserted into the provided 2mL collection tube and labelled. MAIT 
cells in RNA LaterTM were pelleted at 10,000g for 5 minutes and the supernatant 
was removed. Next 350µL of TRK Lysis buffer was added to the pellet and the 
cells were homogenised by pipetting and vortexing, followed by the addition of 
350µL of 70% ethanol (Sigma) (Figure 2.5). Suspension was vortexed thoroughly 
and the total volume of 700µL of the sample was transferred to the HiBind RNA 
Mini Column, which was centrifuged at 10,000g for 1 minute. The filtrate was 
discarded, and the membrane was washed with 500µL of RNA Wash Buffer I, 
followed by centrifugation at 10,000g for 30 seconds. Next, 500µL of RNA Wash 
Buffer II was added to the columns. The tubes were centrifuged for 10,000g for 1 
minute and the filtrate was discarded. Wash with RNA Wash Buffer II was 
repeated once more, as above. Then the columns were spun on maximum speed 
for 4 minutes to dry the HiBind RNA Mini Column membrane. Next the columns 
were transferred into labelled 1.5mL RNAse free tubes and 40µL of DEPC water 
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was applied straight to the middle of the membrane. The tubes were centrifuged 
at maximum speed for 2 minutes to elute mRNA (Figure 2.5). 
Figure 2.5 Isolation and quantification of RNA. Diagram depicting steps 
involved in RNA isolation using E.Z.N.A Total RNA kit I and RNA quantification 
with Nanodrop2000. Adapted from E.Z.N.A. Total RNA kit I manual. 
 
 
2.7.3. mRNA quantification 
After mRNA isolation, mRNA was quantified using NanodropTM 2000 
spectrophotometer (ThermoFisher Scientific). Nanodrop software settings were 
set up to measure RNA nucleic acids and the instrument was blanked using 1μL 
of DEPC water. All samples were measured and concentration of RNA (μg/μL) 
and 260:230 ratios were noted. RNA was diluted to the desired concentration, 
uniform for each batch of the samples between 35ng-100ng/μL, depending on 
the initial concentration of RNA in the samples.  
 
2.7.4. cDNA synthesis 
Synthesis of cDNA was performed using qScript cDNA Synthesis kit (QuantaBio). 
Each reaction contained 500ng of RNA. Total volume of each reaction was equal 
to 20μL, composed of up to 15μL of RNA (if RNA was very concentrated this 
volume was made up to 15μL with molecular grade nuclease free water), 4μL of 
concentrated master mix (tittered primer blend, qPCR optimised dNTP blend, 
flexible magnesium titration) and 1μL of qScript reverse transcriptase. The cDNA 
Lysis of MAIT cells 
in TRK Lysis buffer
Addition of 70% 
ethanol
Transfer of sample 
into HiBind RNA 
Mini Column
Centrifugation
Wash with RNA 
Wash Buffer I
Wash with RNA 
Wash Buffer II
x2
Drying of the 
membrane
Elution of RNAEluted RNARNA 
quantification
42 
reaction was prepared in 0.2mL Corning Thermowell GOLD PCR tubes (Sigma) 
and ran on G- Storm Thermal Cycler (Gene Technologies Ltd). First the samples 
were heated up to 22oC for 5minutes, next the temperature was increased to 
42oC for 30 minutes and 85oC for further 5 minutes, before the temperature was 
dropped to 0oC. After cDNA synthesis, samples were diluted 1:5 with molecular 
grade water (Sigma) and kept at -20oC. 
 
2.7.5. Realtime RT-qPCR 
Real time RT-qPCR was performed using PerfeCTa SYBR Green FastMix 
Reaction Mix (Green Fastmix, ROXTM) (QuantaBio) and primers as per table 2.1 
below (Sigma). Primers were resuspended in molecular grade water (Sigma) as 
per manufacturer’s instructions to obtain a stock of 100μM, and then further 
diluted with molecular grade water to 4μM working solution. A master mix of the 
SYBR Green and primers was prepared, which contained 5μL of SYBR Green 
Enzyme Mix, 1.25μL of forward primer, 1.25μL of reverse primer, 0.5μL of 
molecular grade water per sample. 8μL of the master mix was added into 
appropriate wells in the 96 well reaction plate (MicroAmp Fast 96-well reaction 
plate (0.1mL) (Life Technologies) and 2μL of the cDNA template was added. After 
addition of the master mix and cDNA template, the plate was covered with an 
adhesive coverslip (MicroAmp Optical Adhesive film) (ThermoFisher Scientific) 
and spun for 5 seconds at 1800rpm. The plate was loaded into a PCR instrument 
(Applied Biosystems) and appropriate program was used as follows. The 
temperature was increased to 95oC for 30 seconds, this was followed by the cycle 
of 95oC for 10 seconds, 57oC for 15 seconds and 70oC for 10 seconds. This cycle 
was repeated 45 times for all primers and tests. Samples were run in duplicate 
for each treatment and target. A melt curve was also performed from 60oC to 
95oC at 2oC steps to assess primer integrity. Controls genes used included IPO8 
(coding for nuclear import protein, which transports miRNA), TBP (coding for 
TATA-box binding protein; transcription factor) and RPL13A (coding for a 
ribosomal component), based on a study by Ledderose et al.  and 
recommendations from Doreen Cantrell’s laboratory, Dundee (Ledderose et al., 
2011). Results were analysed using DDCT method. Average of the three control 
genes was used to normalise the expression of the gene of interest to the 
housekeeping genes. Results of the control subjects and people with obesity 
were further normalised to their own basal expression.  
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2.8.1. ELISA Experimental set up 
MAIT cells were expanded and purified as per section 2.5.5, 2.6.1 and 2.6.2. Next 
MAIT cells were counted and plated at 1x106 per well, in 48 flat bottom well plate 
(Sarstedt) in a total volume of 1mL. To assess the metabolic requirements for 
MAIT cell function, cells were stimulated with TCR Dynabeads 1:1 bead to cell 
ratio (DynabeadsTM Human T activator CD3/CD28) (ThermoFisher Scientific) and 
with IL-12/IL-18 at 50ng/mL each (BioLegend) in the presence or absence of 2DG 
(10mM), Rapamycin (20nM) and CB-839 (10μM) in cRPMI for 24 hours. To 
investigate the requirement of amino acid transport via LAT1, cells were 
stimulated with TCR Dynabeads (DynabeadsTM Human T activator CD3/CD28) 

























(ThermoFisher Scientific) and with IL-12/IL-18 at 50ng/mL each (BioLegend) in 
the presence or absence of BCH (50mM) for 24 hours. For this experimental set 
up the 1mL volume of cells consisted of complete RPMI diluted 1:2 with HBSS. 
Following the 24-hour stimulation, the plate was spun at 300g for 10 minutes and 
900μL of the supernatant was collected and frozen. 
 
2.8.2. ELISA testing 
Prior to the testing all the reagents were resuspended as per manufacturer’s 
instructions for IFNγ, IL-17, IL-17F, IL-22, IL-32 ELISA kits (DuoSet ELISA 
development systems; R&D). Capture antibody was diluted to the required 
working concentration in PBS. NUNC-Immuno 96 well plate was immediately 
coated with 50μL of the diluted antibody per well (ThermScientific). The plate was 
sealed and incubated at room temperature overnight. As per figure 2.6, the 
following day the plate was washed with a wash buffer (PBS & 0.05% Tween20). 
Each well was filled with approximately 300μL of the wash solution. This process 
was repeated three times and was followed by gentle tapping of the plate against 
a clean towel to blot any residual fluid out of the wells. Every wash step in this 
protocol was performed as described here. Next the plate was blocked using 
150μL of reagent diluent (1% bovine serum albumin (BSA) in PBS; filtered) per 
well and incubated at room temperature for an hour. Next the standards and 
samples were prepared. Standard curve samples were prepared by adding 
appropriate amount of the reconstituted standard into a total volume of 1mL of 
reagent diluent to achieve the recommended concertation of top standard for 
each separate analyte measured. Next, a six-point serial dilution of the top 
standard was performed in reagent diluent and for the last standard point reagent 
diluent was used. If required, samples were diluted in reagent diluent in a 96 well 
plate. Following the blocking step, the plate was washed and blotted as descried 
above and 50μL of standards or samples was added to the appropriate wells. 
The plate was incubated in the fridge at 4oC overnight. Next day, the plate was 
washed, and the detection antibody was diluted to the recommended 
concentration. 50μL of the solution was added into all wells and the plate was 
incubated for two hours at room temperature and then washed. HRP-Avidin was 
diluted to the recommended concentration and 50μL of the solution was added 
into the wells. The plate was incubated at room temperature, protected from light 
for 20 minutes, which was followed by the wash step. Next TMB substrate 
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solution was prepared by adding equal volumes of Substrate A and Substrate B 
(BioLegend) and 50μL of the solution was added to the wells. The plate was 
incubated at room temperature protected from light up to 20 minutes and the 
reaction was stopped using 50μL of stop solution (1M Sulphuric acid) (Sigma-
Aldrich). The plate was lightly tapped to ensure mixing of the reagents. Optical 
density was determined using a microplate reader (ThermoFisher) and 
measurements were taken at 450nm and 540nm. Raw data was analysed in 
Prism 9 Software.  
Figure 2.6 ELISA steps. Diagram depicting steps involved in ELISA testing using 
R&D Duoset ELISA kit. Image created with BioRender. 
 
2.9. Seahorse 
2.9.1. Seahorse experimental set up 
MAIT cells were expanded and purified as per section 2.5.5, 2.6.1 and 2.6.2. 
Once successfully expanded, the cells were removed from the culture and plated 
in a 24 well plate at 2x106 per well in a total volume of 1mL. To investigate the 
glycolysis levels in control individuals and people with obesity, cells were plated 
in complete RPMI and stimulated with IL-12/IL-18 each at 50ng/mL and TCR 
microbeads at 25ng/mL (T cell Activation/Expansion kit, prepared as per 
manufacturer’s instructions) (Miltenyi Biotec) for 18 hours. To investigate the 
impact of inhibition of amino acid influx, the cells were plated in complete media 
which was diluted 1:2 with HBSS. To the inhibitor well, BCH (50mM) was added 
and the cells were stimulated as above.  
 
2.9.2. Seahorse protocol 
Seahorse XFe96 sensor cartridge (Agilent) was hydrated with 200µL per well with 
Seahorse XF Calibrant Solution (Agilent) and left at 37oC in a non-CO2 incubator 
for 18 hours prior to use. Seahorse XF phenol-free DMEM media, pH 7.4 (Agilent) 
was prepared by adding glucose and glutamine to final concentration of 10mM 
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and 2mM respectively. This media has limited buffering capacity, therefore is 
sensitive to any changes in the pH, which is used to calculate ECAR. Media was 
kept at 37oC. Next Cell-Tak (Agilent) for 96 well plate was prepared at a final 
concentration of 3.5μg/cm2. 2979μL of sodium bicarbonate (Sigma) at 0.1M pH8, 
16.7μL of cell-tak at 1.85mg/ml (Agilent), and 4.65μL of 1M sodium hydroxide 
(Sigma-Aldrich) were mixed and 25μL of the solution was added to each well of 
the XF96 cell culture microplates plate (Agilent). The plate was incubated for 20 
minutes at room temp. Next Oligomycin (Sigma), FCCP (Sigma), Rotenone 
(Sigma), 2DG (Sigma) inhibitors were prepared as per table 2.2 and kept on ice. 
Then, cells were harvested, counted and the exact number of cells was removed 
from each sample treatment. The cells were pelleted and washed twice in 500μL 
of pre-warmed seahorse DMEM media at pH 7.4 (Agilent) at 1800rpm for 8 
minutes and resuspended at 2x105 cells per 180μL of pre-warmed seahorse 
media. The cells-tak was washed with sterile deionised water (Baxter), by adding 
170-200μL of water into each well and aspirating water with p200 multichannel 
pipette. Ensure no droplets of water remain in the wells before proceeding. The 
samples were plated in quadruplicates at 2x105 cells per 180μL per well. 180μL 
of seahorse media was also added to all unused wells. The plate was spun at 
300g without break for 3 minutes and the wells were check under the microscope 
to ensure even monolayer of the cells in the wells. The plate was left in a non-
CO2 incubator, while the inhibitors were loaded into the injection ports of the 
sensor cartridge in the following order - oligomycin, FCCP, Rotenone, 2DG as 
per table 2.2, using template guide. The plate was calibrated on the Seahorse XF 
instrument (Agilent), the location of the sample wells was defined, and protocol 
was selected. The protocol used to run was defined as adding 4 injections of the 
inhibitors into the cells in the order of oligomycin, FCCP, Rotenone and 2DG. 
Once the calibration was completed, the plate with the cells was loaded onto the 
instrument. The results were exported into prism file and analysed in prism.  
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Table 2.2. Seahorse inhibitors injection. A table showing injection ports 
sequence and final concentrations of the inhibitors in the seahorse wells. 
2.10. Flow Cytometry 
2.10.1. MAIT cell glycolytic metabolism 
Isolated PBMC plated at 0.5-1x106 (depending on the experiment) in a 96 round 
bottom well plate (Sarstedt) in a total of 250μL of complete RPMI per well for 
analysis of MAIT cell metabolism associated proteins. To assess expression of 
GLUT1, CD98, HKII, LDHA and PKM2 and cells were incubated in the media 
alone (control) or with IL-12/IL-18 each at 50ng/mL and TCR microbeads at 
25ng/mL (T cell Activation/Expansion kit, prepared as per manufacturer’s 
instructions) (Miltenyi Biotec) or TCR Dynabeads 1:1 bead to cell ratio 
(DynabeadsTM Human T activator CD3/CD28) for 18 hours at 37oC. After 18 
hours, the cells were harvested and stained for flow cytometric analysis as per 
table 2.3 and section 2.10.5 or 2.10.6 using extracellular or extracellular and 
intracellular staining protocols.  
 
2.10.2. MAIT cell amino acid requirements for activation 
To assess MAIT cell cytokine production, PBMC were plated at 0.5-1x106 in a 96 
round bottom well plate (Sarstedt) in a total volume of 250μL. To investigate IFNγ 
production, PBMC were incubated in cRPMI with 12/IL-18 each at 50ng/mL and 
TCR Dynabeads 1:1 bead to cell ratio (DynabeadsTM Human T activator 
CD3/CD28) for 18 hours at 37oC in the presence of 1x of protein transport 
inhibitor cocktail (Brefeldin A and Monensin) (Invitrogen). To investigate the role 
of amino acid influx on MAIT cell metabolism and function, PBMC were plated as 
above in full media diluted 1:2 with HBSS for investigating the role of amino acid 
influx on MAIT cell metabolism and function. Cells were incubated in 
cRPMI:HBSS alone (control) or with IL-12/IL-18 (each 50ng/mL) and TCR 
microbeads at 25ng/mL (T cell Activation/Expansion kit, prepared as per 
manufacturer’s instructions) (MiltenyiBiotec) in the presence or absence of  BCH 
(50mM) for 18 hours at 37oC in the presence of the 1x of protein transport inhibitor 








Port A Oligomycin 20μM 180 20 2μM
Port B FCCP 10μM 200 22 1μM
Port C Rotenone 1.21μM 222 20 0.1μM
Port D 2DG 393mM 240 20 30mM
48 
cocktail (Brefeldin A and Monensin) (Invitrogen). After 18 hours, the cells were 
harvested for extracellular and intracellular flow cytometric staining.  
 
2.10.3. Expression of CD25  
To investigate the effect of MAIT cell activation on the high affinity IL-2 receptor 
(CD25) expression PBMC were plated at 0.5x106 in a 96 round bottom well plate 
(Sarstedt) in a total of 250μL of complete RPMI per well. Cells were incubated in 
the media alone (control) or were stimulated with TCR Dynabeads 1:1 bead to 
cell ratio (DynabeadsTM Human T activator CD3/CD28) or in combination with IL-
12/IL-18 (each 50ng/mL) and TCR Dynabeads in the presence or absence of 
2DG (10mM) for 18 hours at 37oC. After stimulation, the cells were harvested and 
stained for flow cytometric analysis as per table 2.3 and section 2.10.5 using 
extracellular staining protocols.  
 
2.10.4. Antibodies and panels used in this thesis 
Staining used in this thesis is detailed as per table 2.3. Whereas details of the 
clones of flow cytometric antibodies are detailed in table 2.4.  
 
Table 2.3. Flow cytometry panels for studying of MAIT cells 
 
BL1 YL1 YL4 RL1 RL3 VL1 VL2 VL4
Excitation laser (nm) 480 516 516 638 638 405 405 405
Emission filter (nm) 530/30 585/16 780/60 670/14 780/60 440/50 512/25 530/30
MAIT Purification Va7.2
MAIT Frequencies Va7.2 CD161* CD161* CD3
CTV CD3 Va7.2 CD161 CD8 CTV
Viability CD3 Va7.2 CD161 CD8 Viability dye
LDHA, GLUT1,HKII LDHA GLUT1 Va7.2 HKII CD161 CD3
PKM2 PKM2 Va7.2 CD161 CD3
CD98 CD98 Va7.2 CD161 CD3
pS6 pS6 MAIT Tetramer CD3
IFNγ IFNγ Va7.2 CD161 CD3
Kynurenine CD3 MAIT Tetramer Kynurenine
CD25 CD3 Va7.2 CD161 CD25
* CD161 APCCy7 used for only for IL-2 expansion experiments
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Table 2.4. Clones of antibodies used in this thesis 
 
2.10.5. Extracellular and intracellular staining in tubes 
Cells were harvested from the culture (between 0.5-1x106), transferred into 
labelled 5mls FACS tubes (BD Falcon) and washed in 1ml of stain buffer (PBS 
with 1% (v/v) FCS) at 1800 rpm for 8 minutes. The supernatant was removed, 
and the cell pellets were stained with the fluorochrome conjugated surface 
antibodies (as per table 2.3) as per recommendations. Cells were vortexed and 
incubated in a total volume of 100μL of stain buffer per test, at 4oC for 20-30 
minutes in darkness. Next, cells were washed as described above and fixed in a 
300μL of a 1X fix working solution (True-Nuclear Transcription Factor Buffer set) 
(BioLegend) vortexed and incubated for 30 minutes at 4oC. Then, 1mL of 1X 
Perm Buffer was added to the tubes (True-Nuclear Transcription Factor Buffer 
set) (BioLegend) and centrifuged at 1800 rpm for 10 minutes. If no further staining 
was required, the cells were resuspended in 300μL of staining buffer and ran on 
flow cytometer. If cells required intracellular staining, intracellular antibodies 
conjugated to the fluorochromes were added to the washed cells (as per table 
2.3), as per previous lab optimisation protocol, vortexed and incubated in a total 
volume of 100μL of 1X Perm Buffer (True-Nuclear Transcription Factor Buffer 
Antibody Fluorochrome Clone Manufacturer
V!7.2 PE-Vio770 REA179 Miltenyi Biotec
V!7.2 PE/Cyanine7 3C10 BioLegend
V!7.2 APC 3C10 BioLegend
CD161 APC REA631 Miltenyi Biotec
CD161 APC/Cyanine7 NKR-P1A BioLegend
CD8 APC-Vio770 REA734 Miltenyi Biotec
CD3 PE REA613 Miltenyi Biotec
CD3 VioGreen REA613 Miltenyi Biotec
CD3 PE-Vio770 REA613 Miltenyi Biotec
IFNγ FITC 45-15 Miltenyi Biotec
CD98 FITC Bright REA387 Miltenyi Biotec
GLUT1 PE EPR3915 Abcam
HKII AlexaFluor647 EPR20839 Abcam
LDHA AlexaFluor488 EP1563Y Abcam
PKM2 PE EPR10138(B) Abcam
pS6 PE REA454 Miltenyi Biotec
CD25 BV711 M-A251 BioLegend
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set) (BioLegend) per test, at 4oC for 30 minutes in darkness. Next, 1mL of stain 
buffer was added and the tubes were centrifugated at 1800rpm for 8 minutes. 
The pellet was resuspended in 300μL of stain buffer for flow cytometry analysis. 
Unstained and fluorescence minus one (FMO) controls were stained and ran with 
every experiment. The instruments used for analysis included AttuneNxT 
(Thermofisher). Data was analysed with FlowJo software. 
 
2.10.6. Extracellular and intracellular staining in plates 
Cells were removed from the culture plate (between 0.5-1x106 cells) and placed 
in a new 96 round bottom well plate for staining. The cells were centrifuged for 
5min at 1500rpm to remove media. Next 250μL of staining buffer was added to 
the wells and the cells were spun as detailed above. The fluorochrome 
conjugated surface antibodies were added to each well as per recommendations, 
in a total volume of 50-100μL staining volume, mixed well. The plate was 
incubated at 4oC for 20-30 minutes in darkness and was washed by adding 150-
200μL of staining buffer to the wells by spinning at 1500rpm for 5 minutes. The 
supernatant was discarded. The cells were fixed in 150μL of 1X fix working 
solution (True-Nuclear Transcription Factor Buffer set) (BioLegend) for 30 
minutes, at 4oC in darkness, and then 100μL of 1X Perm Buffer was added to the 
wells (True-Nuclear Transcription Factor Buffer set) (BioLegend) and centrifuged 
at 1500 rpm for 5 minutes and the supernatant was discarded. If no intracellular 
staining was required, cells were resuspended in 200μL of staining buffer, 
transferred to tubes, topped up to 300μL total volume and ran on flow cytometer. 
If staining for intracellular targets, after discarding the supernatant intracellular 
antibodies conjugated to the fluorochromes were added to the cells in a master 
mix of 100μL per well, which was made up in 1X Perm Buffer (True-Nuclear 
Transcription Factor Buffer set) (BioLegend). The plate was incubated at 4oC for 
30 minutes in darkness. Next 150μL of staining buffer was added into each well 
and the cells were spun at 1500rpm for 5minutes. The supernatant was removed, 
and the cell were resuspended in 200μL of staining buffer, next they were 
transferred to tubes, topped up to 300μL of staining buffer and ran on included 
AttuneNxT (ThermoFisher Scientific) with unstained and FMO controls. Data was 




2.10.7. Gating of MAIT cells 
PBMC isolated as per section 2.3 were stained for extracellular MAIT cell surface 
markers as per section 2.10.5 or 2.10.6 and table 2.3. First lymphocytes were 
identified and gated using forward and side scatter. Next doublets were excluded 
using FSC-area and FSC-height parameters (Figure 2.7). This allowed for further 
characterisation and identification of MAIT cells among the lymphocyte 
population using the specific fluorochrome bound antibodies and/or MAIT cell 
tetramer. MAIT cells were first identified by the positive expression of CD3, a 
surface T cell marker. From the CD3 positive population, MAIT cells were 
identified by their high expression of CD161 molecule and the co-expression of 
Vα7.2 TCR on their cell surface (Figure 2.7) or by binding to MAIT cell tetramer 
(Figure 2.8).  
Figure 2.7 MAIT cell identification using flow cytometric antibodies.  
Identification of MAIT cells using extracellular antibodies specific to CD3, CD161 





























Figure 2.8 MAIT cell identification using flow cytometric antibodies and 
MAIT cell tetramer. 
 
2.10.8. Viability staining 
Cells were stained with a fixable viability dye eFluorTM506 (FVD) (eBioscience, 
Invitrogen) prior to extracellular or intracellular staining. Cells (between 0.5-
1x106) were moved to a new 96 well round bottom plate for staining, spun at 
1500rpm for 5 minutes. The supernatant was removed, the cells were washed 
twice with 250µL of protein free and azide free PBS by centrifugation at 1500 rpm 
for 5 minutes and the supernatant was decanted. FVD dye was diluted 1:1000 in 
PBS and the cells were quickly resuspended in 100µL of the working solution. 
The plate was incubated in the refrigerator, protected from light for 30 minutes. 
Next the cells were washed twice with 150µL of flow staining buffer, centrifuging 
at 1800rpm for 5 minutes. After this step, other antibody-based flow cytometry 
staining was performed as per section 2.10.6. 
 
2.10.9. Kynurenine Assay 
Kynurenine (Sigma) stock of 800µM was made up fresh in HBSS. 2 aliquots of 
the stock were prepared where 1 was kept at 37oC whereas the other was kept 
at 4oC. Also, 2 aliquots of HBSS were prepared and kept at 37oC or 4oC prior to 
the beginning of the assay. Cryopreserved cells or expanded MAIT cells were 
counted as per section 2.4. First, 1x106 cells per condition were stained with 
extracellular flow cytometry antibodies (without the fixation and permeabilisation 
step) as per section 2.10.5. After staining, cells were resuspended in 200µL per 


















cold HBSS and kept on ice. For the first control, cells and the reagents were kept 
at 37oC. To the 200µL of cells, 200µL of HBSS was added and kept at 37oC. For 
the second control, cell and reagents were kept at 4oC. To the 200µL of cells, 
100µL of HBSS and 100µL of kynurenine was added and kept at 4oC. For 
kynurenine uptake, cells and reagents were kept at 37oC. 100µL of Kynurenine 
and 100µL of HBSS were added to the 200µL of the cells and kept at 37oC. To 
investigate the effect of BCH on kynurenine uptake, cells and reagents were kept 
at 37oC. 100µL of HBSS, 100µL of Kynurenine and 100µL of BCH at 25mM was 
added to the 200µL of the cells. The addition of the warm reagents was performed 
sequentially in the water bath, whereas the addition of the cold reagents was 
performed on ice at the same time. The cells and reagents were incubated for 4 
minutes and the reaction was stopped by adding 125µL of 4% paraformaldehyde 
(PFA) (Sigma) and incubated for further 30 minutes at room temperature 
protected from light.  Next the cells were washed twice in PBS buffer with 0.5% 
of BSA and resuspended in 300µL of the buffer for flow cytometry. Kynurenine 


















3.1.1. MAIT cells 
MAIT cells are a non-classical subset of T lymphocytes in humans. To date, MAIT 
cells have been identified at multiple sites, including the liver, where they 
comprised up to 45% of total T cells (Dusseaux et al., 2011), and peripheral blood 
where they represent up to 10% of circulating T cells (Gherardin et al., 2018b; Le 
Bourhis et al., 2010). In humans, MAIT cells were also found in lungs, female 
reproductive tract, skin or adipose tissue (Carolan et al., 2015; Gibbs et al., 2017; 
Hinks et al., 2016). Peripheral blood MAIT cells are typically CD8+ or double 
negative, with a very small population expressing CD4 (Gherardin et al., 2018b; 
Kurioka et al., 2017; Walker et al., 2012). They also display an effector-memory 
phenotype, as identified by the lack of CCR7, CD62L, CD45RA (Dusseaux et al., 
2011; Gold et al., 2013).  
 
MAIT cells are defined by the expression of a highly conserved, semi-invariant 
ab T cell receptor, which is accompanied by high expression of CD161 (C-type 
lectin-like receptor) molecules (Dusseaux et al., 2011; Lepore et al., 2014; 
Porcelli et al., 1993; Tilloy et al., 1999). In humans, the alpha chain is composed 
of TRAV1-2 (Va7.2) and TRAJ33/12/20 (Ja33/12/20) (Va19- Ja33 in mice) and 
is paired with a limited number of beta chains (Lepore et al., 2014; Porcelli et al., 
1993; Tilloy et al., 1999). The confined TCR repertoire indicates a narrow antigen 
range, suggesting that MAIT cell response can be very rapid. The alpha chain 
rearrangement was first identified by Porcelli et al.in 1993, during analysis of TCR 
expression by human peripheral blood CD4- CD8- cells (Porcelli et al., 1993). 
Later Tilloy et al. described a homologous Va7.2-Ja33 in the murine T cell 
repertoire, suggesting that this TCR receptor is highly conserved among species 
(Tilloy et al., 1999). The MAIT cell TCR recognises MR1, another highly 
conserved molecule across species. MR1 is associated with B2-microglobulin 
and is expressed by antigen presenting cells or epithelial cells (Gold et al., 2010; 
Treiner et al., 2003; Yamaguchi and Hashimoto, 2002). The type of ligand 
presented by the MR1 molecule remained unknown for a long time, however 
some studies have suggested they are expressed during microbial infections 
(Gold et al., 2010; Le Bourhis et al., 2010). Landmark study by Kjer-Nielsen et al. 
in 2012 finally revealed that MR1 presents non-peptide antigens to MAIT cells, 
which were identified as vitamin B metabolites produced by various strains of 
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bacteria (Kjer-Nielsen et al., 2012). During that study, the primary ligand which 
bound to MR1 molecule was named as 6-formyl pterin (6-FP), a derivative of folic 
acid. Binding of 6-FP to MR1 lead to increase in the expression of the antigen 
presenting complex on the cell surface, but it didn’t induce MAIT cell activation 
(Kjer-Nielsen et al., 2012). Upon closer investigation of the riboflavin 
biosynthesis, it’s precursor 5-A-RU was pinned as the key intermediate, which 
induced MAIT cell activation. Free amine of 5-A-RU binds non-enzymatically to 
methylglyoxal, metabolite of glycolysis, to form a more potent 5 OP-RU antigen. 
5 A-RU can also bind with glyoxal to form less potent 5-(20oxoethyludeneamino)-
6-D-ribitylaminouracil (5-OE-RU) (Corbett et al., 2014). Riboflavin is synthesised 
by certain bacteria and yeast such as Staphylococcus or Candida species, but 
not by humans, making it a unique antigen capable of inducing a response to 
variety of microbial infections (Le Bourhis et al., 2010). Up to date, a limited 
number of other MAIT cell antigens have been identified. Some drugs were found 
to bind to the MR1 molecule such as derivatives of salicylic acid or metabolites 
of an anti-inflammatory drug diclofenac but these have limited effects on MAIT 
cell activation (Keller et al., 2017). Activation of MAIT cells via their engagement 
with MR1 has been shown to be indispensable during infections with riboflavin 
synthesising microorganisms (Figure 3.1). This has been elegantly shown by Le 
Bourhis et al. during infection with E. coli, where addition of anti-MR1 antibodies, 
prevented MAIT cell activation (Le Bourhis et al., 2010).   
 
MAIT cells are activated independently of their TCR via cytokine stimulation 
(Figure 3.1). Indeed, MAIT cells were shown to express a variety of cytokine 
receptors including IL-2R, IL-7R, IL-12R, IL-15R, IL-18R and IL-23R, suggesting 
they can respond to a range of stimuli (Figure 3.2) (Dusseaux et al., 2011; Gracey 
et al., 2016; Sattler et al., 2015; Wallington et al., 2018; H. Wang et al., 2019; 
Wilgenburg et al., 2018). Study by Ussher et al. and van Wilgenburg et al. 
reported that MAIT cells stimulated by IL-12 or IL-18 alone do not modulate 
expression of IFNγ, however combination of these cytokines enhanced 
production IFNγ (Ussher et al., 2014; Van Wilgenburg et al., 2016). Van 
Wilgenburg et al. has explored the effect of a larger number of cytokines on IFNγ 
production by MAIT cells. They found that incubation of the cells with a 
combination of IL-12 and IL-15 led to similar IFNγ production as the IL-12/IL-18 
stimulation, whereas combination of IFN-a or -b with IL-12, IL-15 or IL-18 led to 
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variable results (Van Wilgenburg et al., 2016). MAIT cells were also shown to be 
activated independently of TCR engagement in a mouse study, which 
investigated the role of MAIT cells in influenza infections (Wilgenburg et al., 
2018). MR1 deficient mice who received adoptive transfer of MAIT cells have 
shown no significant difference in their activation in comparison to the wild type 
mice, whereas deletion of receptors for IL-12, IL-18, IL-15 and IFNa cytokines 
significantly impacted MAIT cell activation (Wilgenburg et al., 2018). TCR 
independent activation of MAIT cells is very beneficial in response against 
pathogens, which don’t produce antigens recognised by these cells. These 
include viruses or bacteria and yeast which don’t use riboflavin synthesis 
pathway. Due to this mechanism, MAIT cell can provide a much greater 
protection to the host. Although MAIT cells can be activated in a TCR dependent 
or independent manner, it is very likely that in vivo they combine both signals 
where available, to reach their full effector capacity. Studies in vitro have shown 
that stimulation of MAIT cells using TCR and cytokine stimulation can enhance 
their activation. For example, Gracey et al. have shown that MAIT cells primed 
with IL-7 prior to TCR stimulation significantly enhanced their cytokine and 
granzyme B production (Gracey et al., 2016). 
Figure 3.1. MAIT cell activation. MAIT cells can be activated via TCR-
dependent or independent manner. This results in MAIT cell proliferation and 
production of effector molecules such as cytokines and cytotoxic mediators 
(Pisarska et al., 2020). 
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PLZF is crucial transcription factor required for the innate function and cytokine 
production of MAIT cells, however it is co-expressed with multiple other 
transcription factors including RORγT governing type17 response; T-bet, 
Eomesodermin (Eomes) and B-lymphocyte-induced maturation protein -1 (Blimp-
1) associated with Type 1 immunity and CAAT/enhancer-binding protein gamma 
(C/EBPδ) required for the expression of appropriate tissue homing molecules 
(Koay et al., 2016; C. H. Lee et al., 2018; Leeansyah et al., 2015) (Figure 3.2). In 
contrast to T cells, MAIT cell RORγT and T-bet were shown to be co-expressed 
(Kurioka et al., 2015; Leeansyah et al., 2015). Expression of T-bet implicated that 
MAIT cells might engage in type 1 immune response by producing IFNγ. Upon 
stimulation MAIT cells indeed significantly upregulated their IFNγ production 
(Dusseaux et al., 2011; Van Wilgenburg et al., 2016). Similarly, to CD8 T cells, 
activation of MAIT cells led to higher expression of cytotoxic proteins, which in T 
cells were controlled by T-bet, Eomes and Blimp-1 transcription factors. Upon 
stimulation MAIT cells produced granzyme B, granzyme A, granzyme K and 
perforin (Dusseaux et al., 2011; Kurioka et al., 2015; Van Wilgenburg et al., 
2016), whereas granulysin was expressed but the levels were not modified upon 
activation (Le Bourhis et al., 2013; Sobkowiak et al., 2019). This indicates direct 
killing capabilities of MAIT cells. Indeed, MAIT cells primed with E. coli were 
shown to kill antigen presenting cells infected with this microorganism in an MR1 
dependent manner (Kurioka et al., 2015). MAIT cells also expressed RORγT and 
IL-17, markers typical for type 17 phenotype (Dusseaux et al., 2011; Hinks et al., 
2019; Lamichhane et al., 2019). IL-17 is a major pro-inflammatory cytokine, 
implicated in multiple immune mediated diseases. It was originally identified as a 
cytokine produced by the cells of the adaptive system, namely Th17 cells, 
however as new data emerged, it became clear that MAIT cells also contribute to 
the production of IL-17 in many inflammatory diseases (Pisarska et al., 2020). 
Similarly, to conventional T cells, MAIT cells express IL-23R, which is known to 
facilitate IL-23 signalling and differentiation of cells towards type 17 profile. It is 
not yet fully understood whether IL-23 may contribute to the transition of MAIT 
cells to type 17 cells, however IL-23 acts directly on the cells and enhances their 
proliferation (Raychaudhuri et al., 2020; H. Wang et al., 2019). Other less 
described cytokines expressed by MAIT are IL-17F and IL-22, of which both are 
members of the IL-17 family. Lu et al. who investigated the role of MAIT cells in 
pneumonia in children, have reported higher expression of IL-17F producing 
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MAIT cells in the samples of bronchial lavage versus blood in children with 
infection (Lu et al., 2020). On the other hand, Gibbs et al. identified IL-17 and IL-
22 producing MAIT cells in mucosa of the female genital tract and suggested this 
phenotype may be protective against microbial infections (Gibbs et al., 2017). 
Figure 3.2. Phenotype of MAIT cells. MAIT cells express Vα7.2 TCR receptor 
which is accompanied by a range of cytokine and chemokine receptors. In 
addition, they express a combination of transcription factors and cytokines which 
are typical for responses of Th1, Th17 and innate cells (Pisarska et al., 2020).  
 
Activation of MAIT cells has been shown to induce their expansion and 
proliferation, although the data is still very limited. Studies which have 
investigated MAIT cell responses in bacterial infections, reported that MAIT cells 
are capable of expansion upon activation (Howson et al., 2018; Wong et al., 
2019). Howson et al. has shown that during infection of human subjects with S. 
enterica, MAIT cells displayed clonal expansion which was followed by a 
contraction phase (Howson et al., 2018). Similar findings were reported by Wong 
et al. who investigated the impact of M. Tuberculosis on MAIT cell function and 
has shown an oligoclonal expansion of MAIT cells in response to the infection 
(Wong et al., 2019). Other studies measured MAIT cell proliferation using Ki67 
marker in order to compare their activation and have shown that MAIT cells from 
individuals with IBD or liver cirrhosis displayed more proliferative in comparison 
to healthy controls (Hegde et al., 2018; Serriari et al., 2014). Recently, Gutierrez-
Arcelus et al. have shown that MAIT cells can proliferate in response to 
CD3/CD28 bead stimulation over 5 days of culture as depicted by 
carboxyfluorescein succinimidyl ester (CFSE) assay (Gutierrez-Arcelus et al., 
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2019). Up to date, the control of MAIT cell expansion and proliferation has not 
been explored in detail. 
 
3.1.2. MAIT cells in obesity 
The impact of obesity on MAIT cell phenotype and function still remains largely 
unexplored. As new studies emerged, it became more evident that obesity is 
associated with alterations in MAIT cell distribution and a switch to more pro-
inflammatory phenotype. Magalhaes et al. and Carolan et al. who assessed MAIT 
cells in the peripheral blood of people with obesity, revealed a significant 
decrease in their frequencies in comparison to the control individuals, whereas 
study by Li et al. reported no difference in the percentage of MAIT cells between 
the two groups (Carolan et al., 2015; Li et al., 2020; Magalhaes et al., 2015). The 
inconsistency in the frequencies reported by these studies may be due to the 
difference in the BMI in the cohorts of people with obesity. Cohorts used by 
Magalhaes et al. and Carolan et al. had much higher BMI than the subjects used 
in the study by Li et al. In fact, frequencies of MAIT cells were shown to be 
negatively correlated with BMI, where in some people with obesity MAIT cells 
have not been detected (Magalhaes et al., 2015), however this requires further 
investigation as Carolan et al. reported no association between those two 
parameters (Carolan et al., 2015). People with obesity who underwent bariatric 
surgery, were shown to increase the population of their MAIT cells in the 
peripheral blood, suggesting that this defect is reversible upon weight loss 
(Magalhaes et al., 2015). 
 
In addition, MAIT cells from people with obesity were shown to be largely 
dysfunctional and displayed dysregulation in the proportion of the produced 
cytokines. Carolan et al. reported a decrease in the IFNγ expression by peripheral 
blood MAIT cells from people with obesity, whereas other studies have shown no 
apparent defect in the production of this cytokine (Carolan et al., 2015; 
Magalhaes et al., 2015; Toubal et al., 2020). In contrast, peripheral blood and AT 
MAIT cells from people with obesity displayed strongly enhanced IL-17 
production in comparison to the control individuals (Carolan et al., 2015; 
Magalhaes et al., 2015; O’Brien et al., 2020). Similar results were obtained in a 
mouse study by Toubal et al. where high-fat diet (HFD) mice had a higher 
proportion of IL-17 producing MAIT cells in the ependymal fat in comparison to 
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mice fed on normal diet (Toubal et al., 2020). Collectively this suggests that MAIT 
cells from people with obesity may have a defect in the production of IFNγ, 
however the enhancement in IL-17 may be contributing to the inflammation 
observed in obesity. Indeed Toubal et al. has demonstrated a close relationship 
between MAIT cells and macrophages, which are present in the AT (Toubal et 
al., 2020). Coculture of MAIT cells with M1 macrophages, significantly enhanced 
MAIT cell IL-17 production, whereas activated MAIT cells promoted polarisation 
of macrophages into M1 phenotype (Toubal et al., 2020). This mechanism may 
possibly be contributing to the sustained AT inflammation observed in obesity. 
Although gut dysbiosis has been reported in people with obesity, very little is 
known about possible causes and mechanisms which are involved in the 
development of this condition (Boulangé et al., 2016; Muscogiuri et al., 2019). 
Recently, Toubal et al. has shown that MAIT cells contribute to the alteration in 
the gut microbiota. In HFD mice, MAIT cells were shown to increase gut 
inflammation and leakiness, whereas transfer of the microbiota from HFD mice 
induced dysfunction of the mucosa, leakiness of the gut and enhanced 
inflammation of the gut in the recipient mice (Toubal et al., 2020).  
 
As immunometabolism became a focal point of many immunological studies, a 
recent study focused on the relationship between MAIT cell metabolism and their 
dysfunction in obesity. O’Brien et al. have shown that MAIT cells from people with 
obesity had elevated levels of mitochondrial reactive oxygen species (mROS) 
and mitochondrial membrane potential in comparison to the lean controls. 
Reducing mROS using MitoTEMPO and MitoQ antioxidants, was shown to 
reduce IL-17 production by MAIT cells from people with obesity, suggesting that 
metabolic alterations in MAIT cells may be contributing to their dysfunction 
(O’Brien et al., 2020).  
 
These studies show that obesity significantly affects MAIT cell frequencies and 
function in the peripheral blood as well as other tissues including AT. The 
alterations in their phenotype are shown to support systemic inflammation in 
obesity, which may further lead to development of conditions such as T2DM. 
More studies are required to elucidate the causes of the altered MAIT cell function 
and to identify potential targets for treatment to ameliorate their pro-inflammatory 
responses in obesity and regain homeostasis.   
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3.2. Specific aims of this chapter 
 
The specific aim of this chapter was the characterisation of MAIT cells in cohorts 
of adults with a healthy or obese BMI, and therefore to: 
1. Enumerate MAIT cell frequencies in peripheral blood  
2. Determine the proliferative capacity of MAIT cells  





3.3.1. MAIT cell identification 
MAIT cells have been previously reported to represent 1-10% of peripheral blood 
T cells in healthy individuals (Carolan et al., 2015; Gherardin et al., 2018b; Le 
Bourhis et al., 2010). To confirm their frequencies in the peripheral blood of our 
cohorts of adults with a healthy or obese BMI we utilized multi-colour flow 
cytometry.  
 
The gating strategy used to identify MAIT cells is shown in materials and methods 
figure 2.7. Briefly, PBMC isolated from control individuals were stained using 
antibodies against surface antigens conjugated to appropriate fluorochromes 
namely CD3 (VioGreen), CD161 (APC) and Vα7.2 (PeCy7). To identify MAIT 
cells, we first selected lymphocytes based on their morphology (forward and side 
scatter), next doublets were excluded using forward scatter (FSC)-area and FSC-
height parameters. Finally, MAIT cells were first identified by the positive 
expression of CD3, high expression of CD161 molecule and the co-expression of 
Vα7.2 TCR on their cell surface (Figure 3.3 A&B). MAIT cell frequencies in the 
cohort of control individuals ranged from 0.53% to 13.7% and displayed a mean 
of 3.2% (Figure 3.3 A&B). 
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Figure 3.3 MAIT cell identification using flow cytometry. (A) Scatter plot of 
MAIT cell frequencies in the peripheral blood of control individuals (n=39). (B) 
Representative dot plots showing MAIT cells from 3 control individuals as 














































3.3.2. People with obesity display lower MAIT cell frequencies in the 
peripheral blood 
Previous work from our lab and others has shown obesity related alterations in 
the frequencies and functions of a range of immune cells, including MAIT cells 
(Carolan et al., 2015; Magalhaes et al., 2015). After establishing the range of 
MAIT cell frequencies in the control individuals (Figure 3.3), next we investigated 
the frequencies of these immune cells in people with obesity.  
 
People with obesity had significantly lower frequencies of MAIT cells in the 
peripheral blood, in comparison to the control individuals (Figure 3.4). MAIT cell 
frequencies in people with obesity ranged from 0.11% to 4.9% and had a mean 
of 1.2%.  This data is in line with previously published studies, which have shown 
a significant decrease in circulating MAIT cells in people with obesity (Carolan et 
al., 2015; Magalhaes et al., 2015).  
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Figure 3.4 MAIT cell frequencies in control subjects and individuals with 
obesity. (A) Scatter plot of MAIT cell frequencies in peripheral blood of control 
individuals (n=39) and individuals with obesity (n=19). Representative dot plots 
showing MAIT cell frequencies of (B) two control and (C) two obese individuals 
as percentage of CD3+ cells. MAIT cells identified as V𝛼7.2+ and CD161hi. 
Statistical analysis performed using unpaired student’s t-test, ** p≤0.01. 
  
BP66 Pre expansion D0.fcs
Ungated
219384
BP66 Pre expansion D0.fcs
Single Cells
49805
BP66 Pre expansion D0.fcs
Ungated
219384


























































































































BP66 Pre expansion D0.fcs
Ungated
219384
BP66 Pre expansion D0.fcs
Single Cells
49805
BP66 Pre expansion D0.fcs
Ungated
219384





































































































3.3.3. TCR stimulation induces MAIT cell proliferation 
Proliferation of lymphocytes plays a crucial role in response to microbial 
infections. MAIT cell proliferation remains largely unexplored and to date very 
little evidence is recorded in the literature. Recently, Gutierrez-Arcelus et al. 
investigated the function and proliferation of multiple innate immune cells 
including MAIT cells and suggested that innate immune cells are capable of 
proliferation in response to TCR stimulation, albeit to a much lower extend than 
cells of the adaptive immune response (Gutierrez-Arcelus et al., 2019). The 
proliferation capacity of MAIT cells was also demonstrated in a study by Howson 
et al.. This group utilised an in vivo approach of controlled infection in humans 
with S. Paratyphi A. They found that at the peak of infection, MAIT cells from the 
peripheral blood of the participants were in a state of proliferation, which they 
measured by Ki67 (Howson et al., 2018). Although the proliferation capacity of 
MAIT cells has been identified in response to a general stimulation, we decided 
to explore MAIT cell proliferation in response to the MAIT cell specific antigen, 5-
ARU in combination with MG. 5-ARU has been identified as an intermediate in 
the riboflavin metabolism pathway, and was shown to combine with MG, a by-
product of glycolysis to form a highly 5-OP-RU (Corbett et al., 2014).  
 
MAIT cell expansion was assessed by investigating the proportion of MAIT cells 
expressed as percentage of all T cells present in the culture five days after 
activation. Stimulation of PBMC with 5-ARU-MG resulted in very limited, non-
significant expansion of MAIT cells by day five (Figure 3.5 A&B). To investigate 
this further, MAIT cell proliferation was also assessed using CTV proliferation 
assay. CTV is a fluorescent dye, which allows the traceability of cell proliferation, 
through dye dilution and analysis using flow cytometry. CTV stained PBMC were 
activated with 5-ARU-MG and incubated for 5 days. Although the expansion of 
MAIT cells was shown to be limited (Figure 3.5 A&B), CTV proliferation assay 
revealed that MAIT cells were dividing (Figure 3.5 C&D). This data demonstrates 
that in response to a pathogen derived antigen MAIT cells display limited 
expansion, but enhanced proliferation However, the modest increase in the 
proportion of MAIT cells in the culture suggests limited capability to expand in this 
experimental setting, possibly due to the lack of other signals which could be 
originating from other immune and non-immune cells during active bacterial 
infection.  
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Figure 3.5 MAIT cells proliferate in response to 5-ARU-MG. (A) Scatter plot 
of MAIT cell proliferation from control subjects represented as a percentage of 
CD3+ population. (B) Data depicts MAIT cells prior to proliferation (pre-
proliferation) and on day 5 of proliferation. PBMCs were unstimulated (pre-
proliferation) or stimulated (day 5) with 5-ARU (1μg/mL) and MG (100μL) (C) 
Scatter plot and (D) representative histograms of MAIT cell proliferation as 
measured by the uptake and dilution of CTV (5μM). Data depicts CTV uptake 
prior to expansion (pre-proliferation) and on day 5 of culture. Statistical analysis 
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Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP101 5 ARUMG DYE no IL2.fcs MAIT cells 668 24026 
BP101 Max(1).fcs MAIT cells 867 122757 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP102 5 ARUMG DYE no IL2.fcs MAIT cells 580 14307 
BP102 Max.fcs MAIT cells 1119 114856 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP103 5 ARUMG DYE no IL2.fcs MAIT cells 441 27277 








































3.3.4. TCR triggering upregulates expression of IL-2 receptor on MAIT cell 
surface 
Stimulation of MAIT cells has been shown to enhance the expression of multiple 
cytokine and chemokine receptors such as IL-2R, IL-12R, IL-18R, CCR2, CCR4 
or CCR6 (Chen et al., 2019; C. H. Lee et al., 2018; Sattler et al., 2015; Van 
Wilgenburg et al., 2016). Binding of the specific ligands to their receptors can 
shape the immune response to achieve the optimal protection of the host. IL-2 is 
known to be an immunomodulatory cytokine that can regulate multiple processes 
in immune cells such as controlling the fate of CD4+ T cell differentiation, 
modulation of CD8+ T cell function as well as T cell proliferation (Ross and 
Cantrell, 2018). In the context of MAIT cell proliferation, next we investigated 
whether stimulation of MAIT cells through TCR alone or in combination with IL-
12/IL-18 cytokines for 18 hours can induce high affinity IL-2 receptor (IL-
2R/CD25) expression on MAIT cell surface. TCR triggering alone was sufficient 
to significantly enhance IL-2R expression on MAIT cell surface (Figure 3.6 A&B). 
Addition of IL-12 and IL-18 in combination with TCR stimulation further enhanced 
IL-2R expression in comparison to TCR stimulation alone (Figure 3.7 A&B). This 
data demonstrates a TCR-mediated increase in the expression of IL-2R, which 
might facilitate the engagement of MAIT cells in proliferation. 
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Figure 3.6 TCR stimulation of MAIT cells increases IL-2 receptor (CD25) 
expression. (A) Scatter plot and (B) representative histograms of CD25 (IL-2R) 
expression by MAIT cells from control individuals, basally or upon stimulation with 
TCR Dynabeads (1:1 bead to cell ratio) for 18 hours. Statistical analysis 
performed using paired student’s t-test, ***p≤0.001. 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP110 DYNA.fcs MAIT cells 600 9163 
BP110 BASAL.fcs MAIT cells 688 292 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP111 DYNA.fcs MAIT cells 2210 6532 
BP111 BASAL.fcs MAIT cells 3098 28.4 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP110 DYNA.fcs MAIT cells 600 9163 
BP110 BASAL.fcs MAIT cells 688 292 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP111 DYNA.fcs MAIT cells 2210 6532 
BP111 BASAL.fcs MAIT cells 3098 28.4 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
N008 DYNA.fcs MAIT cells 1261 3703 
N008 BASAL.fcs MAIT cells 1368 -2138 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
N006 DYNA.fcs MAIT cells 1149 3230 



































Figure 3.7 TCR triggering in combination with IL-12 and IL-18 cytokine 
stimulation enhances expression of IL-2 receptor (CD25) by MAIT cells. (A) 
Scatter plot and (B) representative histograms of CD25 expression by MAIT cells 
from control individuals, basally, upon stimulation with TCR Dynabeads (1:1 bead 
to cell ratio) with or without IL-12/IL-18 (50ng/mL each) for 18 hours. . Statistical 
analysis performed using paired student’s t-test, **p≤0.01. 
  
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP115 DYNA1218.fcs MAIT cells 651 12713 
BP115 DYNA.fcs MAIT cells 810 3839 
BP115 BASAL.fcs MAIT cells 934 -3575 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
N008 DYNA.fcs MAIT cells 1261 3703 
N008 BASAL.fcs MAIT cells 1368 -2138 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
N006 DYNA1218.fcs MAIT cells 1281 7095 
N006 DYNA.fcs MAIT cells 1149 3230 
N006 BASAL.fcs MAIT cells 1539 -2957 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP113 BASAL.fcs MAIT cells 1465 -4219 
BP113 DYNA1218.fcs MAIT cells 1036 4367 



















































3.3.5. IL-2 supplementation enhances MAIT cell proliferation and expansion 
Stimulation of MAIT cells via their TCR was shown to induce MAIT cell 
proliferation with a limited expansion (Figure 3.5) and a significant upregulation 
of IL-2R (Figure 3.6). To further investigate the proliferative capabilities of MAIT 
cells, we investigated the effect of exogenous IL-2 supplementation in 
combination with 5-ARU-MG activation on MAIT cell proliferation and expansion. 
Activation of PBMC with 5-ARU-MG and supplementation with exogenous IL-2 
over a period of 28 days resulted in the significant expansion of MAIT cells from 
day 7 onwards (Figure 3.8 A&B). Expansion of MAIT cells peaked around day 11 
after initial stimulation, which was followed by a period of contraction, where 
despite IL-2 supplementation, the percentage of MAIT cells in the culture 
decreased (Figure 3.8 A&B). To confirm this further, MAIT cell proliferation was 
also assessed using CTV, where stained PBMC were stimulated with 5-ARU-MG 
and IL-2 for five days. It was confirmed that MAIT cells were capable of significant 
proliferation over a five-day period in the presence of exogenous IL-2, where 
between five and six generations could be identified with CTV (Figure 3.9). This 
suggests that additional factors such as IL-2, which may be produced during 





































































































Figure 3.8 MAIT cells expand in response to 5-ARU-MG and IL-2 over 28 
days. (A) Representative dot plots of MAIT cell proliferation from 3 control 
subjects observed over 28 days of culture in response to 5-ARU-MG and IL-2. 
PBMCs were stimulated with 5-ARU (1μg/mL) and MG (100μL) on day 0 and fed 
with a low dose of IL-2 (6.75ng/mL) on day 1 followed by high doses of IL-2 
(33.3ng/mL) on days 4, 7, 11, 14,18 and 21. (B) Scatter plot of MAIT cell 
expansion from control subjects (n=10; n=6 on day 14) over 28 days of culture. 
Statistical analysis performed using one-way ANOVA with Tukey’s correction, 
















































Figure 3.9 MAIT cells proliferate in response to 5-ARU-MG and IL-2. (A) 
Scatter plot of MAIT cell proliferation as measured by uptake and dilution of Cell 
Trace Violet (CTV) at 5μM, on day 0 and day 5 of culture. PBMCs were 
unstimulated (pre-proliferation) or stimulated (day 5) with 5-ARU (1μg/mL) and 
MG (100μL) on day 0 and received a low dose of IL-2 (6.75ng/μL) on day 1 
followed by a high dose of IL-2 (33.3ng/μL) on day 4 (n=11). (B) Representative 
histograms from 3 control subjects of MAIT cell proliferation over 5 days of 
culture. Statistical analysis performed using paired student’s t-test, ****p<0.0001. 
  
A. B.
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP68 5ARUMG + DYE D5.fcs MAIT cells 1874 4415 






Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP69 5ARUMG + DYE D5.fcs MAIT cells 17078 2484 
BP69 Max D0.fcs MAIT cells 2234 104459 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP70 5ARUMG + DYE D5.fcs MAIT cells 8128 2255 




































3.3.6. MAIT cells from people with obesity display limited expansion 
capacity in response to 5-ARU-MG and IL-2 
It is now well established that people with obesity have reduced frequencies of 
peripheral blood MAIT cells (Figure 3.4) (Carolan et al., 2015; Magalhaes et al., 
2015). In addition to reduction in the frequencies, MAIT cells from people with 
obesity were shown to have impaired function as assessed by their cytokine 
production. However, up to now no one has investigated whether the proliferative 
capacity of MAIT cells in these individuals is affected (Carolan et al., 2015; 
Magalhaes et al., 2015).  
 
To assess expansion of MAIT cells from individuals with obesity and control 
subjects over 28 days, PBMC were treated as described in section 3.3.5. MAIT 
cell expansion from individuals with obesity was significantly lower in comparison 
to control individuals (Figure 3.10 A&B). To confirm this further, we stimulated 
PBMC from people with obesity and control individuals with 5-ARU-MG and IL-2 
over 7 days and determined their fold expansion. MAIT cells from people with 
obesity displayed significantly lower fold increase at days 7 after cell activation, 
further indicating a defect in MAIT cell expansion in people with obesity (Figure 
3.10 C). To investigate this in more detail, MAIT cell proliferation was measured 
using CTV assay as described in section 3.3.5 and has shown no significant 
difference in proliferation rates of MAIT cells between people with obesity and 
control individuals (Figure 3.11 A&B). This data suggests that the expansion 
capacity of MAIT cells from people with obesity is impaired, but their proliferation 











































































































Figure 3.10 MAIT cells from people with obesity show impaired expansion 
in response to 5-ARU-MG and IL-2. (A) Representative dot plots of MAIT cell 
expansion from 3 individuals with obesity, observed over 28 days of culture in 
response to 5-ARU-MG and IL-2. PBMCs were stimulated with 5-ARU (1μg/mL) 
and MG (100μL) on day 0 and received a low dose of IL-2 (6.75ng/μL) on day 1 
followed by high doses of IL-2 (33.3ng/μL) on days 4, 7, 11, 14, 18 and 21 (B) 
Scatter plots of control (n=10) and people with obesity (n=5) expansion over 28 
days of culture. (C) Scatter plot of MAIT cell fold expansion of control subjects 
(n=8) and people with obesity (n=8) over 7 days of culture. Statistical analysis 
performed using one-way ANOVA with Tukey’s correction or unpaired student’s 



























































Figure 3.11 MAIT cells from people with obesity show similar proliferation 
profile in response to 5-ARU-MG and IL-2. (A) Scatter plot of MAIT cell 
proliferation as measured by uptake and dilution of Cell Trace Violet (CTV) at 
5μM, on day 0 and day 5 of culture from control individuals (n=11) and people 
with obesity (n=5). PBMCs were unstimulated (pre-proliferation) or stimulated 
(day 5) with 5-ARU (1μg/mL) and MG (100μL) on day 0 and received a low dose 
of IL-2 (6.75ng/μL) on day 1 followed by a high dose of IL-2 (33.3ng/μL) on day 
4. (B) Representative histograms from 2 control and 2 subjects with obesity of 
MAIT cell proliferation over 5 days of culture. Statistical analysis performed using 




OSA015 5 ARUMG DYE.fcs
MAIT cells
846
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
OSA015 5 ARUMG DYE.fcs MAIT cells 846 4880 
OSA015 Max.fcs MAIT cells 280 85092 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
OZ7 5ARUMG DYE D5.fcs MAIT cells 78.0 27700 
OZ7 max abs D0.fcs MAIT cells 427 113978 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
OZ10 5ARUMG DYE D5.fcs MAIT cells 76.0 7065 
OZ10 max abs D0.fcs MAIT cells 256 117443 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP66 dye (inhib).fcs MAIT cells 149 5200 
BP66 max D0.fcs MAIT cells 642 112107 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP65 dye (inhib).fcs MAIT cells 7369 2542 
BP65 max D0.fcs MAIT cells 2923 97887 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP67 dye (inhib).fcs MAIT cells 1158 4473 
BP67 max D0.fcs MAIT cells 1090 103861 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP66 dye (inhib).fcs MAIT cells 149 5200 
BP66 max D0.fcs MAIT cells 642 112107 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP65 dye (inhib).fcs MAIT cells 7369 2542 
BP65 max D0.fcs MAIT cells 2923 97887 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP67 dye (inhib).fcs MAIT cells 1158 4473 

























































3.3.7. MAIT cells produce IFNγ  
Previous studies have reported MAIT cells are potent producers of multiple 
cytokines including IFNγ and can express a wide repertoire of transcription 
factors (Koay et al., 2019; Leeansyah et al., 2015). Expression of IFNγ has been 
shown to be induced with TCR dependent and independent stimulation, 
suggesting its production by MAIT cells can be induced in a variety of infections 
(Hinks et al., 2019; Ussher et al., 2014; Van Wilgenburg et al., 2016). 
Transcription control of MAIT cell cytokine expression has been only investigated 
in the past five years. Koay et al. reported co-expression of T-bet and RORγT at 
stage 3 of MAIT cell maturation in humans (Koay et al., 2016). Lamichhane et al. 
investigated the transcription profile of activated CD8+ MAIT cells activated via 
TCR or cytokines stimulation and reported an upregulation of T-bet and RORγT 
in MAIT cells on both a transcriptional and protein level (Lamichhane et al., 2019).  
 
Here, we sought to confirm these findings in our cohort by assessing the cytokine 
and transcription factor profile of peripheral blood MAIT cells. Stimulation of 
PBMC using TCR Dynabeads, IL-12 and IL-18 for 18 hours, significantly 
increased the percentage of IFNγ producing MAIT cells (Figure 3.12 A&B). To 
determine whether the enhancement in IFNγ production was due to the direct 
effect of TCR and cytokine activation on MAIT cells, rather than indirect effect 
exerted by other cells in the PBMC culture, we stimulated expanded MAIT cells 
using TCR Dynabeads and cytokines for 4 hours for mRNA analysis or 24hours 
to measure protein expression. Upon activation MAIT cells significantly 
upregulated protein and mRNA expression of IFNγ (Figure 3.12 C&D). This was 
accompanied by significant enhancement in the expression of T-bet (TBX21) 
mRNA in our cohort of control individuals following stimulation (Figure 3.12 E). 
Overall, these results indicate that TCR and cytokine co-stimulation of MAIT cells 
increase their expression of T-bet which is likely to facilitate the upregulation of 
IFNγ synthesis (Figure 3.12 A-D).  
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Figure 3.12 MAIT cell produce IFNγ upon stimulation. (A) Representative dot 
plots and (B) scatter plot showing MAIT cell IFNγ production by control individuals 
basally or upon stimulation with TCR microbeads (Milteneyi 25ng/mL), IL-12 and 
IL-18 (50ng/mL each) for 18 hours (n=11). (C) Scatter plot showing IFNγ 
production (pg/mL) by purified MAIT cells basally and upon stimulation with TCR 
Dynabeads (Dynabeads; 1:1 ratio), IL-12 and IL-18 (50ng/mL each) for 24 hours 
(n=11). (D) and (E) Scatter plots showing normalized expression of IFNG and 
TBX21 mRNA by expanded and purified MAIT cells in response to TCR 
microbeads (Dynabeads; 1:1 ratio) IL-12 and IL-18 (50ng/mL each) for 4 hours 



























































































































3.3.8. MAIT cells produce IL-17A 
As described in chapter one, MAIT cells are involved in a range of bacterial and 
viral infections (Lal et al., 2020; Le Bourhis et al., 2010; Spaan et al., 2016). 
However, in addition to their role in host protection, MAIT cells have also been 
implicated in a range of chronic inflammatory diseases, such as obesity or MS 
(Carolan et al., 2015; Willing et al., 2018). In particular, type 17 MAIT cells have 
been highlighted as a potentially pathogenic subset. Th17 cells were originally 
established as the primary producers of IL-17, however as research in this area 
progressed, MAIT cells were identified to be a significant contributor to the pool 
of this cytokine during inflammation.   
 
In order to further explore MAIT cell function, next we investigated the ability of 
MAIT cells to produce IL-17 in our cohort of control individuals. Expanded MAIT 
cells, activated as per section 3.3.7 significantly increased IL-17A protein 
production (Figure 3.13 A) and mRNA expression (Figure 3.13 B). This is in line 
with previously published data, which presented MAIT cells as potent producers 
of IL-17A (Pisarska et al., 2020). 
 
As previously discussed in section 3.3.6, Koay et al. and Lamichhane et al. 
reported co-expression of T-bet and RORγT transcription factors by MAIT cells. 
Having confirmed that TBX21 (T-bet) mRNA is upregulated upon stimulation of 
MAIT cells from our cohort of control individuals (Figure 3.12 E), next we sought 
to investigate whether expression of mRNA coding for RORγT follows a similar 
pattern to TBX21. Indeed, stimulation of expanded MAIT cells as per section 
3.3.7 significantly increased RORC mRNA expression (Figure 3.13 C). This data 
shows that TCR and cytokine stimulation is sufficient to increase mRNA 
expression for RORγT and enhance expression of IL-17A by MAIT cells.  
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Figure 3.13 MAIT cells produce IL-17A upon stimulation. (A) Scatter plot 
showing IL-17A production (pg/mL) by purified MAIT cells from control individuals 
basally and upon stimulation with TCR Dynabeads (Dynabeads; 1:1 ratio), IL-12 
and IL-18 (50ng/mL each) for 24 hours (n=11). (B) Scatter plots showing 
normalized expression of IL17A and (C) RORC mRNA by expanded and purified 
MAIT cells in response to TCR microbeads (Dynabeads; 1:1 ratio) IL-12 and IL-
18 (50ng/mL each) for 4 hours (n=13). Statistical analysis performed using paired 





































































3.3.9. MAIT cell produce less IFNγ and more IL-17 cytokines in obesity 
Dysregulation of MAIT cell cytokine production has been reported in obesity. 
MAIT cells were shown to have impaired production of IFNγ and enhanced IL-17 
expression in comparison to their lean counterparts (Carolan et al., 2015; 
Magalhaes et al., 2015). Here we sought to confirm these findings in our cohort 
of people with obesity.  
 
Expanded MAIT cells from people with obesity or control individuals were 
stimulated with TCR Dynabeads, IL-12 and IL-18 cytokines for 4 hours for mRNA 
analysis or 24 hours for the measurement of protein expression. MAIT cells from 
people with obesity displayed lower IFNγ production upon activation in 
comparison to the controls (Figure 3.14 A). This was also reflected at the 
transcriptional level where stimulated MAIT cells from people with obesity had 
lower levels of IFNG mRNA in comparison to the control individuals (Figure 3.14 
B). As we have shown that transcription of TBX21 mRNA is significantly 
upregulated upon MAIT cell activation (Figure 3.12 E), next we investigated 
whether transcription of TBX21 is impacted in people with obesity. We showed 
that the expression of mRNA coding for T-bet upon activation was lower in people 
in obesity in comparison to the control individuals (Figure 3.14 C). Investigation 
of IL-17 expression by MAIT cells from individuals with obesity, demonstrated a 
significant increase in IL-17 protein expression upon activation in comparison to 
the control individuals (Figure 3.15 A), however no significant difference was 
observed in the expression of mRNA for IL-17 or RORγT (Figure 3.15 B&C). 
These results further confirm dysregulation in cytokine production by MAIT cells 
in obesity and provide additional information regarding the transcriptional 
phenotypic differences between the two cohorts. 
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Figure 3.14 MAIT cell production of IFNγ upon stimulation is reduced in 
obesity. (A) Scatter plots of IFNγ protein production by control individuals and 
individuals with obesity in response to TCR microbeads (Dynabeads; 1:1 ratio) 
IL-12 and IL-18 (50ng/mL each) for 24 hours (control n=28; obese n=21). (B) 
Scatter plots of IFNG (IFNγ) and (C) TBX21 (T-bet) mRNA transcription by MAIT 
cells from healthy and people with obesity basal or upon stimulation with TCR 
Dynabeads (1:1 bead to cell ratio), IL-12 and IL-18 (50ng/mL each) for 4 hours 
(control n=13; obese n=6). Statistical analysis performed using one-way ANOVA 

























































































































Figure 3.15 MAIT cells from individuals with obesity, display enhanced IL-
17 protein production, but no difference in the transcription of IL17A & 
RORC upon stimulation in comparison to the controls. (A) Scatter plots 
showing IL-17A protein production by control individuals (n=12) and individuals 
with obesity (n=10) in response to TCR microbeads (Dynabeads; 1:1 ratio) IL-12 
and IL-18 (50ng/mL each) for 24 hours. (B) Scatter plots showing normalized 
expression of IL17A (controls n=12; obese n=6) and (C) RORC (controls n=13; 
obese n=6) mRNA by expanded and purified MAIT cells from controls and 
individuals with obesity in response to TCR microbeads (Dynabeads; 1:1 ratio) 
IL-12 and IL-18 (50ng/mL each) for 4 hours. Statistical analysis performed using 




























































































































3.3.10. MAIT cells produce an expanded repertoire of cytokines 
At present, the majority of the studies that investigated the role of MAIT cells in 
the immune system, have largely focused on the production of the well-studied 
cytokines, IFNγ, IL-17A and TNF-α (Provine and Klenerman, 2020). Interestingly, 
it has been reported that MAIT cells are capable of producing other cytokines 
such as IL-22 and IL-17F (Gibbs et al., 2017; Lu et al., 2020; Toussirot et al., 
2018). To further characterise MAIT cells in the control subjects, expression of 
IL-17F, IL-22 and IL-32 was measured. Expanded MAIT cells were activated as 
described in section 3.3.9. MAIT cells displayed an increase in their expression 
of protein and mRNA for IL-17F and IL-22 cytokines (Figure 3.16 A&B; D&E). A 
more modest increase in IL-32 was noted (Figure 3.16 C), while the transcription 
of IL32 mRNA was reduced upon activation (Figure 3.16 F). Overall, these results 
indicate that although MAIT cells are potent producers of IFNγ, they are also 
capable of producing other cytokines such as IL-17F, IL-22 and IL-32. As these 
cytokines play a role in inflammation, the contribution of MAIT cells to the levels 
produced during an immune response should be further investigated. 
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Figure 3.16 Stimulation of MAIT cells induces the production of IL-17F, IL-
22 and IL-32 cytokines. (A-C) Scatter plots showing concentration of IL-17F, IL-
22 & IL-32 in the cell supernatants, produced by the expanded and purified MAIT 
cell upon stimulation with TCR microbeads (Dynabeads; 1:1 ratio) IL-12 and IL-
18 (50ng/mL each) for 24 hours (IL-17F n=11; IL-22 n=4; IL-32 n=7). (D-F) 
Scatter plots showing normalized expression of IL17F, IL22, IL33 by expanded 
and purified MAIT cells in the control population in response to TCR microbeads 
(Dynabeads; 1:1 ratio) IL-12 and IL-18 (50ng/mL each) for 4 hours (IL-17F n=7; 
IL-22 n=12; IL-32 n=12) Statistical analysis performed using paired student’s t-




























































































































3.3.11.  Individuals with obesity display no significant difference in the 
expression of other immune cytokines 
Investigations around MAIT cells phenotypes in people with obesity has focused 
on IFNγ and IL-17, the most studied cytokines produced by these cells. Here, we 
decided to examine whether alteration of MAIT cell function extends beyond the 
imbalances observed with IFNγ and IL-17.  
 
Expanded MAIT were activated as per section 3.3.9. MAIT cells from people with 
obesity produced IL-17F and IL-32 protein upon stimulation, but no significant 
difference was observed in the expression between people with obesity and 
control individuals (Figure 3.17 A&B). mRNA expression coding for IL-17F 
mirrored its protein synthesis and showed no significant alteration in transcription 
between the two cohorts (Figure 3.17 C). On the other hand, stimulation of MAIT 
cells from people with obesity revealed a defect in the downregulation of IL32 
mRNA expression in comparison to the control subjects. In fact, MAIT cells from 
people with obesity produced higher levels of IL-32 protein upon stimulation in 
comparison to the control individuals, however the difference in the expression 
was not significant (Figure 3.17 B&D). Investigation of IL22 transcription upon 
stimulation of MAIT cells from people with obesity revealed no significant 
difference in the expression between the two cohorts (Figure 3.17 E), however 
this data must be confirmed on the protein level. Collectively, this data shows 
non-significant alterations in expression of these three cytokines by MAIT cells 
from people with obesity. Increasing the number of experiments on MAIT cells 
from people with obesity and control individuals may provide more definite 
answers in the future.  
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Figure 3.17 Stimulation of MAIT cells reveals no difference in IL17F and IL22 
mRNA transcription by the cells from healthy and obese individuals but 
shows impairment in IL32 transcription. (A-B) Scatter plots showing 
concentration of IL-17F and IL-32 in the cell supernatants, produced by the 
expanded and purified MAIT cell upon stimulation with TCR microbeads 
(Dynabeads; 1:1 ratio) IL-12 and IL-18 (50ng/mL each) for 24 hours (IL-17F 
control =18, obese n=8; IL-32 control =21, obese n=9). (C-E) Scatter plots 
showing normalized expression of IL17F, IL22, IL32 by expanded and purified 
MAIT cells in the control population in response to TCR microbeads (Dynabeads; 
1:1 ratio) IL-12 and IL-18 (50ng/mL each) for 4 hours (IL17F control =7, obese 
n=4; IL32 control =12, obese n=5; IL22 control =12, obese n=5). Statistical 





































































































































































































































































3.4  Discussion 
MAIT cells comprise 1-10% of circulating T cells in healthy individuals (Gherardin 
et al., 2018b; Le Bourhis et al., 2010). In line with these publications, we report 
that MAIT cell frequencies in the peripheral blood of our cohort of control 
individuals ranged from 0.5% to 13.7%. To further characterise MAIT cells, next 
we described their proliferative and expansion capacity in response to TCR 
activation. Stimulation of MAIT cells with their cognate antigen resulted in limited 
proliferation. This data aligns with previous studies which demonstrated MAIT cell 
proliferation in vitro in response to E. coli or 5-OP-RU (Dias et al., 2016; Kurioka 
et al., 2017; Rahimpour et al., 2015). In agreement with published data, TCR 
stimulation enhanced IL-2 receptor expression, suggesting it may play a role in 
MAIT cell function and proliferation (Van Wilgenburg et al., 2016; Vorkas et al., 
2018). It has been well established that IL-2 supports T cell proliferation, therefore 
we hypothesized that the increase in IL-2R combined with antigen stimulation 
and exogenous IL-2 supplementation may enhance proliferation of MAIT cells. 
Indeed, here we showed that the combination of TCR and IL-2 signals led to 
significantly greater expansion and proliferation of MAIT cells in vitro. This 
suggested that appropriate combination of signals in vivo can potentially drive 
expansion of MAIT cells in response to a pathogen.  
 
Next, we examined the repertoire of cytokines and transcription factors 
expressed by MAIT cells upon activation. IFNγ a cytokine which is highly 
implicated in supporting anti-microbial responses, has been shown to be 
upregulated upon TCR and/or cytokine stimulation (Dusseaux et al., 2011; Van 
Wilgenburg et al., 2016; Wang et al., 2018). In line with these findings, we 
demonstrated that the activation of MAIT cells using TCR, IL-12 and IL-18 led to 
the transcription of mRNA coding for IFNγ and T-bet, followed by an increase in 
IFNγ protein. This is consistent with the study published by Lamichhane et al. 
who reported an increase in the expression of mRNA coding for IFNγ and T-bet 
upon stimulation of MAIT cells (Lamichhane et al., 2019).  Another cytokine 
produced by MAIT cells which has been of particular interest is IL-17, due to its 
potent pro-inflammatory properties (Pisarska et al., 2020). IL-17+ MAIT cells have 
been confirmed at the site of inflammation in multiple diseases including MS and 
RA (Kim et al., 2017; Willing et al., 2018). In agreement with published data, 
stimulation of MAIT cells upregulated IL-17A production and enhanced 
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transcription of mRNA coding for RORγT (Lamichhane et al., 2019). Collectively, 
this data showed that the activation of MAIT cells induced a very rapid alteration 
in the transcription events. MAIT cells respond by increasing the expression of 
transcription factors, most likely to facilitate the increased demand for synthesis 
of these cytokines in response to the activation signals. As the research 
progressed, the range of cytokines produced by MAIT cells expanded. Recently, 
other cytokines of the IL-17 cytokine family, IL-17F and IL-22 have gained more 
attention (Gibbs et al., 2017; Lamichhane et al., 2019; Toussirot et al., 2018). In 
line with Lamichhane et al., we showed an enhancement in the synthesis of IL-
17F and IL-22 upon MAIT cell stimulation (Lamichhane et al., 2019). In addition, 
these cells expressed IL-32, a cytokine which has not been previously described 
to be produced by MAIT cells. These results illustrate that MAIT cells can produce 
a much wider repertoire of pro-inflammatory cytokines, although further studies 
are required to explore what other effector molecules are expressed by these 
cells.  
 
After the characterisation of MAIT cell functional responses in the control 
subjects, next we sought to describe their activity in people with obesity. In line 
with other studies, people with obesity presented with lower MAIT cell 
frequencies in the peripheral blood in comparison to the control subjects (Carolan 
et al., 2015; Magalhaes et al., 2015; Toubal et al., 2020) and displayed severely 
impaired expansion upon cell activation. Surprisingly, no difference was observed 
in the rate of proliferation assessed using CTV. This may be due to the limitations 
associated with the CTV assay. This method allowed for tracking MAIT cell 
proliferation only up to five days, whereas the defects in MAIT cells expansion 
from people in obesity has been observed seven days after activation and was 
sustained for up to 14 days. To date proliferation of MAIT cells in obesity was 
only briefly assessed in adipose tissue using Ki67 expression. MAIT cells from 
individuals with obesity were shown to have higher proliferative capacity in the 
AT in comparison to the peripheral blood, however this study didn’t compare Ki67 
expression between people with obesity and lean controls (Magalhaes et al., 
2015). Toubal et al. has shown that MAIT cells from the adipose tissue of the 
control and HFD mice displayed no difference in proliferation as measured by 
expression of Ki67, however proliferation capacity from the peripheral blood was 
not assessed (Toubal et al., 2020). We propose that the impairment in MAIT cell 
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expansion in people with obesity may be contributing to the low frequencies of 
MAIT cells observed in their peripheral blood. However, other factors such as 
activation induced cell death or MAIT cell migration to the site of inflammation 
should be studied in more detail to provide a more comprehensive explanation.  
 
As obesity had a profound impact on MAIT cell frequencies and proliferation, next 
we assessed their cytokine production upon cell activation. In comparison to the 
control individuals, MAIT cells from people with obesity displayed lower 
expression of IFNγ which was accompanied by decreased transcription of T-bet 
transcription factor. This is in line with Carolan et al. who demonstrated an 
impairment in the frequencies of IFNγ producing MAIT cells in obesity (Carolan 
et al., 2015). Magalhaes et al. displayed contradicting results, as in their hands 
people with obesity had a higher proportion of IFNγ producing MAIT cells in 
comparison to the lean controls (Magalhaes et al., 2015). This discrepancy may 
be due to the fact Magalhaes used a pan activator of cells (PMA/Ionomycin), 
whereas our study used a more specific approach in activating MAIT cells. This 
data indicates that the deficiency in IFNγ expression by MAIT cells from people 
with obesity occurs at the transcription level. This cytokine plays a central role in 
fighting microbial infections, therefore loss of IFNγ may contribute to the greater 
susceptibility to infections associated with obesity. In contrast to IFNγ, MAIT cells 
from people with obesity produced more IL-17 cytokine than the control 
individuals but displayed no difference in the transcription of mRNA for IL-17A or 
RORγT. This suggested that the defect, which leads to enhanced IL-17 
production occurs at the post-transcriptional level. Similar observations were 
published by Carolan et al. and Magalhaes et al., who also reported an 
enhancement in IL-17 production by MAIT cells in obesity. There is growing 
evidence indicating that overexpression of IL-17 is harmful and contributes to the 
chronic inflammation observed in obesity and therefore may contribute to the 
development of T2DM (Chehimi et al., 2017; Liu and Nikolajczyk, 2019). Further 
studies have revealed that MAIT cells from people with obesity display lower 
(non-significantly) expression of IL-17F and IL-22 in comparison to the controls. 
In addition, MAIT cells from people with obesity failed to suppress transcription 
of IL32 mRNA upon stimulation, which resulted in an enhanced albeit non-
significant expression of IL-32 cytokine in comparison to the controls. This data 
suggested that IL-17F and IL-22 may not play an important role in maintaining 
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the pro-inflammatory environment in obesity, however the role of IL-32 should be 
further investigated.  
 
Collectively this study has provided more insight into MAIT cell proliferation and 
cytokine production. We show that MAIT cells can proliferate and express a wide 
range of cytokines and transcription factors, whereas MAIT cells from people with 
obesity display a marked deficiency in MAIT frequencies and expansion and 
significant alterations in the cytokine expression (Figure 3.18). This may lead to 
the lower frequencies, susceptibility to infections and inflammation observed in 
obesity. 
Figure 3.18 Summary of MAIT cell function in control and people with 
obesity. Stimulation MAIT cells enhances expression of IL-2 receptor, induces 
their proliferation, transcription of T-bet and RORγT transcription factors and 
production of IFNγ, IL-17A, IL-17F, IL-22 and IL-32 cytokines. MAIT cells from 
people with obesity (red) display diminished proliferation and alterations in the 




















4.1.1. Glycolysis in immunometabolism 
As the field of immunometabolism advances, it becomes clear that glycolysis is 
essential to support immune cell survival and function. Glucose is one of the few 
fundamental nutrients required for T cell function, therefore it is no surprise 
glycolysis has become a focal point of multiple studies of immunometabolism. In 
order for glucose to enter the cell, it requires glucose transporters. Glucose 
transporters can be put into two main categories of sodium-glucose linked 
transporters (SGLT) and facilitated diffusion glucose transporters (GLUT) 
(Navale and Paranjape, 2016). The category of glucose transporters which are 
expressed by immune cells and are largely studied are GLUTs. This family of 
transporters consists of 12 members and to date, T cells were found to express 
GLUT1, 3, 4, 6 and 8 (Kavanagh Williamson et al., 2018; Macintyre et al., 2014), 
of which GLUT1 is the major and most thoroughly studied glucose transporter in 
T cells (Palmer et al., 2016). Surface expression of this transporter is markedly 
increased upon their TCR & CD28 activation (Jacobs et al., 2008; Ricciardi et al., 
2018; Wieman et al., 2007). Expression of the transporter is controlled at multiple 
stages including transcription and trafficking to the cell membrane, however 
shuffling of GLUT1 to the cell surface was shown to be the key event responsible 
for the rapid upregulation of its expression (Jacobs et al., 2008; Macintyre et al., 
2014).  
 
Upon uptake of glucose, the carbohydrate enters glycolysis, which takes place in 
the cytosol of the cell and is central to cell metabolism. This process breaks down 
glucose into pyruvate, which further feeds into the Kreb’s cycle to contribute to 
the energy production for cellular function via oxidative phosphorylation (Almeida 
et al., 2016). Glucose and glycolysis are crucial in T cell function. One of the first 
scientists who identified that glycolysis is linked to T cell activity was Robson 
MacDonald in 1977. Using glycolysis inhibitor 2DG, MacDonald reported 
inhibition of the cytotoxic activity of T cells (Robson MacDonald, 1977). More 
recent studies have shown that indeed glycolysis plays a central role in T cells 
during activation. CD8 effectors cells, Th1 and Th17 cells can substantially 
upregulate their glycolysis upon stimulation (Gubser et al., 2013; Michalek et al., 
2011), whereas the substitution of glucose with galactose in the culture media 
impairs IFNγ production by CD4 T cells (Chang et al., 2013). Inhibition of 
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glycolysis with 2DG promotes the development of Treg rather than Th17 cells, 
highlighting the role of glycolysis in determining the fate of naïve T cells (Shi et 
al., 2011). As more studies emerge, it is becoming clear that for some aspects of 
T cell activation, especially IFNγ production, the role of glycolysis extends beyond 
energy production. 
 
A study by Chang et al. identified a key role for glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), which is one of the multiple enzymes involved in 
glycolysis, in T cell functional responses. In the resting state of T cells, GAPDH 
binds to IFNγ mRNA and prevents its translation. Upon cell activation and 
triggering of glycolysis, GAPDH dissociates from the IFNγ mRNA strand and 
reverts back to fulfil its function in the glycolysis pathway (Chang et al., 2013). 
IFNγ is also controlled metabolically at the transcription level in T cells. 
Acetylation of histones affects the access of transcription enzymes to the IFNγ 
gene. Acetyl Co-A is produced during oxidation of pyruvate, the end product of 
glycolysis and can be used to acetylate proteins, including histones (Peng et al., 
2016). An intermediate of glycolysis, phosphoenolpyruvate (PEP), was also 
found to impact IFNγ production. PEP inhibits the activity of endoplasmic 
reticulum calcium transporter sarcoendoplasmic reticulum calcium ATPase 
(SERCA), which shuffles calcium from the cytoplasm to endoplasmic reticulum.  
This leads to the activation of the calcium dependent nuclear factor of activated 
T cells (NFAT) signalling and transcription of IFNγ (Ho et al., 2015). Although 
glycolysis plays a role in multiple ways to impact IFNγ production, metabolic 
intermediates produced as a result of this process, may also be supporting 
lymphocytes in their metabolism and function. Pyruvate, the end product of 
glycolysis, can be used in synthesis of amino acids and fatty acids (Figure 4.1) 
(O’Neill et al., 2016), however it has been also shown to play a role in CD4 
effector memory cell survival by stabilising mitochondrial membrane potential to 
prevent apoptosis. Dimeloe et al. have shown that independely of oxygen 
availability, disruption of glycolysis results in an increased expression of apoptotic 
proteins. This was associated with decreased mitochondrial membrane potential, 
which was shown to be rescued by addition of pyruvate(Dimeloe et al., 2016). 
However, pyruvate isn’t the only product of glycolysis, which supports the cell 
metabolism. Metabolic intermediates produced during this process, such as 
glucose-6-phosphate can enter PPP to produce ribose, which is required for 
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nucleotides synthesis (Figure 4.1) (O’Neill et al., 2016). This suggests that the 
involvement of glycolysis in the control of immune cells function is more complex 
than first anticipated. Current findings uncover a very exciting area for further 
research, emphasising the extensive influence of metabolic processes on 
immune responses. 
Figure 4.1 Glycolysis. Glucose is metabolised to pyruvate during glycolysis, 
which can enter Kreb’s cycle. Glycolysis also leads to synthesis of multiple 
intermediates, which can feed into other metabolic pathways and contribute to 





mTOR is an evolutionarily conserved serine/ threonine kinase, which regulates 
the activation and function of multiple proteins (Saxton and Sabatini, 2017). 
mTOR integrates an array of signals including growth factor signals, oxygen level, 
cell energy, nutrient availability and antigen receptor signalling. Based on the 
received signals, it controls cell metabolism, growth, differentiation and apoptosis 
(Salmond, 2018; Saxton and Sabatini, 2017). mTOR is the key catalytic 
component of two complexes it can be associated with, namely mTORC1 and 
mTORC2 (Figure 4.2) (Salmond, 2018). Although these complexes share three 
subunits- mTOR, mLST8 (mammalian lethal with sec13 protein 8) and DPETOR 
(DEP domain containing mTOR interacting protein). mTORC1 further associates 
with Raptor (regulatory protein associated with mTOR) and PRSA40 (proline-rich 
AKT substrate 40kDa), whereas mTORC2 is defined by the presence of Rictor 






Sabatini, 2017). Out of these two complexes, mTORC1 is shown to be of 
particular importance in immune cell function and control of glycolysis (Delgoffe 
et al., 2011, 2009; Finlay et al., 2012; Sinclair et al., 2013) 
 
mTORC1 plays a substantial role in regulating cell growth, proliferation and 
activation. Activation of T cells via TCR or cytokine stimulation increases 
mTORC1 activity indicating a role for mTORC1 in T cell function (Rao et al., 2010; 
Ray et al., 2015). Expression of mTORC1 is shown to influence the fate of T cells, 
as CD4 T cells which lack mTORC1 fail to develop into Th1, Th2 or Th17, but 
rather favour Treg differentiation (Delgoffe et al., 2011, 2009). On the other hand, 
enhanced activity of mTORC1 in CD8 T cells leads to highly activated effector 
cells, which fail to transition into memory cells (Pollizzi et al., 2015). This indicates 
that tight control of mTORC1 is essential for maintaining T cell homeostasis.  
 
As multiple factors can activate mTORC1, the regulation of this kinase is very 
complex. Among various points of control, changes in the cellular environment 
such as nutrient, energy and oxygen availability, can affect the activity of the 
kinase via the action of AMP-activated protein kinase (AMPK) (Saxton and 
Sabatini, 2017). Glucose restriction was shown to activate AMPK, leading to the 
phosphorylation of raptor or tuberous sclerosis complex 2 (TSC2) (regulator of 
mTORC1) and attenuation of the mTORC1 complex (Rolf et al., 2013; Saxton 
and Sabatini, 2017). Although mTORC1 is sensitive to glucose concentration, it 
was also shown to be absolutely required for control of glycolytic metabolism. 
mTORC1 is required to maintain high levels of glycolytic activity to support T cell 
function (Finlay et al., 2012). Treatment of T cells with rapamycin, an inhibitor of 
mTORC1, impairs glucose uptake induced by TCR signalling. It also prevents the 
upregulation of glucose transporters and glycolytic enzymes (Finlay et al., 2012; 
Hukelmann et al., 2016). Similar findings were obtained by Donnelly et al. in a 
study of natural killer (NK) cells, which demonstrated that stimulation of mTORC1 
is responsible for the control of enhanced glycolysis and production of IFNγ and 
Granzyme B (Donnelly et al., 2014).  
 
Amino acids were also shown to affect mTORC1 signalling. Although amino acids 
are required for protein synthesis and their enhanced import during cell activation 
is important to facilitate the increased nutrient demands of the cells, it is the 
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concentration of leucine, which directly affects the activity of mTORC1(Figure 
4.2) (Saxton and Sabatini, 2017). The presence of amino acids activates Rag, a 
GTPase, which in turn mediates the translocation of mTORC1 to the lysosomes. 
This facilitates the lysosome bound Ras homolog enriched in brain (Rheb) to 
activate mTORC1 (Figure 4.2) (Saxton and Sabatini, 2017). Activity of Rag is 
controlled by the interaction between Sestrin2, a protein which controls cell 
metabolism and GATOR, which is a Rag activating protein (Figure 4.2) (Kim et 
al., 2015). Briefly, Kim et al. reported that Sestrin2 binds to GATOR2 resulting in 
its inhibition. GATOR2 is a negative regulator of GATOR1, therefore this 
interaction results in the liberation of GATOR1 from GATOR2 complex and its 
activation. The release of GATOR1 inhibits the activity of the Rag protein resulting 
in suppression of mTORC1 activity (Kim et al., 2015). Sestrin2 itself is a leucine 
sensor. Leucine binds to Sestrin2, leading to the freeing of GATOR2, which binds 
to GATOR1, allowing Rag mediated activation of mTORC1 (Chantranupong et 
al., 2014; Saxton et al., 2016; Wolfson et al., 2016). This method of mTORC1 
control was shown to be relevant in T cells. Sinclair et al. described that deletion 
of amino acid transporter LAT1, which transports leucine, leading to the 
downregulation of mTORC1 activity in murine T cells (Sinclair et al., 2013).  
Figure 4.2. Regulation of mTORC1 activity. mTORC1 is tightly controlled by 
cellular and environmental signals such as growth factors, nutrient availability, 
DNA damage or energy availability.  All combined signals incorporated by 




4.1.3. Amino acid metabolism  
Although glucose and glycolysis are central in T cell homeostasis and function, 
the role of amino acid metabolism cannot be underestimated. Amino acids are 
essential building blocks of proteins, but their role in the cell function was reported 
to be far more complex. It has been established that interruption to amino acid 
transport or metabolism impairs immune cell function, however the mechanisms 
behind this altered immune response have begun to emerge in recent years (Ma 
et al., 2017; Rodriguez et al., 2007; Sinclair et al., 2013). The role of multiple 
amino acids is currently under investigation in the field. However, leucine and 
glutamine have been the focus of this study due to their effects on T cell activation 
(Nakaya et al., 2014; Sinclair et al., 2013; Wolfson et al., 2016).  
 
Amino acids are transported into the cells by a wide range of membrane bound 
transporters. Leucine, one of the essential amino acids, was found to be 
transported into the cells by LAT1 (Hsu and Dzhagalov, 2019). LAT1 belongs to 
a family of four L-type amino acid transporters, which are sodium independent 
and transport neutral amino acids. In addition to leucine, they facilitate the influx 
of isoleucine, valine, phenylalanine and methionine (Hsu and Dzhagalov, 2019). 
This family of transporters includes LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 
(SLC43A1) and LAT4 (SLC43A2), with LAT 1 is the most studied member of this 
family. LAT1 forms a heterodimer with CD98 (SLC3A2) and was shown to be an 
antiporter, which imports leucine in exchange for intracellular glutamine (Hsu and 
Dzhagalov, 2019). SLC7A5 was found to be upregulated in human and murine T 
cells upon stimulation (Hayashi et al., 2013; Sinclair et al., 2013). Study by 
Sinclair et al. elegantly showed that T cells require LAT1 for differentiation into 
the effector cells. Deletion of SLC7A5 in mice resulted in a reduction in T cell 
differentiation into Th1, Th17 and CTL cells, however, Treg differentiation 
remained unaffected (Sinclair et al., 2013). As leucine was shown to be 
transported via LAT1 and the activation of mTOR, the defect in T cell proliferation 
and differentiation in the absence of SLC7A5 expression was linked to the lack 
of this amino acid and failure to induce the appropriate metabolism response to 
support the cell function (Sinclair et al., 2013). Further investigation into the 
association between amino acid transport via LAT1 and T cell function revealed 
that SLC7A5 deficient T cells failed to reprogram their metabolism and resembled 
c-Myc null cells. It was shown that an influx of amino acids via LAT1 L-system 
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transporter was required to sustain the expression of c-Myc transcription factor 
in T cells, which is critical for cell metabolic reprogramming, proliferation and 
survival (Gnanaprakasam and Wang, 2017; Sinclair et al., 2013). This was also 
confirmed by another study, which investigated the role of amino acids for NK cell 
function and activation. They also highlighted a role for glutamine, rather than 
leucine in supporting the c-Myc expression (Loftus et al., 2018). Furthermore, 
Hayashi et al. confirmed the upregulation of LAT1 expression by human primary 
T cells upon stimulation. In line with the findings by Sinclair et al., Hayashi showed 
that the inhibition of LAT1 with a specific inhibitor, JPH203, or transfection with 
LAT1 specific siRNA, resulted in a decrease of leucine uptake and cytokine 
production by activated T cells. This study showed that TCR stimulation of T cells 
upregulates LAT1 in a NFkB and activator protein-1 (AP-1) dependent manner 
(Hayashi et al., 2013), whereas Sinclair at al. suggested SLC7A5 expression is 
controlled by ERK/MAPK and NFAT pathway (Sinclair et al., 2013). Another study 
by Sinclair et al., which studied the transport of kynurenine, a tryptophan 
metabolite, via SLC7A5 in T cells, depicted a very comprehensive method to 
investigate uptake of this metabolite and indirectly assess the function of the 
amino acid transporter. This paper formed the basis for the investigation of this 
amino acid metabolism and uptake by MAIT cell for this thesis (Sinclair et al., 
2018). Expression patterns and function of other amino acids transporters 
including LAT2-4 in the cells of the immune system remains largely unexplored. 
Similarly, to LAT1, LAT2-4 transport large neutral amino acids (Babu et al., 2003; 
Bodoy et al., 2005; Yan et al., 2020). In addition, LAT2 was shown to also support 
transport of small neutral amino acids such as serine or alanine (Yan et al., 2020). 
Although the specific amino acids transported by LAT3 remain to be elucidated, 
it has been shown that LAT4 transports essential and branched chained amino 
acids such as phenylalanine, methionine and leucine or valine (Bodoy et al., 
2005). Further research is required to assess the expression, function and 
importance of amino acid transporters other than LAT1 for the cells of the immune 
system. In addition, more detailed studies are vital to assess, whether all neutral 
amino acids are equally transported by all four transporters. 
 
Among other amino acids, glutamine has also attracted a lot of attention from 
researchers in the context of immunometabolism. Glutamine is synthesised de 
novo by the cell or absorbed from the diet and imported into the cells through a 
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range of glutamine transporters, such as sodium coupled neutral amino acid 
transporters (SNAT)1-4 (SLC38A1-SLC38A4), and the most heavily studied 
glutamine importer Alanine, Serine, Cysteine Transporter 2 (ASCT2/SLC1A5) 
(Hsu and Dzhagalov, 2019). Upon entry, glutamine can be used for multiple 
purposes such as generation of energy thorough feeding into the Kreb’s cycle. 
Mitochondrial glutaminase enzyme converts glutamine to glutamate, which can 
be further metabolised to a-ketoglutarate and enter the Kreb’s cycle to produce 
ATP and contribute to the fatty acid synthesis via reductive carboxylation (Altman 
et al., 2016). In addition, glutamine can be also directed for synthesis of 
nucleotides, glutathione or O-GlcNAcylation of proteins (Altman et al., 2016).  
 
Uptake of glutamine as well as expression of the glutamine transporters and 
enzymes involved in glutaminolysis are upregulated upon T cell stimulation, 
which in turn are dependent on the c-Myc pathway (Carr et al., 2010; Nakaya et 
al., 2014; Wang et al., 2011). The importance of glutamine uptake was 
highlighted by Nakaya et al., who showed that the deletion of ASCT2 in mice led 
to impaired differentiation of Th1 and Th17 cells, and failure to produce their 
signature cytokines (Nakaya et al., 2014). ASCT2 was also required for 
successful mTOR signalling, suggesting that the influx of glutamine via this 
transporter is important for the intracellular pool of glutamine, to be exchanged 
for leucine by transport via LAT1. Although glutamine is required for T cell 
proliferation, surprisingly deficiency in ASCT2 does not negatively affect 
proliferation (Carr et al., 2010; Nakaya et al., 2014), suggesting other glutamine 
transporters must be implicated. Indeed, Carr et al. and Raposo et al. have 
reported that T cell stimulation leads to the upregulation of other amino acid 
transporters, namely SNAT1 (SLC38A1) and SNAT2 (SLC38A2) (Carr et al., 
2010; Raposo et al., 2015), whereas inhibition of SNAT glutamine transporters, 
reduces T cell proliferation and production of IFNγ and IL-2 (Raposo et al., 2015).  
 
Research in the area of amino acid metabolism and immune response was 
shown to be very exciting, allowing for better understanding of the relationship 
between cell metabolism and immune cell function. Study of amino acids 
revealed their complex roles in the activity of the cell. It is now known, they are 
not merely substrates used for protein synthesis, but can also act as signalling 
molecules to support the immune cell function. Although a progress has been 
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made in understanding the role of amino acids in T cells, up to date there were 
no studies published, which would investigate their importance in MAIT cell 





4.2. Specific aims of this chapter 
 
The specific aim of this chapter was the characterisation of MAIT cell metabolism 
in both healthy individuals and people with obesity.  
Therefore, to: 
1. Investigate nutrient transporter expression by MAIT cells in health and 
obesity 
2. Elucidate metabolic pathways used by MAIT cells 
3. Determine metabolic regulators of MAIT cell metabolism  
4. Compare MAIT cell metabolism rates between healthy individuals and 




4.3.1. MAIT cells express glucose transporters GLUT1, GLUT3 and GLUT4  
As outlined, research has provided us with substantial evidence, which shows T 
cells require glucose and glycolysis to successfully perform their effector 
functions. It has been shown that stimulation of T cells leads to substantial 
upregulation of glycolysis, suggesting that glucose is one of the key nutrients, 
which supports T cell activation (Gubser et al., 2013; Michalek et al., 2011; Wang 
et al., 2011). In order for glucose to be metabolised, it must be transported into 
the cell. Among the 14 GLUT glucose transporters, which have been identified to 
be expressed by humans, T cells have been shown to express GLUT1, 3, 4, 6 
and 8 (Kavanagh Williamson et al., 2018; Macintyre et al., 2014). At present, the 
majority of studies investigating a role of GLUT1 and GLUT3 in T cell function 
have reported an upregulation of their expression upon T cell stimulation 
(Hukelmann et al., 2016; Macintyre et al., 2014; Palmer et al., 2015). To the best 
of our knowledge, the expression of glucose transporters by MAIT cells has not 
yet been described. 
 
We first determined the expression of glucose transporters GLUT 1, 3 and 4 on 
expanded MAIT cells using real time RT-qPCR. Expanded MAIT cells were found 
to express mRNA for these three GLUT transporters (Figure 4.3 A, D&E). 
Stimulation of expanded MAIT cells with TCR Dynabeads, IL-12 and IL-18 
cytokines for 4 hours showed no significant difference in the SLC2A1 mRNA level 
coding for GLUT1 in comparison to the basal expression (Figure 4.3 A) However, 
as GLUT1 is the best studied glucose transporter in T cells and its expression is 
known to be controlled at the point of trafficking of the complex from the cytosol 
to the cell surface, we decided to measure the expression of GLUT1 protein on 
the surface of MAIT cells by flow cytometry (Wieman et al., 2007). GLUT1 protein 
was expressed on the cell membrane of MAIT cells, and its expression was 
significantly decreased upon stimulation of PBMC via TCR, and cytokines after 
18 hours (Figure 4.3 B&C). Analysis of mRNA expression of the other two glucose 
transporters by expanded MAIT cells stimulated via TCR and cytokines for 4 
hours revealed significant increase in the transcription of SLC2A3 (GLUT3) and 
SLC2A4 (GLUT4) (Figure 4.3 D&E). This data indicates that MAIT cells express 
mRNA for the four major transporters tested and display a limited alteration in 
their expression upon stimulation at the chosen timepoints.   
107 
Figure 4.3 MAIT cells express mRNA and protein for glucose transporter 
GLUT1 and mRNA for GLUT3&4. (A) Scatter plot of normalized MAIT cell 
mRNA expression of glucose transporter GLUT1(SLC2A1) by purified MAIT cells 
basally and upon stimulation with TCR Dynabeads (cell to bead ratio 1:1), IL-12 
and IL-18 (at 50ng/mL each) for 4 hours in the control population sample(n=11). 
(B) Scatter plot of surface MFI GLUT1 expression by MAIT cells from a PBMC 
culture; unstimulated or stimulated with TCR Dynabeads (cell to bead ratio 1:1) 
IL-12 and IL-18 (at 50ng/mL each) for 18 hours (n=8). (C) Representative 
histograms of two control samples showing GLUT1 expression on MAIT cells 
basally or upon stimulation with TCR Dynabeads cell to bead ratio 1:1), IL-12 and 
IL-18 (at 50ng/mL each) for 18 hours. (D-E) Scatter plot of normalized MAIT cell 
mRNA expression of glucose transporters GLUT3 and GLUT4 (SLC2A3-4) by 
purified unstimulated MAIT cells and cells stimulated with Dynabeads (cell to 
bead ratio 1:1), IL-12 and IL-18 (at 50ng/mL each) for 4 hours in the control 
population sample (n=11). Statistical analysis performed using paired student’s 





Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP3 STIM.fcs MAIT cells 1427 342 
BP3 BASAL.fcs MAIT cells 2190 446 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP75 STIM.fcs MAIT cells 2701 335 
BP75 BASAL.fcs MAIT cells 2753 479 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP4 STIM.fcs MAIT cells 4811 337 
BP4 BASAL.fcs MAIT cells 5168 479 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP3 STIM.fcs MAIT cells 1427 342 
BP3 BASAL.fcs MAIT cells 2190 446 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP75 STIM.fcs MAIT cells 2701 335 



























































































































4.3.2. MAIT cells from individuals with obesity display no difference in 
glucose transporters mRNA expression 
MAIT cells from the control individuals expressed GLUT1, 3 and 4 glucose 
transporters and displayed modulation of their expression upon activation (Figure 
4.3), therefore next investigated the impact of obesity on the expression of these 
glucose transporters by MAIT cells. Similarly, to control subjects, MAIT cells from 
people with obesity expressed mRNA for all three glucose transporters (Figure 
4.4 A-C). Expanded MAIT cells from people with obesity, stimulated as per 
section 4.3.1 displayed no significant differences in the expression of mRNA 
coding for GLUT1, 3 and 4, when compared to the cohort of control individuals 
(Figure 4.4 A-C). This investigation showed that during early stages of MAIT 
activation, people with obesity display no defect in transcription of mRNA for 
glucose transporters GLUT1, 3 and 4. 
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Figure 4.4 MAIT cells from people with obesity showed no difference in 
mRNA expression for GLUT glucose transporters. (A-C) Scatter plot of 
normalized MAIT cell mRNA expression of glucose transporters SLC2A1, 
SLC2A3 and SLC2A4 (GLUT1,3 and 4) by purified unstimulated MAIT cells and 
cells stimulated with Dynabeads (cell to bead ratio 1:1), IL-12 and IL-18 (at 
50ng/mL each) for 4 hours derived from the controls and people with obesity 
(control n=11; obese n=6. Statistical analysis performed using one-way ANOVA 

































































































































4.3.3. MAIT cells express glutamine transporters ASCT2, SNAT1 and SNAT2 
Having established the expression of the major glucose transporter, we next 
investigated if MAIT cells express glutamine transporters. Glutamine is a non-
essential amino acid, implicated in multiple cell processes including the 
production of ATP by feeding into Kreb’s cycle, synthesis of nucleic acids by a 
provision of biosynthetic precursors and in protein O-GlcNAcylation (Altman et 
al., 2016; Hsu and Dzhagalov, 2019). Although glutamine can be synthesised de 
novo, it may also be obtained from the diet, requiring transport via glutamine 
transporters (Hsu and Dzhagalov, 2019). Glutamine can be transported in and 
out of the cells through a range of amino acid transports. ASCT2 and LAT1 have 
been reported as the main glutamine transporter in T lymphocytes (Hsu and 
Dzhagalov, 2019; Nakaya et al., 2014), however the family of SNAT, especially 
SNAT1 and SNAT2 were also shown be involved in glutamine transport in T cells 
(Hsu and Dzhagalov, 2019).  
 
Expression of the glutamine transporters was measured by real time RT-qPCR 
and expanded MAIT cells expressed mRNA coding for ASCT2, SNAT1 and 
SNAT2 transporters (Figure 4.5 A-C). Upon stimulation with TCR Dynabeads, IL-
12 and IL-18 for 4 hours, MAIT cells greatly increased their expression of SLC1A5 
(ASCT2) neutral amino transporter (Figure 4.5 A). More modest increases in the 
expression of SLC38A1 (SNAT1) and SLC38A2 (SNAT2) were observed (Figure 
4.5 B&C). MAIT cells were shown to display a similar pattern in the expression of 
glutamine transporters to the reported expression of these transporters by T cells. 
In addition, upregulation of transcription of the glutamine transporter SLC1A5 
(ASCT2) this early into activation of MAIT cells suggests that the transport of 
glutamine into MAIT cells may play an important role in their activation and 
function.  
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Figure 4.5 MAIT cells express mRNA for glutamine transporters ASCT2 and 
SNAT1&2. (A-C) Scatter plots of normalized MAIT cell mRNA expression of 
glutamine transporters (A) SLC1A5 (ASCT2) (n=9) and (B-C) SLC38A1-2 
(SNAT1-2) (n=11) by purified unstimulated MAIT cells and cells stimulated with 
TCR Dynabeads (cell to bead ratio 1:1), IL-12 and IL-18 (at 50ng/mL each) for 4 
hours in the control population sample. Statistical analysis performed using 
















































































4.3.4. MAIT cells from individuals with obesity display no difference in 
expression of mRNA for glutamine transporters 
We next decided to extend our investigations in obesity by investigating the 
mRNA expression pattern of ASCT2, SNAT1 and SNAT2 glutamine transporters 
on MAIT cells from people with obesity. Expanded MAIT cells from individuals 
with obesity were stimulated as per section 4.3.3. MAIT cells expressed SLC1A5 
(ASCT2), SLC38A1(SNAT1) and SLC38A2 (SNAT2) mRNA at levels comparable 
to the control individuals (Figure 4.6 A-C). This suggests that similarly to the 
expression of mRNA for glucose transporters (Figure 4.4), MAIT cells from 
people with obesity, display no defect in the transcription of mRNA for glutamine 
transporters at 4 hours post activation with TCR Dynabeads, IL-12 and IL-18.  
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Figure 4.6 MAIT cells from donors with obesity showed no difference in 
mRNA expression for SNAT glutamine transporters. (A-C) Scatter plot of 
normalized MAIT cell mRNA expression of glutamine transporters (A) SLC1A5 
(ASCT2), (B) SLC38A1 (SNAT1) and (C) SLC38A2 (SNAT2) by purified 
unstimulated MAIT cells and cells stimulated with Dynabeads (cell to bead ratio 
1:1), IL-12 and IL-18 (at 50ng/mL each) for 4 hours by the controls and individuals 
with obesity (SLC1A5 control n=7; obese n=3; SLC38A1 &2 control n=11; obese 
n=6). Statistical analysis performed using one-way ANOVA with Tukey’s 

































































































































4.3.5. MAIT cells express amino acid transporters LAT1- LAT4 
We next decided to investigate another family of amino acid transporters; L-type 
amino acid transporters. Out of this family, LAT1 is the best studied amino acid 
transporter. LAT1 is expressed by T cells and becomes upregulated upon 
stimulation (Sinclair et al., 2013). LAT1 is defined as an anti-porter, as it imports 
neutral essential amino acids into the cells in the exchange for glutamine. This 
particular amino acid transporter was shown to play an important role in mTORC1 
activation, as it facilitates the influx of leucine, which in turn facilitates activation 
of mTORC1, a master regulator of the cells (Sancak et al., 2008; Wolfson et al., 
2016). Functional LAT1 transporter is a heterodimer composed of CD98 heavy 
chain which was shown to be associated with LAT1. Stimulation of expanded 
MAIT cells with TCR Dynabeads, IL-12 and IL-18 for 4 hours resulted in a small 
but significant increase in SLC3A2 (CD98) mRNA expression (Figure 4.7 A). 
Much larger increase in the transcription level in comparison to the resting state 
of the cell was observed with SLC7A5 (LAT1), suggesting that this transporter 
may also play an important role in MAIT cell function (Figure 4.7 B).  
 
We next assessed whether the increases in mRNA expression of LAT1 
components are reflected at the protein level using flow cytometry and a CD98 
specific antibody. CD98 protein was expressed on MAIT cells and was 
upregulated upon stimulation of PBMC with TCR Dynabeads, IL-12 and IL-18 
cytokines for 18 hours (Figure 4.7 C&D). This data shows that the increase in the 
transcription of LAT1 (SLC7A5) & CD98 (SLC3A2) is reflected on the protein 
level, further reinforcing that this amino acid transporter may be central to MAIT 
cell function.  Investigation of the expression of other LAT amino acid transporters 
showed a varied response. There was no significant difference in the expression 
of SLC7A8 (LAT2) mRNA upon stimulation, whereas a significant increase in the 
transcription of SLC43A1 (LAT3) was observed (Figure 4.7 E&F). SLC43A2 
(LAT4) expression was significantly downregulated upon stimulation in 
comparison to the transcription in the resting cells (Figure 4.7 G). These results 
are in line with previously published data, which demonstrated upregulation of 
LAT1 expression upon stimulation by T cells. This suggests that amino acids 
transported via LAT1 are of particular importance for not only for T cell function 
but also may play a role in supporting function of MAIT cells.   
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Figure 4.7. MAIT cells express mRNA and protein for CD98 subunit of LAT1 
amino acid transporter and mRNA for LAT2-4. (A) Scatter plot of normalized 
MAIT cell mRNA expression of SLC3A2 (CD98) and (B) SLC7A5 (LAT1) by 
purified unstimulated MAIT cells and cells stimulated with Dynabeads (cell to 
bead ratio 1:1), IL-12 and IL-18 (at 50ng/mL each) for 4 hours in the control 
population sample (n=11). (C) Scatter plot of surface MFI CD98 expression by 
MAIT cells from a PBMC culture and (D) representative histogram of two control 
samples showing MFI CD98 surface expression; unstimulated or stimulated with 
TCR microbeads at 25ng/mL (Miltenyi), IL-12 and IL-18 (at 50ng/mL each) for 18 
hours in the control population sample (n=7). (E-G) Scatter plot of normalized 
MAIT cell mRNA expression of amino acid transporters SLC7A5, SLC43A1, 
SLC43A2 (LAT2-4) by purified unstimulated MAIT cells and cells stimulated with 
Dynabeads (cell to bead ratio 1:1), IL-12 and IL-18 (at 50ng/mL each) for 4 hours 
in the control population sample (n=11). Statistical analysis performed using 



















Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP13 TCR1218.fcs MAIT cells 663 8905 
BP13 BASAL.fcs MAIT cells 934 6130 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP15 TCR1218.fcs MAIT cells 580 11954 



























Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP13 TCR1218.fcs MAIT cells 663 8905 
BP13 BASAL.fcs MAIT cells 934 6130 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP15 TCR1218.fcs MAIT cells 580 11954 







































































































































4.3.6. MAIT cells in obesity express lower level of LAT1, but show no 
significant difference in transcription of other amino acid transporters 
We again extended our investigations into obesity. Stimulation of expanded MAIT 
cells from people with obesity as per section 4.3.5 led to modest upregulation of 
SLC3A2 (CD98) mRNA transcription and there was no difference noted between 
the two cohorts (Figure 4.8 A). However, the expression of SLC7A5 mRNA was 
diminished in people with obesity (Figure 4.8 B). We also noted decreased 
expression of CD98 protein on the cell surface of MAIT cells from people with 
obesity in comparison to the control individuals (Figure 4.8 C&D). Next, we 
investigated whether MAIT cells from people with obesity have altered 
transcription of the other three LAT transporters. Stimulation of the expanded 
MAIT cells as per section 4.3.5 showed no difference in the expression of mRNA 
for LAT2 (SLC7A8) or LAT3 (SLC43A1) between two cohorts (Figure 4.9 A&B). 
Expression of SLC43A2 (LAT4) mRNA showed a similar trend of downregulation 
of transcription upon cell activation, however MAIT cells from people with obesity 
displayed an impaired expression of the LAT4 transcription in comparison to the 
cohort of control individuals (Figure 4.9 C). Collectively, this data shows that MAIT 
cells from people with obesity show a defect in the expression of LAT1 amino 
acid transporter, which may have downstream impact on the transport of amino 
acids into the cells and thus may lead to their impaired function.   
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Figure 4.8 MAIT cells from obese donors show lower expression of LAT1 
transporter. (A)Scatter plot of normalized MAIT cell mRNA expression of 
SLC3A2 (CD98) and (B) SLC7A5 (LAT1) by purified unstimulated MAIT cells and 
cells stimulated with Dynabeads (cell to bead ratio 1:1), IL-12 and IL-18 (at 
50ng/mL each) for 4 hours by control and obese individuals (lean n=11; obese 
n=6). (C) Scatter plot of surface MFI CD98 expression by MAIT cells from a 
PBMC culture (lean n=3; obese n=3) and (D) representative histogram of two 
control samples showing CD98 surface expression; unstimulated or stimulated 
with TCR microbeads at 25ng/mL (Milteneyi), IL-12 and IL-18 (at 50ng/mL each) 
for 18 hours by the control and obese samples (n=3). Statistical analysis 
performed using one-way ANOVA with Tukey’s correction, ns-not significant, ** 






































C. D. Sample Name Subset Name Count Geometric Mean : Comp-BL1-ACTRL2 Stim.fcs MAITs 1204 7424 
CTRL2 Basal.fcs MAITs 1218 5694 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
1783 Stim.fcs MAITs 517 4555 
1783 Basal.fcs MAITs 500 3173 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
CTRL2 Stim.fcs MAITs 1204 7424 
CTRL2 Basal.fcs MAITs 1218 5694 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
1783 Stim.fcs MAITs 517 4555 
1783 Basal.fcs MAITs 500 3173 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
CTRL3 Stim.fcs MAITs 1820 8948 
CTRL3 Basal.fcs MAITs 2234 6095 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
1784 Stim.fcs MAITs 631 6092 
1784 Basal.fcs MAITs 495 3972 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
CTRL3 Stim.fcs MAITs 1820 8948 
CTRL3 Basal.fcs MAITs 2234 6095 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
1784 Stim.fcs MAITs 631 6092 



































































































Figure 4.9 MAIT cells from obese donors express similar levels of LAT2-4 
mRNA level to the control samples. (A-C) Scatter plot of normalized MAIT cell 
mRNA expression of glucose transporters SLC7A5, SLC43A1, SLC43A2 (LAT2-
4) by purified unstimulated MAIT cells and cells stimulated with Dynabeads (cell 
to bead ratio 1:1), IL-12 and IL-18 (at 50ng/mL each) for 4 hours from controls 
and individuals with obesity (lean n=11; obese n=6). Statistical analysis 




































































































































4.3.7. Stimulation of MAIT cells increases their size 
Having determined the expression of the major nutrient transporters on MAIT 
cells and the impact of activation, we next aimed to define the metabolic profile 
of MAIT cells. A study by Howden et al., which investigated the proteome of CD4+ 
and CD8+ T cells found that naïve CD8+ had a higher protein content than naïve 
CD4+ cells. This was reflected in the FSC measurement, where CD8+ cells were 
larger than CD4+ cells (Howden et al., 2019). The authors suggested the size of 
the cells was proportional to the protein content of that cell. Upon cell activation 
the protein content increases, of which a substantial proportion of the proteins 
are related to metabolism (Howden et al., 2019). Therefore, this data suggests 
that the size of a cell can be used to estimate the metabolic activity. The size of 
immune cells can be easily evaluated using the flow cytometry by measuring the 
FSC. Based on this observation from Howden et al., we assessed whether the 
size (therefore metabolic activity) of MAIT cells was altered upon stimulation with 
5-ARU and MG for five days and observed an increase in MAIT cell size (Figure 
4.10 A&B). This indicates that MAIT cells upregulate the synthesis of a large 





Figure 4.10 MAIT size increases upon extended stimulation. (A) Scatter plot 
and mean MAIT cell size (FSC-A) basally and after 5 days of stimulation. PBMC 
were unstimulated (basal) or stimulated (stim) with 5-ARU (1μg/mL) and MG 
(100μL) on day 0 and received a low dose of IL-2 (6.75ng/μL) on day 1 followed 
by a high dose of IL-2 (33.3ng/μL) on day 4 (n=17). (B) Representative 
histograms from 2 control subjects of MAIT cell size after 5 days of culture. 
Statistical analysis performed using paired student’s t-test, ****p≤0.0001.  
Sample Name Subset Name Count Mean : FSC-A
BP56 5ARUMG ONLY D5.fcs MAIT cells 1448 8.17E5 
BP56 pre-prolif PBMC no violet.fcs MAIT cells 1617 5.00E5 
Sample Name Subset Name Count Mean : FSC-A
BP57 5ARUMG ONLY D5.fcs MAIT cells 856 6.60E5 
BP57 pre-prolif PBMC no violet.fcs MAIT cells 1050 5.19E5 
Sample Name Subset Name Mean : FSC-A
BP58 5ARUMG ONLY D5.fcs MAIT cells 6.56E5 
BP58 pre-prolif PBMC no violet.fcs MAIT cells 5.53E5 
Sample Name Subset Name Count Mean : FSC-A
BP67 5 ARU MG only (inhib).fcs MAIT cells 12208 5.91E5 































4.3.8. MAIT cells upregulate glycolysis upon stimulation 
As discussed in section 4.1, the role of glucose and glycolysis in T cell function 
is very well established (Cham et al., 2008; Chang et al., 2013; Jacobs et al., 
2008; Shi et al., 2011). Having demonstrated the expression of glucose 
transporters by MAIT cells, we next investigated the level of glycolysis in resting 
and stimulated MAIT cells using extracellular flux analysis (Seahorse). 
Extracellular flux analysis allows for the measurement of glycolysis rate by 
measuring the ECAR. Upon transport of glucose into the cell, the molecule is 
metabolised through glycolysis to pyruvate and lactate, releasing protons during 
this process. As the protons are exported from the cell, this leads to acidification 
of the cell culture media. The concentration of these protons is measured during 
seahorse assay and is directly proportional to the rate of glycolysis. Expanded 
MAIT cells were unstimulated or stimulated with TCR microbeads, IL-12 and IL-
18 for 18 hours prior to the seahorse analysis. Once placed on the seahorse 
instrument, data on the rates on MAIT cell glycolysis was collected by measuring 
ECAR over an hour. During the real-time measurement oligomycin, and ATP 
synthase inhibitor, was injected 15 minutes into the incubation to inhibit oxphos 
and forced the cells to fully switch to use glycolytic metabolism to support their 
function. At 35 minutes 2DG was injected to inhibit glycolysis and show that the 
ECAR measured in the experiments was due to the glycolysis and no other cell 
processes. Here, we demonstrated increased rates of ECAR by MAIT cells upon 
stimulation (Figure 4.11 A&B). This data shows that MAIT cells engage in 
glycolytic metabolism upon activation. In addition to ECAR rates, glycolytic 
capacity was measured by adding oligomycin, which inhibits ATP synthase and 
thus OxPhos. This forces the cell to use glycolysis to its maximal capacity in order 
to produce ATP to sustain cell function. There was no significant difference in the 
glycolytic capacity between basal and stimulated MAIT cells, however a trend 





Figure 4.11 MAIT cells upregulate glycolysis upon stimulation. (A) 
Representative Seahorse trace and (B) scatter plot of ECAR rate as wells as (C) 
scatter plot of glycolytic capacity of MAIT cells basally or upon stimulation with 
TCR microbeads (Miltenyi 25ng/mL) and IL-12/IL-18 cytokines (at 50ng/mL each) 
for 18 hours (n=4). Statistical analysis performed using paired student’s t-test, ns-





































4.3.9. Stimulation of MAIT cells modulates expression of enzymes of 
glycolysis 
With our observation that MAIT cells increase their glycolytic rate upon 
stimulation (Figure 4.11), we next aimed to confirm this finding by investigating 
the expression of key glycolytic enzymes, such as Hexokinase 2 (HK2), Pyruvate 
kinase (PKM) and Lactate dehydrogenase A (LDHA). Upon stimulation of 
expanded MAIT cells with TCR Dynabeads, IL-12 and IL-18 for 4 hours we 
observed increased mRNA expression of HK2 and PKM indicating enhanced 
glycolytic metabolism (Figure 4.12 A&B). To assess whether the increase in 
transcription of these enzymes is reflected on the protein level, we used flow 
cytometry and noted increased MAIT cell HK2 expression upon stimulation of 
PBMC with TCR Dynabeads, IL-12 and IL-18 for 18 hours (Figure 4.12 C&F). In 
contradiction to the molecular results, PKM2 expression at 18 hours post 
stimulation was shown to be unchanged (Figure 4.12 D&G). In addition, we 
investigated the protein level of LDHA in activated MAIT cells and found 
significantly enhanced expression of this enzyme (Figure 4.12 E&H). In summary 




Figure 4.12 MAIT cells upregulate expression HKII and LDHA, but not PKM2 
protein expression upon stimulation (A-B) Scatter plot of HK2 (n=13) and PKM 
(n=9) mRNA produced by purified MAITs basally upon stimulation with TCR 
Dynabeads (1:1 cell to bead ratio) and IL-12/IL-18 (50ng/mL each) cytokines for 
4 hours. (C-E) Scatter plot and (F-H) representative histograms of HK2 (n=8), 
PKM2 (n=4) and LDHA (n=8) enzymes respectively, produced by MAIT cells from 
a PBMC culture basally and upon stimulation with TCR Dynabeads and IL-12/IL-
18 cytokines for 18 hours (n=8). Statistical analysis performed using student’s t-


































Sample Name Subset Name Count Geometric Mean : Comp-RL1-A
BP76 STIM.fcs MAIT cells 4439 6642 
BP76 BASAL.fcs MAIT cells 4237 1554 
Sample Name Subset Name Count Geometric Mean : Comp-RL1-A
BP78 STIM.fcs MAIT cells 408 8960 
BP78 BASAL.fcs MAIT cells 562 2139 
Sample Name Subset Name Count Geometric Mean : Comp-RL1-A
BP75 STIM.fcs MAIT cells 2701 12686 





Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP80 STIM.fcs MAIT cells 1318 408 
BP80 BASAL.fcs MAIT cells 2035 1323 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP82 STIM.fcs MAIT cells 1299 86.4 
BP82 BASAL.fcs MAIT cells 853 266 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP80 STIM.fcs MAIT cells 1318 408 
BP80 BASAL.fcs MAIT cells 2035 1323 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP82 STIM.fcs MAIT cells 1299 86.4 
BP82 BASAL.fcs MAIT cells 853 266 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP81 STIM.fcs MAIT cells 2690 207 
BP81 BASAL.fcs MAIT cells 1700 473 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP80 STIM.fcs MAIT cells 1318 408 
BP80 BASAL.fcs MAIT cells 2035 1323 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP82 STIM.fcs MAIT cells 1299 86.4 
BP82 BASAL.fcs MAIT cells 853 266 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP80 STIM.fcs MAIT cells 1318 408 
BP80 BASAL.fcs MAIT cells 2035 1323 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP82 STIM.fcs MAIT cells 1299 86.4 
BP82 BASAL.fcs MAIT cells 853 266 
Sample Name Subset Name Count Geometric Mean : Comp-YL1-A
BP81 STIM.fcs MAIT cells 2690 207 






Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP77 STIM.fcs MAIT cells 417 25108 
BP77 BASAL.fcs MAIT cells 618 7685 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP75 STIM.fcs MAIT cells 2701 28100 
BP75 BASAL.fcs MAIT cells 2753 6236 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP77 STIM.fcs MAIT cells 417 25108 
BP77 BASAL.fcs MAIT cells 618 7685 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP75 STIM.fcs MAIT cells 2701 28100 
BP75 BASAL.fcs MAIT cells 2753 6236 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP76 STIM.fcs MAIT cells 4439 8873 
BP76 BASAL.fcs MAIT cells 4237 4470 
Sample Name Subset Name Count Geometric Mean : Comp-BL1-A
BP1 STIM.fcs MAIT cells 3844 10678 








































































4.3.10. MAIT cells from people with obesity display impaired glycolysis 
Having demonstrated that glycolytic metabolism is central to MAIT cell activation 
(Figure 4.11 & 4.12), we next investigated the impact of obesity on MAIT cell 
metabolism. Stimulation of expanded MAIT cells from people with obesity with 
TCR Dynabeads, IL-12 and IL-18 for 18 hours did not increase their rates of 
glycolysis (Figure 4.13 A&B). MAIT cells form people with obesity also failed to 
increase their glycolytic capacity upon stimulation. In addition, glycolytic capacity 
of stimulated MAIT cells from people with obesity was significantly lower in 
comparison to the control group (Figure 4.13 C). To explore this failure to 
upregulate glycolysis in more detail, expression of mRNA for glycolytic enzymes 
was measured. In comparison to the control cohort, we noted no differences in 
the expression of either HK2 or PKM upon stimulation for 4 hours with TCR 
Dynabeads and cytokines (Figure 4.14 A&B). Despite the fact that MAIT cells 
from people with obesity displayed no impairment in the expression of mRNA for 
glucose transporters in comparison to the control individuals (Figure 4.4), this 
data indicates a clear defect in the rates of glycolysis. Collectively this data 
indicates that obesity not only impacts MAIT cells proliferation and cytokine 
production (chapter three), but also glycolytic metabolism.  
  
126 
Figure 4.13 MAIT cells from people with obesity don’t upregulate glycolysis 
upon stimulation. (A) Representative Seahorse trace and (B) a scatter plot of 
MAIT cells ECAR rate as wells as (C) a scatter plot of glycolytic capacity of MAIT 
cells basally or upon stimulation with TCR microbeads (Miltenyi 25ng/mL) and IL-
12/IL-18 cytokines (at 50ng/mL each) for 18 hours (control n=6; obese n=6). 
Statistical analysis performed using one-way ANOVA with Tukey’s correction, ns-
































































Figure 4.14 MAIT cells from people with obesity display a non-significant 
alteration mRNA expression of HKII and PKM2 enzymes. Scatter plot of (A) 
HK2 (control n=13, obese n=6) and (B) PKM (control n=9, obese n=4) mRNA 
expression by purified MAITs from control and obese cohort, basally and upon 
stimulation with TCR Dynabeads (1:1 cell to bead ratio) and IL-12/IL-18 (50ng/mL 
each) cytokines for 4 hours. Statistical analysis performed using one-way ANOVA 






















































































4.3.11. MAIT cells actively use LAT1 amino acid transporters 
We next investigated a role for LAT1 in MAIT cell metabolism, as it was the most 
abundantly expressed transporter on activated MAIT cells (Figure 4.7 A-D). 
Although LAT1 is known to transport multiple amino acids including leucine, 
kynurenine a metabolite of t-tryptophan is reported to be a substrate of LAT1 
(Sinclair et al., 2018). Kynurenine was shown to be auto fluorescent, and this 
feature was used by Sinclair et al. to develop a kynurenine uptake assay, which 
allows for the measurement of kynurenine uptake via LAT-1 by immune cells 
using flow cytometry (Sinclair et al., 2018). In this study we used the kynurenine 
assay developed by Sinclair et al. to assess the activity of the LAT1 amino acid 
transporter in MAIT cells and the efficiency BCH to inhibit transport via LAT1 
(Sinclair et al., 2018). We observed significant kynurenine uptake over 4-minute 
incubation by basal MAIT cells from PBMC samples (Figure 4.15 A&B) and 
expanded MAIT cells (Figure 4.15 C&D), which was significantly reduced upon 
incubation with LAT1 specific BCH inhibitor (Figure 4.15 A&B; Figure 4.15 C&D). 
This data indicates that LAT1 expressed by MAIT cells is active and capable of 
importing LAT1 specific substrates, whereas BCH was shown to specifically 
inhibit LAT1 mediated transport.   
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Figure 4.15 MAIT cells import kynurenine via LAT1 amino acid transporter. 
(A) Scatter plot and (B) representative histograms of basal uptake of kynurenine 
(200μM) in the presence or absence of BCH (20mM) by MAIT cells from PBMC 
of healthy individuals during 4 minutes of incubation (n=4) (C) Scatter bar and (D) 
representative histograms of basal uptake of kynurenine (200μM) by expanded 
MAIT cells from healthy individuals in the presence or absence of BCH (20mM) 
during 4 minutes (n=10). Statistical analysis performed using one-way ANOVA 





























Sample Name Subset Name Count
KYN DT BCH 37 basal.fcs MAIT cells 347 
Kyn DT Kyn 37 basal.fcs MAIT cells 394 
Kyn DT HBSS basal.fcs MAIT cells 334 
Sample Name Subset Name Count
Kyn RP BCH Basal.fcs MAIT cells 1909 
Kyn RP Kyn 37 basal.fcs MAIT cells 1919 
Kyn RP HBSS basal.fcs MAIT cells 2045 
Sample Name Subset Name Count
KYN DT BCH 37 basal.fcs MAIT cells 347 
Kyn DT Kyn 37 basal.fcs MAIT cells 394 
Kyn DT HBSS basal.fcs MAIT cells 334 
Sample Name Subset Name Count
Kyn RP BCH Basal.fcs MAIT cells 1909 
Kyn RP Kyn 37 basal.fcs MAIT cells 1919 










































Sample Name Subset Name Count Geometric Mean : VL1-A
C18 4d.fcs MAIT cells 56735 425 
C18 BCH.fcs MAIT cells 43299 670 
C18 37d.fcs MAIT cells 42568 1782 
Sample Name Subset Name Count Geometric Mean : VL1-A
C19 BCH.fcs MAIT cells 50573 620 
C19 37d.fcs MAIT cells 51492 1698 
C19 4d.fcs MAIT cells 42369 489 
Sample Name Subset Name Count Geometric Mean : VL1-A
C18 4d.fcs MAIT cells 56735 425 
C18 BCH.fcs MAIT cells 43299 670 
C18 37d.fcs MAIT cells 42568 1782 
Sample Name Subset Name Count Geometric Mean : VL1-A
C19 BCH.fcs MAIT cells 50573 620 
C19 37d.fcs MAIT cells 51492 1698 












4.3.12. MAIT cells from people with obesity display defective LAT1 
mediated transport 
 
Previously we had demonstrated a decrease in the expression of LAT1 
transporter by MAIT cells from people with obesity (Figure 4.8). Therefore, we 
next investigated Kynurenine uptake by MAIT cells from people with obesity and 
demonstrated impaired kynurenine uptake in comparison to healthy controls 
(Figure 4.16 A&B). Collectively this data suggests that lower expression of LAT1, 
leads to this reduced uptake of kynurenine and potential large neutral amino 
acids.   
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Figure 4.16 Obese MAIT cells have impaired uptake of kynurenine via LAT1 
amino acid transporter. (A) Scatter plot and (B) representative histograms of 
basal uptake of kynurenine by MAIT cells from PBMCs culture of control and 
obese individuals (n=4). Statistical analysis performed using one-way ANOVA 













































Kyn 1664 Kyn 37 basal.fcs
MAIT cells
119
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
Kyn 1664 Kyn 37 basal.fcs MAIT cells 119 7357 
Kyn 1664 HBSS basal.fcs MAIT cells 124 1099 
Kyn 1665 Kyn 37 basal.fcs
MAIT cells
301
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
Kyn 1665 Kyn 37 basal.fcs MAIT cells 301 5751 













































Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
Kyn DT Kyn 37 basal.fcs MAIT cells 394 8699 
Kyn DT HBSS basal.fcs MAIT cells 334 1058 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
Kyn RP Kyn 37 basal.fcs MAIT cells 1919 8881 







Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
KYN DT BCH 37 basal.fcs MAIT cells 347 1842 
Kyn DT Kyn 37 basal.fcs MAIT cells 394 8699 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
Kyn RP BCH Basal.fcs MAIT cells 1909 1888 










Kyn 1664 Kyn 37 basal.fcs
MAIT cells
119
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
Kyn 1664 Kyn 37 basal.fcs MAIT cells 119 7357 
Kyn 1664 HBSS basal.fcs MAIT cells 124 1099 
Kyn 1665 Kyn 37 basal.fcs
MAIT cells
301
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
Kyn 1665 Kyn 37 basal.fcs MAIT cells 301 5751 














4.3.13. MAIT cells require amino acid influx via LAT1 to activate mTORC1 
and glycolysis 
Published studies have shown that LAT1 is responsible for the influx of leucine 
into T cells, which was shown to activate mTOR, a master regulator of cellular 
metabolism. We first investigated if MAIT cells utilize mTOR by assessing 
mTORC1 activity as measured by the phosphorylation of S6, a downstream 
target of mTORC1. Upon stimulation of MAIT cells with TCR microbeads, IL-12 
and IL-18 for 18 hours, phosphorylation of S6 was significantly increased (Figure 
4.17 A&B). We next assessed the impact of LAT1 inhibition on mTORC1 activity 
and noted a non-significant reduction in the phosphorylation of S6 protein (Figure 
4.17 C&D). As mTOR is known to orchestrate the metabolism of T cells, including 
the control of glycolysis, next we decided to investigate whether limiting amino 
acid influx will alter the rate of glycolysis. To address this question, we used the 
ECAR assay as described in section 4.3.8. Expanded MAIT cells were 
unstimulated or stimulated with TCR microbeads, IL-12 and IL-18 for 18 hours in 
the presence or absence of BCH before the cells were put on the Seahorse 
instrument for analysis. Limiting the amino acid influx using BCH resulted in the 
significant reduction in glycolysis as well as glycolytic capacity (Figure 4.18 
A,B,C). This data suggests that amino acids imported via LAT1, most likely 
leucine, are required for activation of mTORC1, which in turn is required for 
upregulation of glycolysis.  
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Figure 4.17 Amino acid transport via LAT1 is important for mTOR 
activation. (A) Scatter plot and (B) representative histogram of pS6 expression 
by MAIT cells from PBMCs culture of control individuals. Cells unstimulated or 
stimulated with TCR microbeads at 25ng/mL (Milteneyi), IL-12 and IL-18 (at 
50ng/mL each) for 18 hours (n=3). (C) Scatter plot and (D) representative 
histogram of pS6 expression by MAIT cells from PBMCs culture of control 
individuals. Cells stimulated with TCR microbeads at 25ng/mL (Milteneyi), IL-12 
and IL-18 (at 50ng/mL each) for 18 hours with or without BCH inhibitor (50mM) 
































Sample Name Subset Name Count Geometric Mean : Comp-PE-A
Samples_RM Stim.fcs MAITs 874 3570 
Samples_RM Basal.fcs MAITs 2244 2554 
Sample Name Subset Name Count Geometric Mean : Comp-PE-A
Samples_RM BCH.fcs MAITs 795 2969 





















Figure 4.18 Amino acid transport via LAT1 is necessary for upregulation of 
glycolysis. (A) Representative Seahorse trace and (B) a scatter plot of MAIT 
cells ECAR rate as wells as (C) a scatter plot of glycolytic capacity of MAIT cells 
basally or upon stimulation with TCR microbeads (Miltenyi 25ng/mL) and IL-
12/IL-18 cytokines (at 50ng/mL each) in the presence or absence of BCH (50mM) 
for 18 hours. Cells cultured in media diluted 1:2 with HBSS (n=4). Statistical 
analysis performed using one-way ANOVA with Tukey’s correction, ns-not 















































Over the past decade, research in the area of immunometabolism has massively 
increased. Elaborate studies have illustrated that T cell function heavily relies on 
the precisely orchestrated cell metabolism. This aspect of immune cell activity 
has been largely taken for granted and overlooked for many years, however it is 
now well established that altered cell metabolism can have detrimental effects on 
immune cell function. Therefore, in this study we aimed to elucidate for the first 
time, which metabolic pathways control MAIT cell activation. 
 
We found that MAIT cells express mRNA for glucose transporters GLUT1, 3 and 
4, the expression of which was modestly upregulated at an early point during their 
activation. The literature suggests that glucose transporters expression is 
controlled during transcription and protein synthesis, as stimulation of T cells 
increased the mRNA and protein levels (Cretenet et al., 2016; Frauwirth et al., 
2002; Kavanagh Williamson et al., 2018). Our data indicates that the stimulation 
of MAIT cells also leads to the initiation of early metabolic reprogramming, to 
support the influx of glucose by increasing transcription of some of the GLUT 
transporters. Parallel work from our lab has shown that the activation of MAIT 
cells increases uptake of glucose after overnight stimulation (O’Brien et al. 2019; 
Figure 1D). Together these results illustrate an important role for glucose in 
supporting MAIT cell activation.  
 
Studies in T cells have established that glycolysis is the dominant pathway used 
by effector T cells during activation (Chang et al., 2013; Gubser et al., 2013; 
Michalek et al., 2011; Procaccini et al., 2016). Our study shows that MAIT cells, 
a potent effector cell subset, also upregulate the rate of glycolysis upon 
stimulation, however there is no significant difference in the glycolytic capacity 
between basal and stimulated cells. This was elucidated by measuring the 
extracellular acidification rate, which assessed the glycolytic rate in MAIT cells in 
real time. Enhancement of glycolysis was accompanied by significant 
upregulation of hexokinase 2, the first enzyme of the glycolytic pathway. On the 
other hand, short-time stimulation of MAIT cells significantly increased the 
expression of transcripts for pyruvate kinase, the last enzyme of the glycolysis 
pathway. However, after overnight stimulation, the level of PKM2 enzyme was 
non-significantly lower in comparison to the resting cells. This suggested that the 
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transcription of this enzyme is more important at earlier timepoints in MAIT cell 
activation. Expression of LDHA, an enzyme involved in the conversion of 
pyruvate into lactic acid was higher after overnight stimulation, suggesting that 
MAIT cells were still converting pyruvate into lactate. Collectively this data is in 
line with results published on effector T cell metabolism. It indicates that MAIT 
cells engage in a similar metabolic programme upon activation, during which they 
significantly increase glycolysis, likely to support the demand for ATP production 
and provision of intermediates required for the synthesis of proteins such as 
cytokines or lipids and nucleic acids required for cell division.  
 
Recent research has highlighted the importance of leucine in controlling 
mTORC1 activation, which is responsible for control of glycolysis in T cells 
(Saxton et al., 2016; Sinclair et al., 2013; Wolfson et al., 2016), therefore next we 
decided to investigate how the import of this amino acid affects the glycolytic 
metabolism of MAIT cells. Leucine is imported into the cells via large amino acid 
transporters, of which LAT1 mediates is majority of the transport (Maimaiti et al., 
2020; Scalise et al., 2018; Sinclair et al., 2013), therefore we measured this 
transporter expression by MAIT cells. Transcription of mRNA for both 
components of LAT1 heterodimer was significantly increased upon MAIT cell 
stimulation, which was reflected on the protein level. This is in line with the data 
reported by Sinclair et al. who demonstrated enhancement of LAT1 expression 
by conventional CD8+ T cells upon stimulation (Sinclair et al., 2013). Transcription 
of other members of the LAT family of transporters varied upon stimulation. The 
observed diversity in the expression pattern may occur as a result of the induction 
of different amino acid transporters at different timepoints. Although LAT1-3 
presented a trend towards upregulation of transcription of those transporters, 
expression of LAT4 has been downregulated. LAT4 has been shown to transport 
a range of amino acids including essential and branched chained amino acids, 
suggesting that transport of these amino acids via LAT4 may not play a critical 
role in activated MAIT cells (Bodoy et al., 2005). As upregulation of LAT1 has 
been the most prominent, next we evaluated it’s transport capacity using a 
kynurenine assay developed by the Cantrell lab (Sinclair et al., 2018). 
Kynurenine, a metabolite of tryptophan, is a substrate of LAT1. The fluorescent 
properties of kynurenine allowed for a rapid measurement of its uptake by the 
immune cells, and hence allowed for indirect assessment of the efficiency of 
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transport of amino acids via this amino acid transporter (Sinclair et al., 2018). In 
line with the data published by Sinclair et al., our study found that LAT1 expressed 
by MAIT cells is functional and imports kynurenine into these cells. To assess the 
effect of amino acid transport via LAT1 on MAIT cell glycolytic metabolism, we 
limited the influx of amino acids using BCH, a LAT1 specific inhibitor. Despite the 
activation signals, restraining of the amino acid transport resulted in a significant 
reduction in the rate of glycolysis, which resembled the rate of unstimulated MAIT 
cells, as well as significant reduction of glycolytic capacity was observed. This 
data indicated that LAT1 mediated amino acid transport is indispensable for 
modulation of the glycolysis rate.  
 
mTORC1 is the master regulator of metabolism, which controls multiple 
processes including glycolysis (Salmond, 2018). Direct inhibition of mTORC1 
activity with rapamycin during T cell stimulation or deletion of mTORC1 
component Rheb, has been shown to have a detrimental effect on glycolysis, 
leading to impairment in its upregulation (Hukelmann et al., 2016; Pollizzi et al., 
2015). mTORC1 is sensitive to the influx of leucine, which is largely mediated by 
LAT1 amino acid transporter (Saxton et al., 2016; Sinclair et al., 2013; Wolfson 
et al., 2016). Sinclair et al. has elegantly shown that T cells absolutely require 
LAT1 for metabolic reprogramming, and control of mTORC1 activity (Sinclair et 
al., 2013). Here we hypothesised that blocking LAT1 during MAIT cell stimulation, 
may result in impairment in activation of mTORC1 complex. Indeed, activation of 
mTORC1 as measured by phosphorylation of S6 protein, was reduced upon 
MAIT cell activation in the presence of LAT1 inhibitor. This was confirmed in 
expanded MAIT cells (O’Brien et al. 2019 Figure 4I), where the inhibition of LAT1 
mediated transport, resulted in significant reduction in mTORC1 activity. This is 
in line with study published by Loftus et al. on NK cells where the blocking of 
amino acid transport via LAT1, led to the reduction in pS6 protein expression and 
c-Myc activation (Loftus et al., 2018). Parallel work from our lab has also revealed 
that the inhibition of mTORC1 with rapamycin in MAIT cells, significantly impairs 
their glycolytic metabolism as shown through the measurement of extracellular 
acidification rate (O’Brien et al. 2019 Figure 3E). Similar reports were published 
by Hukelmann et al. and Donnely et al. in T cells and NK cells respectively, 
indicating mTORC1 is crucial for controlling of glycolysis in lymphocytes 
(Donnelly et al., 2014; Hukelmann et al., 2016).  
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Collectively this data shows that MAIT cells undergo metabolic reprogramming 
upon stimulation. Activation of MAIT cells increases the expression of LAT1 
amino acid receptor on the cell surface, which facilitates the uptake of amino 
acids including leucine, to support the activated state of the cell. Detection of 
leucine by mTORC1 increases its activity and leads to upregulation of the 
glycolysis rate (Figure 4.19).  
People with obesity display a significant defect in MAIT cell proliferation and 
cytokine production, however the underpinning mechanism responsible for those 
defects has not yet been described. Having established some of the metabolic 
pathways required for successful MAIT cell activation, next we investigated those 
in people with obesity. MAIT cells from people with obesity displayed a defect at 
each point of this metabolic pathway. In comparison to the control individuals, 
MAIT cells from people with obesity displayed diminished expression of LAT1. 
This most likely leads to the reduced uptake of kynurenine and hence other LAT1 
substrates such as leucine. This results in lower accumulation of leucine in the 
cell, which is sensed by mTORC1. Lower levels of the amino acid concentration 
may mistakenly provide a signal to the cell indicating there are not enough 
nutrients available for the cell to engage in activation. The failure of leucine to 
reach the appropriate threshold required to induce mTORC1 activity leads to a 
failure to upregulate glycolysis (Figure 4.19). More research is required to 
elucidate why the expression of LAT1 amino acid transporter is lower in people 
with obesity. A defect in LAT1 expression may be due to only partial engagement 
of the cells in a signalling pathway which is activated upon cell stimulation to 
upregulate the expression of mRNA for LAT1 and failure to export fully formed 
LAT1 transporters onto the surface of the cell.  
 
Alterations in the function and metabolism of immune cells from people with 
obesity are not limited to MAIT cells. Children with obesity were shown to have a 
defect in their cytotoxic activity and presented with an activated metabolic 
phenotype in comparison to their lean counterparts (Tobin et al., 2017). This 
study found that NK cells from children with obesity have enhanced basal 
glycolysis in comparison to lean children and failed to upregulate it any further 
upon stimulation. This was accompanied by higher activation of mTORC1 basally 
and failure to significantly upregulate its activity after 18 hours stimulation. These 
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results indicate that resting NK cells from children with obesity are highly 
glycolytic, but fail to enhance their metabolism upon activation, possibly leading 
to the alteration in their function (Tobin et al., 2017). The failure of NK cells to 
increase their glycolytic metabolism upon activation, in part resembles the 
findings from our study of MAIT cells, which are not capable of enhancing their 
glycolytic metabolism to the levels observed in the control subjects. Study by 
Michelet et al. suggested this alteration in NK cell metabolism in people with 
obesity is due to their intracellular accumulation of lipids, which were shown to 
significantly decrease their mTORC1 activity, glycolysis and impaired their 
cytotoxicity (Michelet et al., 2018). In the future, lipid handling by MAIT cells and 
its impact on their metabolism should also be investigated. These studies further 
indicate that obesity has a significant impact on immune cells function and 
metabolism and highlights that immune cell metabolism is closely related to their 
function.  
Figure 4.19 Summary of findings of chapter four. Upon stimulation of MAIT 
cells from control individuals (left), IFNγ and SLC7A5 mRNA is transcribed. 
Expression LAT1 transporter is upregulated, which allows for amino acid influx. 
Transport of amino acids such as leucine, activates mTORC1, which enhances 
glycolysis producing multiple metabolic precursors. This supports increased IFNγ 
production. MAIT cells from people with obesity (right) upon stimulation display 
lower levels of IFNY and SLC7A5 transcription. In addition, LAT1 expression and 
transport is also impaired, leading to defects in mTORC1 activation. This in turn 
results in failure to enhance glycolysis, leading to lower level of metabolic 
precursors and hence lower IFNγ production. 
 
  











Metabolic requirements for 




5.1.1 Immunometabolism and cell function 
Recognition of cellular metabolism as one of the crucial processes that impacts 
the activity of immune cells has led to substantial advancements in our 
understanding of mechanisms which control immune cell function. Understanding 
the complex web of interlinked metabolic pathways poses a great challenge in 
identifying their direct or indirect association with a particular cellular response. It 
is now known that the metabolism of immune cells doesn’t stay constant during 
its lifespan. Metabolism itself is very flexible and is capable of adjusting to the 
energetic and biosynthetic demands of the cell at any given time (Almeida et al., 
2016). Extensive research has identified glycolysis and OxPhos as two key 
pathways implicated in supporting the immune function of T cells. The metabolic 
state of quiescent or effector T cells were shown to be quite distinct. During 
quiescent state, cells primarily engage in Kreb’s cycle and OxPhos, to produce 
high amounts of ATP, whereas stimulation results in rapid metabolic 
reprogramming, leading to the strong enhancement of glycolysis, which becomes 
the dominant metabolic pathway (O’Neill et al., 2016). This provides the cell with 
energy in the form of ATP and a range of metabolic intermediates, which directly 
or indirectly contribute to T cell effector function as described in chapter four. As 
a result, recent research of T cell metabolism has been largely focused on the 
consequences brought on by the disturbance of glycolysis and glycolysis-related 
pathways during cell activation. Indeed, glycolysis was described to support the 
production of cytokines by T cells and impact their proliferation. Glucose 
restriction or inhibition of glycolysis reduced the capability of T cells to produce 
IFNγ (Jacobs et al., 2008; Renner et al., 2015). Similar effects were brought on 
by inhibition of mTORC1 or amino acid influx, which indirectly led to the restriction 
of glycolytic metabolism (Pollizzi et al., 2015; Sinclair et al., 2013; Yang et al., 
2013). The relationship between the glycolytic metabolism and T cell cytokine 
production has been explored in detail in chapter four, therefore here we will focus 
on the association between T cell metabolism and their proliferation. The 
involvement of metabolism in the production of T cell effector molecules is 
beginning to unravel, however details of how metabolism affects T cell 
proliferation is still relatively poorly explored. T cell proliferation is dependent on 
a range of metabolic processes including glycolysis and OxPhos. As early as 
1994, glucose was reported to be essential for T cell proliferation. (Greiner et al., 
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1994). This finding has been revisited since by multiple researchers. Jacobs et 
al. showed that glucose is required for T cell proliferation, as a reduction of 
glucose below 0.5mM in the culture media, significantly affected their proliferation 
capacity (Jacobs et al., 2008). Chang et al. also demonstrated that activated T 
cells rely on glycolysis as their incubation in media without sugars, strongly 
inhibited their proliferation. Substitution of glucose with galactose, which forced 
the cells to switch from glycolysis to OxPhos to support their function, slowed 
down T cell proliferation, but didn’t inhibit it (Chang et al., 2013), as it has been 
observed with direct treatment of T cells with 2DG (Cham et al., 2008). This is in 
line with an earlier study by Delgoffe et al. which investigated the impact of Rheb 
deficiency (mTOCR1) on T cell function in mice. This study showed that mTORC1 
deficiency causes retardation of T cell proliferation, but not a complete inhibition 
(Delgoffe et al., 2011).   
 
As cells have been shown to switch between glycolysis and OxPhos depending 
on their energetic and biosynthetic requirements, the role of OxPhos has been 
investigated in T cell proliferation. Blocking of OxPhos using complex I, III or ATP 
synthase inhibitors does not lead to complete obstruction of proliferation. In fact, 
Chang et al. this study has also presented that inhibition of OxPhos, lead to 
enhancement of glycolysis, likely to compensate for the loss of ATP and 
biosynthetic precursors induced by the inhibitors (Chang et al., 2013). Study by 
Sena et al. has shown that CD4 T cells lacking complex III have retained their 
ability to proliferate during lymphopenia but failed to respond to TCR induced 
proliferation.  Authors of this publication suggested this defect is likely due to the 
lack of mROS required for T cell activation, and not due to the inability to generate 
biosynthetic precursors or ATP (Sena et al., 2013). This data suggests that T 
cells rely on both glycolysis and OxPhos to proliferate, however more research is 
required to elucidate the exact contribution of each of these pathways in 
supporting T cell proliferation.  
 
Amino acids play a role in T cell proliferation. Deletion of SLC7A5, a component 
of LAT1 amino acid transporter in a mouse model severely impacted the 
proliferation of T cells in vitro (Sinclair et al., 2013). Based on the literature and 
results obtained in chapter 4, it can be hypothesised that deletion of SLC7A5 
leads to lower influx of leucine, leading to lower activation of mTORC1 and lower 
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rates of glycolysis. Again, this highlights the importance of glycolytic metabolism 
in T cell proliferation. The role of glutamine in T cell proliferation was also 
investigated. ASCT2 glutamine transporter was shown to be dispensable to T cell 
proliferation, as deletion of ASCT2, did not affect T cell proliferation (Nakaya et 
al., 2014). Although ASCT2 was not deemed indispensable, subsequent study 
by Sener et al. showed glutamine is required for proliferation, as media with no 
glutamine abrogated this process. In addition, inhibition of glutaminase, an 
enzyme which catalyses the metabolism of glutamine to glutamate, also led to 
significant impairment of T cell proliferation (Sener et al., 2016). Collectively these 
studies indicate that glutamine metabolism, similarly to glycolysis and OxPhos 
supports T cell proliferation.  
 
MAIT cells, as a novel subset of T cells, are still very poorly understood in 
comparison to the conventional T cells. The past decade has led to a greater 
appreciation of this subset and their role in disease and health, however the 
mechanisms controlling MAIT cell functions remains largely unexplored. Using 
the knowledge gained during the investigation of MAIT cell metabolism in chapter 
four and the evidence presented in the literature discussed above on the 
associations between immune cell function and cell metabolism, here we decided 




5.2 Specific aims of this chapter 
 
The specific aim of this chapter was to identify the metabolic requirements for 
MAIT cell functional responses.   
Therefore to: 
1. Investigate how glucose availability and glycolysis affects is related to 
MAIT cell proliferation, expansion and IFNγ production 
2. Elucidate how amino acid influx affects MAIT cell proliferation, expansion 
and IFNγ production 
3. Determine whether OxPhos is implicated in supporting MAIT cell 





5.3.1 MAIT cells use glucose to support proliferation 
Having identified that MAIT cells engage in glycolytic metabolism upon activation, 
we next investigated the metabolic requirements for MAIT cell proliferation in the 
control individuals. We first cultured MAIT cells in culture media with varying 
levels of glucose (10mM, 5mM and 1mM) for 5 days and assessed MAIT cell 
proliferation via cell trace violet, CTV. MAIT cells proliferated readily at the 
standard concentration of 10mM glucose (Figure 5.1 A&B). Reduction of glucose 
to 5mM did not affect MAIT cell proliferation (Figure 5.1 C&D), however a 
reduction of glucose concentration in the media to 1mM slowed proliferation 
(Figure 5.1 C&D). As MAIT cell proliferation was dependent on IL-2 (Figure 3.5, 
3.6, 3.8), next we investigated whether glucose restriction (1mM) impacts the 
levels of CD25. In glucose restricted conditions (1mM glucose), reduced IL-2R 
expression was noted in comparison to 10mM glucose (Figure 5.2 A&B). To 
confirm the requirement of glucose for MAIT cell proliferation and expansion, we 
substituted glucose in our culture media with galactose, which limits the rate of 
glycolysis in the cell. We demonstrate that in galactose culture media, MAIT cell 
expansion was greatly reduced in comparison to glucose culture media during 
the five-day incubation period (Figure 5.3 A&B). These results show that MAIT 
cells require an influx of appropriate amounts of glucose to facilitate their 
proliferation and expression of IL-2R, which allows them to respond to 
proliferative signals in the culture. 
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Figure 5.1 MAIT cell proliferation is restricted by glucose availability. (A) 
Scatter plot and (B) representative histograms of two control samples of MAIT 
cell proliferation as measured by uptake and dilution of Cell Trace Violet (CTV) 
at 5μM on day 0 and day 5 of culture. PBMCs were incubated in 10mM glucose 
full media and were unstimulated (Day 0) or stimulated (Day 5) with 5-ARU 
(1μg/mL) and MG (100μL) on day 0 and received a low dose of IL-2 (6.75ng/mL) 
on day 1 followed by a high dose of IL-2 (33.3ng/mL) on day 4 (n=7).  (C) Scatter 
plot of MAIT cell proliferation at 10mM, 5mM and 1mM glucose on day 5 of culture 
(n=7). (D) Representative comparison histograms of MAIT cell proliferation on 
day 5 with glucose at 10mM and 5 mM or 10mM and 1mM. Statistical analysis 
performed using paired student’s t-test or one-way ANOVA with Tukey’s 
correction, * p≤0.05, ****p<0.0001. 
  
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP69 5ARUMG DYE 10 mM glucose D5.fcs MAIT cells 16784 3127 
BP69 Max D0.fcs MAIT cells 2288 104512 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP70 5ARUMG DYE 10mM glucose D5.fcs MAIT cells 5896 3208 
BP70 Max D0.fcs MAIT cells 990 104859 
Pre-proliferation




Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP69 5ARUMG 5mM glucose D5.fcs MAIT cells 11840 2814 
BP69 5ARUMG DYE 10 mM glucose D5.fcs MAIT cells 16784 3127 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP70 5ARUMG 5mM glucsoe D5.fcs MAIT cells 5269 3202 






Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP70 5ARUMG 1mMglucose D5.fcs MAIT cells 3828 4097 
BP70 5ARUMG DYE 10mM glucose D5.fcs MAIT cells 5896 3208 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP69 5ARUMG 1mM glucose A D5.fcs MAIT cells 5181 3782 





Day 5 10mM glucose
Day 5 5mM glucose
Day 5 1mM glucose
A. B.
C. D. 10mM vs 5mM 10mM vs 1mM
















































































Figure 5.2 Restriction of glucose negatively impacts CD25 surface 
expression by MAIT cells. (A) Scatter plot of CD25 (IL-2R) expression by MAIT 
cells. Cells were stimulated with TCR Dynabeads (1:1 cell to bead ratio) in the 
presence of 10mM or 1mM concentration of glucose. (B) Representative 
histograms of 2 control samples showing CD25 expression upon stimulation with 
TCR Dynabeads in the presence of 10mM or 1mM concentration of glucose 
(n=4). Statistical analysis performed using paired student’s t-test, ns- non-
significant. 
  
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP110 DYNA LG.fcs MAIT cells 555 6139 
BP110 DYNA.fcs MAIT cells 600 9163 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP111 DYNA LG.fcs MAIT cells 2129 2101 
BP111 DYNA.fcs MAIT cells 2210 6532 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP110 DYNA LG.fcs MAIT cells 555 6139 
BP110 DYNA.fcs MAIT cells 600 9163 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP111 DYNA LG.fcs MAIT cells 2129 2101 








































Figure 5.3 MAIT cells expansion is restricted by substitution of glucose with 
galactose. (A) Scatter plot and (B) representative dot plots of two control 
samples of MAIT cell expansion as measured by the percentage of CD3 cells on 
day 0 and day 7 of culture. PBMCs were incubated in 10mM glucose or 10mM 
glutamine media and were unstimulated (Day 0) or stimulated with 5-ARU 
(1μg/mL) and MG (100μL) on day 0 and received a low dose of IL-2 (6.75ng/mL) 
on day 1 followed by a high dose of IL-2 (33.3ng/mL) on day 4 (n=6). Statistical 
analysis performed using paired student’s t-test or one-way ANOVA with Tukey’s 

















































































































































5.3.2 MAIT cells require glycolysis for proliferation 
As shown in section 5.3.1 glucose supports proliferation of MAIT cells and 
expression of IL-2R. Therefore, to further explore metabolic requirements for 
MAIT cell proliferation, we decided to investigate the significance of glycolysis in 
this process using a 2-deoxy-d-glucose inhibitor. 2DG is a glucose analogue, 
which enters glycolysis, just as glucose does, however 2DG inhibits hexokinase 
2, the first enzyme of glycolysis and suppresses the entire pathway. PBMC were 
stained with CTV for analysis of MAIT cell proliferation or remained unstained for 
the assessment of MAIT cell expansion. Next cells were activated with 5-ARU-
MG, in the presence or absence of 2DG for the first 18 hours of culture. Then 
cells were stimulated with IL-2 and cultured for a total of 5 days and analysed by 
flow cytometry. Here we demonstrated that glycolysis inhibition significantly 
reduced MAIT cell proliferation and expansion (Figure 5.4 A-D). As expression of 
IL-2R was shown to be sensitive to glucose concentration, next we investigated 
whether inhibition of glycolysis with 2DG also impacts the level of IL-2R present 
on MAIT cell surface. Similar to restriction of glucose (Figure 5.2 A&B), 
stimulation of MAIT cells as per section 5.3.1 in the presence or absence of the 
glycolysis inhibitor for 18 hours significantly reduced IL-2R expression upon 
stimulation (Figure 5.5 A&B). This data suggests that glycolysis is central to MAIT 
cell proliferation, as inhibition of this metabolic process halts expansion of MAITs 
















5.3.3 MAIT cells require an influx of amino acids via LAT1 for proliferation 
Activated MAIT cells were shown to be highly dependent on the transport of 
amino acids via LAT1 transporter in order to enhance their rate of glycolysis 
(Figure 4.18). As glucose and glycolysis were shown to play a central role in MAIT 
cell proliferation (Figure 5.1, 5.3 & 5.4), we next investigated the requirement of 
amino acid transport via LAT1 for MAIT cells proliferation. PBMC were prepared 
and stimulated as described in section 5.3.2 in the presence or absence of BCH. 
Inhibition of amino acid transport by blocking the activity of LAT1 transporter 
using BCH, significantly reduced MAIT cell proliferation (Figure 5.6 A&B) and 
expansion (Figure 5.6 C&D). Collectively with data obtained in chapter four, these 
results highlight the importance of amino acid influx for MAIT cell function. 
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Figure 5.4 MAIT cells require glycolysis to proliferate in response to 5-ARU-
MG and IL-2. (A) Scatter plot and (B) representative histograms of 2 control 
subjects showing MAIT cell proliferation over 5 days of culture with or without the 
addition of 2DG (10mM) as measured by uptake and dilution of Cell Trace Violet 
(CTV) at 5μM, on day 0 and day 5 of culture. (C) Scatter plot and (D) 
representative dot plots of MAIT cell expansion over 5 days of culture with or 
without the addition of 2DG (10mM) as measured by the percentage of CD3 
population. For both experiments, PBMCs were unstimulated (Day 0) or 
stimulated (Day 5) with 5-ARU (1μg/mL) and MG (100μL) on day 0 and received 
a low dose of IL-2 (6.75ng/μL) on day 1 followed by a high dose of IL-2 
(33.3ng/μL) on day 4 in the presence or absence of 2DG (10mM) (n=4/5). 
Statistical analysis performed using one-way ANOVA with Tukey’s correction, ** 




































Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP56 5ARUMG 2DG D5.fcs MAIT cells 150 64818 
BP56 5ARUMG VIOLET D5.fcs MAIT cells 178 14794 
BP56 max absorb pbmc.fcs MAIT cells 1838 89874 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP57 5ARUMG 2DG D5.fcs MAIT cells 107 68597 
BP57 5ARUMG VIOLET D5.fcs MAIT cells 172 15887 
BP57 max absorb pbmc.fcs MAIT cells 1013 101458 
Pre-proliferation
Day 5
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Figure 5.5 MAIT cells require glycolysis to express IL-2 receptor on the cell 
surface. (A) Scatter plot of CD25 (IL-2R) expression by MAIT cells. Cells were 
untreated or stimulated with TCR Dynabeads (1:1 cell to bead ratio) in the 
presence or absence of 2DG (10mM) for 18 hours and analysed by flow 
cytometry. (B) Representative histograms of 2 samples showing CD25 
expression upon stimulation with TCR Dynabeads with or without the addition of 
2DG (10mM) (n=6). Statistical analysis performed using one- ANOVA with 
Tukey’s correction, *p≤0.05.
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP110 DYNA 2DG.fcs MAIT cells 611 2906 
BP110 DYNA.fcs MAIT cells 600 9163 
BP110 BASAL.fcs MAIT cells 688 292 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP111 DYNA 2DG.fcs MAIT cells 2347 1958 
BP111 DYNA.fcs MAIT cells 2210 6532 
BP111 BASAL.fcs MAIT cells 3098 28.4 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP110 DYNA 2DG.fcs MAIT cells 611 2906 
BP110 DYNA.fcs MAIT cells 600 9163 
BP110 BASAL.fcs MAIT cells 688 292 
Sample Name Subset Name Count Geometric Mean : Comp-VL4-A
BP111 DYNA 2DG.fcs MAIT cells 2347 1958 
BP111 DYNA.fcs MAIT cells 2210 6532 











































Figure 5.6 MAIT cells require amino acid influx to proliferate in response to 
5-ARU-MG and IL-2. (A) Scatter plot and (B) representative histograms of 2 
control subjects showing MAIT cell proliferation over 5 days of culture with or 
without the addition of BCH (50mM) as measured by uptake and dilution of Cell 
Trace Violet (CTV) at 5μM, on day 0 and day 5 of culture. (C) Scatter plot and (D) 
representative dot plots of MAIT cell expansion over 5 days of culture with or 
without the addition of BCH (50mM) as measured by the percentage of CD3 
population. For both experiments, PBMCs were unstimulated (Day 0) or 
stimulated (Day 5) with 5-ARU (1μg/mL) and MG (100μL) on day 0 and received 
a low dose of IL-2 (6.75ng/μL) on day 1 followed by a high dose of IL-2 
(33.3ng/μL) on day 4 in the presence or absence of BCH (50mM) (n=6/4). 
Statistical analysis performed using one-way ANOVA with Tukey’s correction, ** 




































Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP66 BCH (BCH).fcs MAIT cells 64.0 56591 
BP66 dye (BCH).fcs MAIT cells 115 6956 
BP66 max D0.fcs MAIT cells 642 112107 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP57 5ARUMG BCH D5.fcs MAIT cells 134 69688 
BP57 5ARUMG VIOLET D5 BCH.fcs MAIT cells 116 24244 
BP57 max absorb pbmc.fcs MAIT cells 1013 101458 
Pre-proliferation
Day 5













































































5.3.4 MAIT cells require mTORC1 for proliferation 
Influx of amino acids was shown to be important for the activation of mTORC1 in 
MAIT cells (Figure 4.17). mTORC1 is known to orchestrate metabolism of T cells. 
Indeed, previous studies in T cells have demonstrated that the activation of 
mTORC1 in part relies on the uptake of leucine, which is transported into the cells 
via LAT1. Activation of mTORC1, was in turn shown to be required for 
upregulation of glycolysis during activation. As both glycolysis and amino acids 
were shown to be required for MAIT cell proliferation, next we investigated the 
role of mTORC1 on MAIT cell proliferation. PBMC were stained with CTV for 
analysis of MAIT cell proliferation or remained unstained for the assessment of 
MAIT cell expansion. Then cells were stimulated with 5-ARU-MG, in the presence 
or absence of Rapamycin for the first 18 hours of culture. Then cells were 
supplemented with IL-2, cultured for a total of 5 days and analysed by flow 
cytometry. Rapamycin, a specific mTORC1 inhibitor, significantly limited MAIT 
cell proliferation (Figure 5.7 A&B) and expansion (Figure 5.7 C&D). This data 




Figure 5.7 MAIT cells require mTORC1 activation to proliferate in response 
to 5-ARU-MG and IL-2. (A) Scatter plot and (B) representative histograms of 2 
control subjects showing MAIT cell proliferation over 5 days of culture with or 
without the addition of Rapamycin (20nM) as measured by uptake and dilution of 
Cell Trace Violet (CTV) at 5μM, on day 0 and day 5 of culture. (C) Scatter plot 
and (D) representative dot plots of MAIT cell expansion over 5 days of culture 
with or without the addition of Rapamycin (20nM) as measured by the percentage 
of CD3 population. For both experiments, PBMCs were unstimulated (Day 0) or 
stimulated (Day 5) with 5-ARU (1μg/mL) and MG (100μL) on day 0 and received 
a low dose of IL-2 (6.75ng/μL) on day 1 followed by a high dose of IL-2 
(33.3ng/μL) on day 4 in the presence or absence of Rapamycin (20nM) (n=6/4). 
Statistical analysis performed using one-way ANOVA with Tukey’s correction, ** 







































Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP58 5ARUMG RAPA D5.fcs MAIT cells 547 43044 
BP58 5ARUMG VIOLET D5.fcs MAIT cells 647 6528 
BP58 max absorb pbmc.fcs MAIT cells 3258 76459 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP61 RAPA D5.fcs MAIT cells 101 63613 
BP61 5ARUMG DYE D5.fcs MAIT cells 272 5926 
BP61 max abs D0.fcs MAIT cells 1277 94443 
Pre-proliferation
Day 5
























































































































5.3.5  MAIT cells require glutamine metabolism and OxPhos for 
proliferation 
Having identified the dependency of MAIT cell proliferation on a LAT1-mTORC1-
Glycolysis axis, we extended our investigations to other metabolic pathways. 
OxPhos has been reported to play a role in supporting conventional T cell 
proliferation (Bailis et al., 2019; Sena et al., 2013). Therefore, we decided to 
investigate the role of OxPhos in MAIT cell proliferation.  
 
OxPhos is the most effective way of producing large amounts of energy in the 
form of ATP by the cell, and proliferation is a very energy and nutrient demanding 
process. In this series of experiments, we decided to explore whether the 
inhibition of particular components of the OxPhos machinery to limit ATP 
production impacts the rate of MAIT cell proliferation. Two inhibitors of the 
electron transport chain were used - oligomycin, an ATP synthase inhibitor or 
antimycin A, an inhibitor of complex III of electron transport chain (ETC). PBMC 
were prepared and stimulated as described in section 5.3.4 in the presence or 
absence of oligomycin or antimycin A for the first 18 hours of the experiment and 
then cells were analysed using flow cytometry. Inhibition of ATP synthase with 
oligomycin significantly reduced MAIT cell proliferation and expansion by day 5 
of culture (Figure 5.8 A-D). Halt in the proliferation occurred early in proliferation, 
similar to what was observed following treatment with 2DG (Figure 5.4) and BCH 
(Figure 5.6), as signified by one to two discrete peaks shown on the 
representative histograms (Figure 5.8 B). Treatment of cells with antimycin A, the 
inhibitor of complex III of the ETC, slowed MAIT cell proliferation and expansion, 
however to a lesser extent (Figure 5.9 A-D). As depicted by the representative 
histograms in Figure 5.9 B, inhibition of complex III of ETC still allowed for MAIT 
cell expansion into multiple generations, shown by the multiple individual peaks 
on the graph.  
 
This data suggests that the generation of ATP via the ETC is necessary for 
effective MAIT cell proliferation. Inhibition of the complex III of ETC has a negative 
impact on MAIT cell expansion, however it may still allow for ATP production. As 
previously mention in section 4.3.3, glutamine can feed into the Kreb’s cycle and 
hence support OxPhos. In order for glutamine to enter the Kreb’s cycle, it must 
undergo glutaminolysis, an enzymatic process during which glutamine is broken 
157 
down into α-ketoglutarate (α-KG), an intermediate of the Kreb’s cycle (O’Neill et 
al., 2016). It has been shown that glutaminase (GLS), the first enzyme involved 
in this process, can be inhibited with a small molecule inhibitor CB-839 in 
leukaemia cells, resulting in their reduced proliferation and function. To assess 
the role of glutamine in supporting MAIT cell proliferation, we used a glutaminase 
inhibitor CB-839. PBMC were prepared and stimulated as described above in the 
presence or absence of CB-839 Treatment with CB-839 slowed MAIT cell 
proliferation (Figure 5.10 A&B), resulting in significantly reduced MAIT cell 
expansion (Figure 5.10 C&D). Overall, these results indicate a role for OxPhos in 
supporting MAIT cell proliferation, most likely through provision of ATP required 
to support the process of proliferation.   
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Figure 5.8 MAIT cells require active ATP synthase to proliferate in response 
to 5-ARU-MG and IL-2. (A) Scatter plot and (B) representative histograms of 2 
control subjects showing MAIT cell proliferation over 5 days of culture with or 
without the addition of oligomycin (2μM) as measured by uptake and dilution of 
Cell Trace Violet (CTV) at 5μM, on day 0 and day 5 of culture. (C) Scatter plot 
and (D) representative dot plots of MAIT cell expansion over 5 days of culture 
with or without the addition of oligomycin (2μM) as measured by the percentage 
of CD3 population. For both experiments, PBMCs were unstimulated (Day 0) or 
stimulated (Day 5) with 5-ARU (1μg/mL) and MG (100μL) on day 0 and received 
a low dose of IL-2 (6.75ng/μL) on day 1 followed by a high dose of IL-2 
(33.3ng/μL) on day 4 in the presence or absence of oligomycin (2μM) (n=6). 







































Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP65 dye oligomycin.fcs MAIT cells 408 40854 
BP65 dye (inhib).fcs MAIT cells 7369 2542 
BP65 max D0.fcs MAIT cells 2923 97887 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP67 dye oligomycin.fcs MAIT cells 49.0 50626 
BP67 dye (inhib).fcs MAIT cells 1158 4473 


































































































Figure 5.9 MAIT cells require OxPhos complex III to proliferate in response 
to 5-ARU-MG and IL-2. (A) Scatter plot and (B) representative histograms of 2 
control subjects showing MAIT cell proliferation over 5 days of culture with or 
without the addition of Antimycin A (4μM) as measured by uptake and dilution of 
Cell Trace Violet (CTV) at 5μM, on day 0 and day 5 of culture. (C) Scatter plot 
and (D) representative dot plots of MAIT cell expansion over 5 days of culture 
with or without the addition of Antimycin A (4μM) as measured by the percentage 
of CD3 population. For both experiments, PBMCs were unstimulated (Day 0) or 
stimulated (Day 5) with 5-ARU (1μg/mL) and MG (100μL) on day 0 and received 
a low dose of IL-2 (6.75ng/μL) on day 1 followed by a high dose of IL-2 
(33.3ng/μL) on day 4 in the presence or absence of Antimycin A (4μM) (n=6). 
Statistical analysis performed using one-way ANOVA with Tukey’s correction, ** 
p≤0.01, **** p≤0.0001.  
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP68 5ARUMG antimycin A D5.fcs MAIT cells 559 12987 
BP68 5ARUMG + DYE D5.fcs MAIT cells 1874 4415 
BP68 Max D0.fcs MAIT cells 1415 106798 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP70 5ARUMG + DYE D5.fcs MAIT cells 8128 2255 
BP70 5ARUMG antimycin A D5.fcs MAIT cells 1137 9424 
BP70 Max D0.fcs MAIT cells 976 104710 
Pre-proliferation
Day 5



































































































































Figure 5.10 MAIT cells require glutamine metabolism to proliferate in 
response to 5-ARU-MG and IL-2. (A) Scatter plot and (B) representative 
histograms of 2 control subjects showing MAIT cell proliferation over 5 days of 
culture with or without the addition of CB-839 (10μM) as measured by uptake and 
dilution of Cell Trace Violet (CTV) at 5μM, on day 0 and day 5 of culture. (C) 
Scatter plot and (D) representative dot plots of MAIT cell expansion over 5 days 
of culture with or without the addition of CB-839 (10μM) as measured by the 
percentage of CD3 population. For both experiments, PBMCs were unstimulated 
(Day 0) or stimulated (Day 5) with 5-ARU (1μg/mL) and MG (100μL) on day 0 
and received a low dose of IL-2 (6.75ng/μL) on day 1 followed by a high dose of 
IL-2 (33.3ng/μL) on day 4 in the presence or absence of CB839 (10μM) (n=8/6). 
Statistical analysis performed using one-way ANOVA with Tukey’s correction, ** 
p≤0.01, **** p≤0.0001.  
A. B.
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP68 5ARUMG CB839 D5.fcs MAIT cells 710 29131 
BP68 5ARUMG + DYE D5.fcs MAIT cells 1874 4415 
BP68 Max D0.fcs MAIT cells 1415 106798 
Sample Name Subset Name Count Geometric Mean : Comp-VL1-A
BP70 5ARUMG CB839 D5.fcs MAIT cells 1230 15034 
BP70 5ARUMG + DYE D5.fcs MAIT cells 8128 2255 
BP70 Max D0.fcs MAIT cells 976 104710 
Pre-proliferation
Day 5






















































































































5.3.6 Glycolysis is required for IFNγ production 
We next investigated the metabolic requirements for MAIT cell cytokine 
production, their primary effector function. Previous studies in T cells have shown 
that glycolysis is crucial for cytokine production. Renner et al. have shown that 
production of IFNγ is intrinsically dependent on glycolytic metabolism (Renner et 
al., 2015). To investigate expanded MAIT cells were stimulated with TCR 
Dynabeads, IL-12 and IL-18 in the presence or absence of 2DG for 24 hours and 
the supernatants were tested using ELISA. Here we demonstrate a strong 
reduction in IFNγ production by MAIT cells (Figure 5.11 A). This data shows that 
MAIT cells upregulate glycolysis upon cell activation, which is required for their 
production of IFNγ. 
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Figure 5.11 Blocking glycolysis with 2DG reduces IFNγ production by MAIT 
cells. (A) Scatter plot of IFNγ production by in vitro expanded and purified MAIT 
cells upon stimulation with TCR Dynabeads (1:1 bead to cell ration) and IL-12/IL-
18 (50ng/mL each) cytokines for 24 hours in the presence or absence of 2DG 



























5.3.7 Amino acid transport is required for IFNγ production 
In chapter 4, we identified a LAT1-mTOR-glycolysis axis in activated MAIT cells. 
We next investigated if LAT1 activity was required for MAIT cell cytokine 
production. Previous studies have demonstrated that the inhibition of LAT1 
function in T cells leads to a decrease in their cytokine production (Hayashi et al., 
2013), however, this has not been investigated in MAIT cells. Using PBMC from 
healthy controls we show that upon activation with TCR microbeads, IL-12 and 
IL-18 for 18 hours MAIT cells increased their IFNγ production (Figure 5.12 A&B), 
and with inhibition of the amino acid flux via LAT1, we observed a reduction in 
IFNγ expression by MAIT cells (Figure 5.12 C&D). To confirm that the LAT1 
inhibitor BCH was acting directly on MAIT cells, MAIT cells were expanded. Upon 
stimulation with TCR Dynabeads, IL-12 and IL-18 for 24 hours, MAIT cells 
produced high levels of IFNγ (Figure 5.12 E), however IFNγ levels were 
significantly reduced in the presence of the LAT1 inhibitor BCH (Figure 5.12 E). 
We next investigated whether the inhibition of amino acid influx had any impact 
on early transcription of mRNA coding for IFNγ and T-bet mRNA. Expanded MAIT 
cells were pre-treated with BCH for 1 hour and then stimulated with TCR 
Dynabeads, IL-12 and IL-18 for further 4 hours. Here we demonstrate no impact 
on the transcription of mRNA for IFNγ or T-bet (Figure 5.12 F&G). The mean fold 
increase of IFNG transcription was higher than transcription of IFNG in the 
absence of the inhibitor, however this difference was not significant (Figure 5.12 
F). To investigate whether the inhibition of amino acids influx has any effect on 
the transcription of key glycolytic enzymes HKII and PKM, expression of mRNA 
for both of these enzymes was measured on expanded MAIT cells treated as 
described for Figure 5.12 F&G. Incubation of cells in the presence of BCH upon 
cell stimulation, revealed no difference in the transcription level of those two 
enzymes of glycolysis (Figure 5.13 A&B). In summary, this data shows that the 
transport amino acids via LAT1 is essential for IFNγ production, but no difference 
in transcription was observed at 4 hours. Inhibition of amino acid flux had also no 
effect on the expression of key glycolytic enzymes at this timepoint.   
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Figure 5.12 Blocking amino acid transport by BCH reduces IFNγ production 
by MAIT cells. (A) Scatter plot and (B) representative dot plots of IFNγ production 
from PBMCs unstimulated or stimulated with TCR microbeads at 25ng/mL 
(Milteneyi), IL-12 and IL-18 (at 50ng/mL each) for 18 in the control individuals 
(n=3). (C) Scatter plot and (D) representative dot plots of IFNγ production from 
PBMCs stimulated with TCR microbeads at 25ng/mL (Milteneyi), IL-12 and IL-18 
(at 50ng/mL each) with or without addition of BCH (50mM) for 18 hours in the 
control population sample (n=3). (E) Scatter plot of IFNγ production by in vitro 
expanded and purified MAIT cells upon stimulation with TCR Dynabeads (1:1 
bead to cell ration) and IL-12/IL-18 (50ng/mL each) cytokines for 24 hours in the 
presence or absence of BCH (50mM) for 24 hours (n=7). (F) Scatter plot of IFNG 
(n=4) and (G) TBX21 (n=5) mRNA transcription by in vitro expanded and purified 
MAIT cells upon stimulation with TCR Dynabeads (1:1 bead to cell ration) and IL-
12/IL-18 (50ng/mL each) cytokines for 4 hours in the presence or absence of 
BCH (50mM) for 1 hour prior to stimulation.  Statistical analysis performed using 
student’s t-test, or one-way ANOVA with Tukey’s correction, ns- non-significant, 





























































































































































































Figure 5.13 Blocking amino acid transport using BCH doesn’t affect the 
transcription of HK2 or PKM by MAIT cells at an early stage during 
activation. (A) Scatter plot of HK2 mRNA and (B) PKM transcription by in vitro 
expanded and purified MAIT cells upon stimulation with TCR Dynabeads (1:1 
bead to cell ration) and IL-12/IL-18 (50ng/mL each) cytokines for 4 hours in the 
presence or absence of BCH for 1 hour prior to stimulation(50mM) (n=5). 
Statistical analysis performed using one-way ANOVA with Tukey’s correction, ns- 




























































5.3.8 mTORC1 is required for IFNγ production 
We next investigated inhibition of mTORC1 has any effect on IFNγ production 
using the specific inhibitor rapamycin Expanded MAIT cells were stimulated as 
per section 5.3.6 in the presence in Rapamycin inhibitor for 24 hours and IFNγ 
production was measured by ELISA. A significant decrease in the production of 
IFNγ cytokine by MAIT cells in the presence of mTORC1 inhibitor was observed 
(Figure 5.14 A). Together this data shows that activity of mTORC1 is required for 




5.3.9 Glutamine metabolism supports IFNγ production 
Inhibition of glutamine metabolism limited MAIT cell proliferation (Figure 5.10); 
however, no studies have been performed to investigate whether the inhibition of 
glutamine metabolism affects MAIT cell cytokine production. We decided to 
investigate the effect of GLS inhibition on MAIT cell IFNγ production. Expanded 
MAIT cells were stimulated as per section 5.3.6 in the presence in CB-839 
inhibitor for 24 hours and IFNγ was measured by ELISA. Inhibition of GLS with 
CB-839 resulted in a modest reduction in IFNγ production (Figure 5.15 A). 
Although the effect of CB-839 was modest in comparison to inhibition of glycolysis 
or mTORC1 with 2DG or Rapamycin respectively (Figure 5.11, 5.14 & 5.15), our 
data suggests a role for glutamine in supporting the MAIT cell function. This is 
further supported by the observed upregulation of ASCT2 amino acid transporter 
mRNA expression during the early stages of MAIT cell activation, what may 
support uptake of glutamine into the cells 
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Figure 5.14 Inhibition of mTORC1 with rapamycin reduces IFNγ production 
by MAIT cells. (A) Scatter plot of IFNγ production by in vitro expanded and 
purified MAIT cells upon stimulation with TCR Dynabeads (1:1 bead to cell ration) 
and IL-12/IL-18 (50ng/mL each) cytokines for 24 hours in the presence or 
absence of Rapamycin (20nM) for 24 hours (n=13). Statistical analysis performed 






























Figure 5.15 Inhibition of glutaminase with CB-839 reduces IFNγ production 
by MAIT cells. (A) Scatter plot of IFNγ production by in vitro expanded and 
purified MAIT cells upon stimulation with TCR Dynabeads (1:1 bead to cell ration) 
and IL-12/IL-18 (50ng/mL each) cytokines for 24 hours in the presence or 
absence of CB839 (10μM) for 24 hours (n=13). Statistical analysis performed 





























This study shows that MAIT cells engage in multiple interconnected metabolic 
pathways upon activation, suggesting that early metabolic reprogramming is 
required to facilitate their effector functions. Multiple studies in T cells and NK 
cells have shown that cell metabolism is in fact required for optimal proliferation 
and cytokine production (Bailis et al., 2019; Chang et al., 2013; Keating et al., 
2016; Loftus et al., 2018; Renner et al., 2015). Therefore, we investigated the 
metabolic requirements for MAIT cell functions within this chapter. 
 
Although the rate of metabolism can be controlled at multiple stages, nutrient and 
substrate availability is one of the key limiting steps for any enzymatic reaction. 
Here we show that by restricting glucose availability to 1mM, this leads to 
impaired MAIT cell proliferation and expansion. This is in line with Jacobs et al. 
who demonstrated that glucose restriction negatively affects T cell proliferation 
(Jacobs et al., 2008). To further explore the role of glucose on MAIT cell function, 
we substituted glucose for galactose. Supplying galactose as the only source of 
carbohydrates, it urges the cell to favour OxPhos over glycolysis (Chang et al., 
2013; Weinberg et al., 2010). MAIT cells cultured in galactose containing media 
displayed delayed expansion in comparison to the cells cultured in media with 
glucose. Chang et al. have recorded very similar findings in T cells, where the 
incubation of T cells in the presence of galactose slowed down their proliferation.  
 
To further investigate the role of glucose and its metabolism on MAIT cell 
function, we inhibited glycolysis using 2DG. The presence of 2DG in culture led 
to a very strong inhibition of MAIT cell proliferation and IFNγ production in 
comparison to the cells cultured without the inhibitor. In line with these results, 
Procaccini et al. have reported a significant reduction in proliferation of T cells 
when activated in the presence of 2DG (Procaccini et al., 2016), whereas others 
have reported that glycolysis and glucose is required for their IFNγ production 
(Dimeloe et al., 2016; Renner et al., 2015; Yin et al., 2015). In addition, restriction 
of glucose or inhibition of glycolysis resulted in the reduction in IL-2 receptor 
expression by MAIT cells upon stimulation. As we showed (in chapter four) 
exogenous supplementation of IL-2 strongly enhances MAIT cell proliferation, we 
therefore hypothesised that the level of glycolysis affects the expression of IL-2 
receptor and hence contribute to the impaired proliferation of MAIT cells.  
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Collectively, our study provides extensive data, which supports the hypothesis 
that glycolysis is central to MAIT cell function as inhibition of glycolysis, through 
the withdrawal or restriction of glucose, induces a significant defect in their 
proliferation and IFNγ production. Here we demonstrate that an abundance of 
glucose and glycolysis are important at the early stages of MAIT cell activation, 
although more studies are required to assess what metabolic events occur at 
later timepoints. The role of augmented glycolysis in MAIT cell activation remains 
to be fully elucidated, however studies conducted on T cells, have shown that the 
metabolic intermediates derived from glycolysis are the primary reason for the 
metabolic switch. For example, the first intermediate of glycolysis, glucose-6-
phosphate, can enter the pentose phosphate pathway to synthesise new nucleic 
acids, essential for cell proliferation. Other intermediates of glycolysis can 
contribute to amino acids synthesis, which may play a role in the augmented 
production of cytokines during cell activation (O’Neill et al., 2016). Intermediates 
of glycolysis were shown to be directly related to IFNγ production in T cells (Ho 
et al., 2015; Peng et al., 2016). In addition, studies of cell cycle and cell 
metabolism reported that cell cycle progression is sensitive to nutrient availability, 
where restriction of glucose or inhibition of glycolysis prevented progression of 
the cell cycle (Kalucka et al., 2015). This suggests that inadequate rate of 
glycolysis or extracellular glucose concentration, may provide a signal to the cell 
indicating that there are insufficient nutrients for cell activation to take place, 
hence preventing cell proliferation and cytokine production. This is of particular 
importance in the hypoglycaemic settings in vivo, such as tumour 
microenvironment. Restricted access of MAIT cells to glucose may hinder their 
potential anti-tumour responses (Godfrey et al., 2018; Vacchini et al., 2020).  
 
As this study has shown that amino acid influx is critical for the upregulation of 
glycolysis upon MAIT cell activation, next we investigated the role of LAT1 
mediated amino acid transport on MAIT cell function. Inhibition of LAT1 using 
BCH resulted in a restriction of proliferation and expansion of MAIT cells. This is 
in line with the results described in chapter four, which depicted the inhibition of 
amino acid influx via LAT1, leads to suppressed mTORC1 activation, that occurs 
most likely due to hindered transport of leucine. Low activity of mTORC1 prevents 
enhancement of glycolysis, which we show is crucial for MAIT cell function. 
Limitation of leucine import most likely contributes to the defect in MAIT cell 
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proliferation. Interruption in the import of methionine via LAT1, an amino acid, 
which is required for methylation of DNA, process required for T cell proliferation 
and differentiation may also fortify this effect (Sinclair et al., 2019). In our study, 
LAT1 amino acid transport was also required for IFNγ protein production by MAIT 
cells. Blocking of amino acid influx upon MAIT cell stimulation didn’t affect early 
transcription of mRNA coding for IFNγ and T-bet or the transcription of glycolytic 
enzymes, HK2 or PKM. This suggests that despite suboptimal uptake of amino 
acids, MAIT cells become activated and initiate transcription of mRNA for the 
proteins required to support their effector functions. This suggests that 
impairment in upregulation of glycolysis and IFNγ synthesis in the presence of 
BCH occurs due to the alterations which occur at translational level. Low 
intracellular concentration of leucine and other amino acids prevents MAIT cells 
from enhancing glycolysis via mTORC1, leading to the impairment in IFNγ 
production. Low cytokine production may be in part due to low levels of amino 
acids required to fulfil translation of the mRNA of the effector proteins. This is in 
line with the literature, as the studies showed that T cells also require amino acids 
to support cytokine production (Hayashi et al., 2013; Ron-Harel et al., 2019; 
Sinclair et al., 2019, 2013).  
 
Leucine has been described to be required to activate mTORC1, which in turn is 
responsible for the regulation of glycolysis. As amino acid transport was shown 
to be required for MAIT cell function, next we investigated how the inhibition of 
mTORC1 with rapamycin would affect MAIT cell proliferation and IFNγ 
production. Similar to the inhibition of glycolysis and amino acid influx, preventing 
mTORC1 activation, decreased the proliferative capacity and production of IFNγ 
by MAIT cells. This is in line with studies which have demonstrated a reduction 
in production of IFNγ and proliferation of T cells when incubated in the presence 
of mTORC1 inhibitor (Chaoul et al., 2015; Herrero-Sánchez et al., 2016; 
Kurebayashi et al., 2012), which has been further confirmed in in vivo studies of 
Rheb or Raptor deficient mice (Pollizzi et al., 2015; Yang et al., 2013). 
Collectively, this data shows that MAIT cells enhance their glycolytic metabolism 
during activation to support their effector functions. Any defect in this pathway, 
that controls the glycolytic rate in the cell, leads to severe impairment of MAIT 
cell proliferation and IFNγ production.  
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It is now widely accepted that T cells use OxPhos as their primary source of 
energy in their quiescent state but switch to glycolysis upon activation (O’Neill et 
al., 2016). Data published on T cell metabolism indicates that engagement of the 
cells in OxPhos during proliferation is important (Bailis et al., 2019; Sena et al., 
2013). After establishing that MAIT cells rely on glycolytic metabolism for their 
cytokine production, proliferation and expansion, next we focused on the role of 
OxPhos in MAIT cell function. Study performed by O’Brien et al. in our laboratory 
and described in her thesis, has shown that OxPhos was not required for 
production of IFNγ by MAIT cells upon stimulation. In contrast to these results, 
here we have shown that although OxPhos may not be critical to MAIT cell 
cytokine production, it plays a role in their proliferation and expansion. Blocking 
of ATP synthase using oligomycin, resulted in the inhibition of MAIT cell 
proliferation and expansion, whereas the inhibition of complex III of ETC, resulted 
in a retardation of proliferation and expansion, rather than inhibition. The 
differences observed between the inhibition of two different components in ETC 
was most likely due to the role they fulfil in this reaction. Inhibition of ATP 
synthase has a more severe impact as it is required for production of all ATP 
generated during the respiration. Inhibition of complex III most likely only slows 
down the reaction, but still produces ATP. As a result, ETC provides the cell with 
a limited amount of energy, leading to suboptimal proliferation. This is in line with 
the data published by Bailis et al. who reported significant defect in the 
proliferation of T cells after inhibiting complex III of ETC (Bailis et al., 2019). In 
addition, we investigated the importance of glutamine in supporting MAIT 
function, by inhibiting GLS with CB-839. Inhibition of glutamine metabolism 
slowed down MAIT cell expansion, proliferation and IFNγ production, but had a 
modest effect in comparison to direct or indirect inhibition of glycolysis. This is in 
line with a study by Carr et al. which showed that glutamine is essential for 
proliferation and cytokine production (Carr et al., 2010). Johnson et al. have also 
shown that a lack of glutamine in media strongly halts T cell proliferation, whereas 
inhibition of GLS with CB-839 modestly slows it down (Johnson et al., 2018).  
 
Collectively this data provides extensive evidence that MAIT cells undergo an 
early metabolic reprogramming upon activation to support cytokine production 
and proliferation. Glycolytic metabolism was shown to be indispensable for MAIT 
cell function. Inhibiting any of the steps required for the modulation of glycolytic 
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metabolism or direct inhibition of glycolysis resulted in profound defects in cell 
proliferation and IFNγ production (Figure 5.16). In this study, we showed that 
MAIT cells from people with obesity have dysregulated glycolytic metabolism and 
fail to adjust glycolysis upon stimulation. We suggest that this deficiency 
underpins the defect in proliferation and IFNγ production by MAIT cells from 
people with obesity. In addition, OxPhos was also shown to support MAIT cell 
proliferation, therefore this also should be assessed in MAIT cells in people with 
obesity. Defects in both metabolic pathways may be responsible for the observed 
impairment in MAIT cell proliferation from people with obesity and thus lead to 
the reduced frequencies observed in the peripheral blood and adipose tissue 
(Carolan et al., 2015; Magalhaes et al., 2015). Although this study provides a 
plausible explanation for the reduction of MAIT cell frequencies observed in 
people with obesity, to elucidate this further activation induced cell death of MAIT 
cells in people with obesity should also be assessed to fully explain lower MAIT 
cells frequencies. 
 
Figure 5.16 Summary of results of chapter five. MAIT cells from control 
individuals require glycolytic metabolism for proliferation and IFNγ production. 
Inhibition of any step in the pathway which controls the rate of glycolysis was 
shown to have a profound impact on MAIT cell function. OxPhos was shown to 
















Nearly thirty years after the discovery of MAIT cells, they still remain largely 
unexplored in comparison to other cells of the innate and adaptive immune 
system. Their high frequencies in multiple human tissues and pleotropic functions 
suggest they play an important role in the protection of their host and 
maintenance of tissue homeostasis.  
 
Advancements in the research of MAIT cell biology and function were possible 
due to the development of monoclonal antibodies against Vα7.2 TCR and 
identification of MAIT cell antigens. This led to the development of tetramers and 
flow cytometric antibodies, which allowed for more detailed studies (Corbett et 
al., 2014; Martin et al., 2009; Rahimpour et al., 2015; Reantragoon et al., 2013). 
MAIT cell phenotype and function have been described in healthy and diseased 
individuals, and it has been shown they are susceptible to the alterations that 
may occur in their environment during the development of illnesses (Provine and 
Klenerman, 2020). In healthy individuals, MAIT cells respond to TCR dependent 
or independent stimulation, through the upregulation of a large number of effector 
proteins including cytokines, chemokines and cytotoxic molecules (Provine and 
Klenerman, 2020). Production of these mediators has been found to support the 
resolution of microbial infection (Chua et al., 2012; Meierovics and Cowley, 
2016). Expression of chemokines induces recruitment of other immune cells to 
the site of inflammation, which are likely to become stimulated by cytokines such 
as IFNγ, TNF-α and IL-17, produced by activated MAIT cells (Meierovics et al., 
2013; Meierovics and Cowley, 2016; Provine and Klenerman, 2020). These 
cytokines play an important role in eradiation of the infection. IFNγ acts on 
macrophages and enhancing phagocytic ability, whereas TNF-α and IL-17 induce 
the production of more pro-inflammatory cytokines and chemokines, other 
immune cells as well as epithelial and mesenchymal cells and hence exacerbate 
inflammation (Gaffen et al., 2014; Wu et al., 2014).  
 
As MAIT cells were identified as potent producers of cytokines, the expression of 
them has been used as markers of their function in the state of disease. 
Dysregulation of MAIT cell function has been identified in multiple inflammatory 
and autoimmune diseases (Cho et al., 2014; Gracey et al., 2016; Willing et al., 
2018). The first alteration observed in many diseases in which the phenotype of 
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MAIT cells is changed, is a decrease in their frequencies in the peripheral blood 
of individuals with diseases such as RA, IBD or SLE (Chiba et al., 2017; Hayashi 
et al., 2016; Serriari et al., 2014). Furthermore, blood MAIT cells largely display 
a pro-inflammatory profile with enhanced IL-17 production and a variable IFNγ 
expression (Pisarska et al., 2020). In RA and IBD increased frequency of type 17 
MAIT cells has been reported at the sites of inflammation in the synovial fluid, gut 
mucosa or sclerotic lesions respectively, suggesting their migration and possible 
contribution to the inflammatory process (Gracey et al., 2016; Tominaga et al., 
2017).  
 
Investigations of MAIT cell function in obesity demonstrated severe alterations 
(Carolan et al., 2015; Magalhaes et al., 2015; Toubal et al., 2020). Activation of 
peripheral blood MAIT cells from people with obesity in vitro revealed a significant 
impairment in their IFNγ production as compared to the controls, whereas IL-17 
levels were strongly enhanced (Carolan et al., 2015; Magalhaes et al., 2015). In 
addition, AT MAIT cells from people with obesity also displayed enhanced IL-17 
but diminished IFNγ production (Carolan et al., 2015; Magalhaes et al., 2015). A 
very similar phenotype of peripheral blood MAIT cells was observed in colorectal 
cancer patients, who displayed a reduction in peripheral blood MAIT cell 
frequencies with impaired IFNγ but enhanced IL-17 production (Ling et al., 2016). 
IFNγ production by MAIT cells has been reported to be diminished in the 
adenocarcinoma and hepatocellular carcinoma lesions (Duan et al., 2019; Melo 
et al., 2019; Sundström et al., 2015). This suggests that cancer and obesity 
induce similar changes in MAIT cell function.  
 
In this study, we confirmed lower frequencies of MAIT cells in the peripheral blood 
in people in obesity in comparison to the control individuals, which also displayed 
altered functional phenotype. In line with previously published data, MAIT cells 
from people with obesity presented with impaired IFNγ production but enhanced 
IL-17 synthesis (Carolan et al., 2015; Magalhaes et al., 2015). Here, for the first 
time, we report that in addition to the alterations in the cytokine production, 
peripheral blood MAIT cells from people with obesity display impaired MAIT cell 
expansion upon activation. This suggests that the failure of MAIT cells to expand 
may be in part responsible for the lower frequencies observed in the peripheral 
blood of people with obesity. What’s more, this data suggests that obesity has 
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even bigger consequences on immune cell function. In fact, MAIT cells are not 
the only population affected by excessive weight gain. Michelet et al. and Tobin 
et al. reported impaired cytokine production and killing capabilities of NK cells 
from people with obesity (Michelet et al., 2018; Tobin et al., 2017).  
 
Although changes in MAIT cell biology have been described in multiple disease 
settings, no clear mechanism controlling their function has yet been established. 
Recent progression in the field of immunometabolism identified an extra layer of 
control points of immune cell activation. Immune cell function is closely related to 
cell metabolism, where the disruption to the glycolytic metabolism or OxPhos 
pathways results in the disruption of their activation or effector functions (O’Neill 
et al., 2016). Resting T cells have been shown to primarily use Kreb’s cycle and 
OxPhos to support energy production and survival (O’Neill et al., 2016). However, 
stimulation of T cells was shown to induce early metabolic reprogramming and 
metabolic switch to the use of glycolytic metabolism, which has been 
hypothesised to be more beneficial to the cell upon activation, due to the 
generation of metabolic intermediates during glycolysis (O’Neill et al., 2016). 
These intermediates can be used to support other metabolic pathways in order 
to synthesise amino acids, fatty acids or other molecules required to facilitate the 
activated state of the cell (O’Neill et al., 2016). Inhibition of glycolysis or glycolysis 
related pathways or restriction of glucose was shown to significantly reduce IFNγ 
production of stimulated T cells as well impair their differentiation (Chang et al., 
2013; Hayashi et al., 2013; Renner et al., 2015; Sinclair et al., 2013). Here we 
have hypothesised that MAIT cells from people with obesity have impaired 
metabolism, which leads to altered MAIT cell function. Due to the lack of data on 
MAIT cell metabolism, we first aimed to characterise the metabolic requirements 
for MAIT activation in control individuals.  
 
For the first time, we have shown that MAIT cells express a range of glucose and 
amino acid transporters, which synthesis level is modulated upon cell stimulation. 
This suggested that MAIT cells upregulate the expression of nutrient transporters 
to enhance the transport of glucose and amino acids to facilitate their activated 
state. Indeed, previous experiments performed by our lab have shown that the 
stimulation of MAIT increases the influx of nutrients, as measured by 2NBDG 
uptake (O’Brien, Loftus & Pisarska et al., 2019; Figure 1 C&D). Potential 
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enhanced transport of glucose further suggested its role in supporting MAIT cell 
activation. Indeed, measurement of the rates of glycolysis, by assessing ECAR 
rates revealed significant upregulation in the glycolytic metabolism upon MAIT 
cell stimulation. This was further supported by the measurement of the 
expression of glycolytic enzymes, which were also enhanced upon activation. To 
test the hypothesis that metabolism of MAIT cells supports their function, we 
investigated the impact of disrupting glycolysis in MAIT cells during their 
activation. Restriction of glucose in the culture media or inhibition of glycolysis 
with 2DG significantly impaired MAIT cell proliferation and expansion. In addition, 
incubation of cells with 2DG significantly inhibited IFNγ production. Collectively, 
this strongly indicates that MAIT cells heavily rely on glycolytic metabolism upon 
their activation to exert their effector function. These results are in line with the 
research performed on T cells, which illustrated that upon stimulation, T cells 
undergo metabolic reprogramming, switching from OxPhos to glycolytic 
metabolism to support their function (O’Neill et al., 2016). Stimulation of T cells 
was shown to upregulate their glycolysis rates, whereas the limitation of glucose 
in the culture media or direct disruption of the glycolysis led to significant 
impairment in T cell cytokine production and proliferation (Chang et al., 2013; 
Gubser et al., 2013; Renner et al., 2015). It still remains to be elucidated why 
glycolysis is strongly favoured over OxPhos during the activation of lymphocytes 
however some hypotheses have been put forward. Although glycolysis is much 
less energy efficient than OxPhos, it provides a wide range of intermediates which 
can be used to de novo synthesis of amino acids, nucleic acids and fatty acids 
(O’Neill et al., 2016). These molecules in turn are thought to play a role in the 
production effector molecules such as cytokines or in providing building blocks 
required for cell proliferation and division. On the other hand, components of 
glycolysis have been identified to have a very direct role in supporting IFNγ 
synthesis. For example, in resting T cells, GAPDH enzyme was shown to bind to 
IFNγ mRNA, preventing it from transcription. Activation of T cells was shown to 
recruit GAPDH to facilitate enhanced glycolysis, freeing IFNγ mRNA for 
translation (Chang et al., 2013). More research is required to establish the direct 
relationship between the glycolysis and immune cell activation and function. 
 
To explore MAIT cell metabolism further, we decided to investigate the role of 
amino acids in supporting MAIT cell function, as expression of LAT1 and ASCT2 
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transporters appeared to be largely enhanced early into their activation. A study 
of T cells by Sinclair et al. highlighted the importance of leucine transport in their 
glycolytic metabolism, therefore, we next focused on the LAT1 mediated 
transport of amino acids. Here, for the first time we have shown that LAT1 
mediated transport of amino acids during MAIT cell activation is required for the 
upregulation of their glycolytic rate. Previous studies in T cells have established 
that leucine is required for the activation of mTORC1, which in turn is required for 
the upregulation of glycolysis (Finlay et al., 2012; Saxton et al., 2016). Therefore, 
we sought to investigate the impact of limiting amino acid influx on mTORC1 
activation. Indeed, blocking of LAT1 diminished the activation of mTORC1. 
Collectively, this indicates that the stimulation of MAIT cells leads to the 
upregulation of LAT1, which facilitates the enhanced transport of amino acids, 
including leucine into the cell. Leucine supports the activation of mTORC1, which 
in turn enhances the rate of glycolysis. Parallel work from our lab has shown that 
mTORC1 activation is required for the upregulation of glycolysis upon MAIT cell 
stimulation, as inhibition of mTORC1 activity with rapamycin resulted in a failure 
of MAIT cells to modulate glycolysis rate upon stimulation (O’Brien, Loftus, 
Pisarska et al, 2019; Figure 3E&F). Inhibition of mTORC1 activity or amino acid 
influx had a strong negative impact on MAIT cell proliferation, expansion and IFNγ 
production, which mimics the effect obtained with the direct inhibition of 
glycolysis. This further indicates that both of these factors control the glycolytic 
metabolism in MAIT cells.  
 
Although studies of T cell activation strongly focused on glycolytic metabolism, 
OxPhos has been shown to support T cell proliferation (Chang et al., 2013). To 
assess whether it also plays a role in the proliferation of MAIT cells, we used 
inhibitors of ETC and found that ATP synthase plays a particularly important role 
for MAIT cell proliferation, suggesting ATP derived during OxPhos is involved in 
supporting MAIT cell proliferation. On the other hand, inhibition of complex III of 
ETC, allowed for MAIT cell proliferation albeit at a slower rate. Similarly, 
preventing metabolism of glutamine, which plays a role in replenishing 
intermediates of Kreb’s cycle, and hence supports OxPhos, led to impairment of 
MAIT cell proliferation, expansion and IFNγ production, but to a much lower 
extent than the inhibition of glycolytic metabolism. Collectively, this data indicates 
that OxPhos supports MAIT cell expansion and proliferation, however, plays a 
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less significant role than glycolysis in supporting MAIT cell function upon 
activation.  
 
In this thesis, we have shown that glycolytic metabolism is central to MAIT cell 
activation and is absolutely required for successful MAIT cell proliferation, 
expansion and IFNγ production. As MAIT cells from people with obesity 
presented with severe impairment of both of these functions, we decided to 
compare their cell metabolism to the metabolism of the control individuals to 
identify any potential flaws, which may lead to the impairment in their function. 
Indeed, we found that MAIT cells from people with obesity fail to upregulate 
glycolysis upon stimulation. In addition, parallel work from our lab revealed that 
the activation of MAIT cells from people with obesity increases mTORC1 
activation, but to a lower extent than in the control individuals (O’Brien, Loftus, 
Pisarska et al, 2019; Figure 3J). This suggests that inability to control the activity 
of mTORC1 leads to failure to enhance the rate of glycolysis. To elucidate this 
further, we measured the expression of LAT1, and the transport capabilities of 
this amino acid transporter required for the influx of leucine to activate mTORC1. 
We found that the expression of LAT1 by MAIT cells is lower in people with 
obesity, which likely leads to the observed lower transport capabilities. 
Collectively, data derived from the control individuals and people with obesity 
indicates that a defect in glycolytic metabolism displayed by MAIT cells from 
people with obesity underpins their impaired function. In this study we show that 
MAIT cells from people with obesity have impaired expression of LAT1 
transporter, which likely leads to lower influx of amino acids including leucine. 
Lower availability of leucine probably leads to impaired mTORC1 activation, 
which further prevents glycolysis from being upregulated. Low rate of glycolysis 
fails to support stimulated MAIT cells, limiting the production of biosynthetic 
precursors which are likely to be required to enhance cytokine production and 
proliferation.  
 
Here, we propose a mechanism responsible for impaired MAIT cell function in 
people in obesity, which may be translated into multiple disease settings, where 
MAIT cells present with a defect in activation, cytokine production or proliferation. 
Identification of the mechanism(s) controlling some of the effector functions 
exerted by MAIT cells will allow for the identification of targets, which could be 
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used to ameliorate immunometabolism in MAIT cells and hence restore their 
function. This data provokes multiple questions regarding MAIT 
immunometabolism and their function in diseases. Future research should focus 
on elucidating what induces the alterations in MAIT cell glycolytic metabolism in 
people with obesity. Here we hypothesise that inadequate influx of leucine due 
to the reduction in LAT1 expression, leads to a cascade of events which 
eventually results in impaired MAIT cell function. To further confirm this, 
measurement of leucine uptake by MAIT cells from individuals with and without 
obesity should be performed. In addition, further research should also investigate 
why the expression of LAT1 is impaired in MAIT cells with people with obesity. 
This defect was shown to be present at the transcriptional level, therefore 
investigations should focus on identifying which signalling pathway is responsible 
for inducing LAT1 transcription and whether it is also impaired in obesity. Sinclair 
et al. has also shown that direct TCR activation of T cells increases expression 
of LAT1, but the mechanism behind this upregulation remains to be elucidated 
(Sinclair et al., 2013). 
 
Independently of this research, there could be also other causes for impaired 
glycolytic metabolism in MAIT cells, which should be considered. In obesity, the 
microenvironment of the cells is often dramatically altered (Fuster et al., 2016; 
Quail and Dannenberg, 2019). As obesity is closely related to the development 
of T2DM, in multiple cases, immune cells may be exposed to hyperglycaemia if 
the individual is unaware, they have diabetes, or their diabetes is badly controlled. 
Study by Hu et al.  showed that the incubation of peripheral blood mononuclear 
cells in media with high glucose concentrations impairs their cytokine production, 
suggesting excessive nutrient concentration may impact immune cell function 
(Hu et al., 2018).  It has been shown that individuals with obesity display elevated 
FFA concentration (Arner and Rydén, 2015; Madak-Erdogan et al., 2019; Ni et 
al., 2015). An excellent paper by Michelet et al., revealed that obesity induced 
intracellular lipid accumulation in NK cells. Increased uptake of lipids led to 
serious impairment of their immunometabolism characterised by lower activation 
of mTORC1, defect in enhancement of glycolysis upon cell activation and 
production of cytotoxic granules and IFNγ production. This resembled a very 
similar phenotype to the one of MAIT cells described in this study. Therefore, the 
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impact of other nutrients on MAIT cell metabolism and function should also be 
investigated in the future.  
 
As obesity is associated with an elevation in multiple pro-inflammatory factors, 
long-term exposure to these may impact MAIT cell function and metabolism. 
Leptin concentration in the peripheral blood has been shown to be elevated in 
people in obesity (Adeyemi and Abdulle, 2000; Considine et al., 1996; Farr et al., 
2015). The consequences of high leptin are yet to be fully understood; however, 
leptin was shown to have pro-inflammatory properties on the cells of the immune 
system and modulate cell function (Wrann et al., 2012). A study by Wrann et al. 
has shown that short term incubation of NK in the presence of leptin increased 
their IFNγ secretion and cytotoxic capabilities, whereas long-term exposure of 
NK cells to leptin impaired their function (Wrann et al., 2012). This suggests that 
long term exposure to leptin could be altering immune cell metabolism, by 
inducing a defect in glycolysis and hence lead to lower IFNγ production.  
 
Although our study provides a very valuable insight into MAIT cell function and 
metabolism it has limitations, which must be taken into consideration when 
interpreting these results. This research was performed using solely only human 
samples. Although primary cells are a wonderful resource, as they allow us to 
investigate the biology of MAIT cells directly from the cohort of interest, they 
introduce a large amount of variation, which can be observed in some of the data 
presented in this thesis. Although MAIT cells are readily detected in the peripheral 
blood, they are very enriched in tissues, hence the profile of these cells may alter 
based on their location in the body. This study uses only peripheral blood 
samples; therefore, these results can only be interpreted in the context of blood. 
Although our obesity cohort is very well characterized clinically, our control 
population is less well defined. Although the fitness of each blood donor is 
assessed before blood donation, it cannot be assumed that these donors don’t 
have any underlying conditions or excessive weight, which could skew the data. 
Another point of note is the degree of obesity within our cohort, the mean BMI is 
47 which is firmly in the morbid/severely obese category. Therefore, our 
conclusions around the impact of obesity may not reflect BMIs in the 30-40 range. 
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All of the experiments were performed in vitro, which poses another limitation to 
this study. All in vitro studies aim to resemble the in vivo environment as much 
as possible, for example, the incubation of cells at 37oC or by providing them with 
an abundance of nutrients normally present in their environment. After conducting 
this study, I believe we should reconsider the culture media we use, especially 
for immunometabolism studies. Standard culture media contains 10mM 
(10mmol/L) glucose. This concentration of glucose in human blood would be 
considered as a hyperglycaemia, as normal fasting blood glucose is considered 
to be below 5.6 mmol/L (American Diabetes Association, 2020; WHO, 2020b). 
This means that all in vitro assays which investigate immune cell activation or in 
fact immunometabolism are performed in hyperglycaemic conditions, which we 
consider to be harmful in vivo. Immune restriction assays performed in this thesis, 
which used 10mM, 5mM and 1mM glucose concentrations, have shown that 
MAIT cell proliferation was not impacted at 5mM, which would resemble normal 
blood glucose. This suggests that 5mM concentration of glucose could be 
sufficient to support the activation of immune cells in vitro, providing the cells with 
conditions, which would be closer to their normal environment. It is important to 
consider than in vivo, under normal conditions, blood glucose is tightly controlled 
by the action of pancreas and insulin, keeping it at a constant concentration of 
around 5mM to maintain homeostasis. Setting up of the experiments in the media 
containing 5mM may lead to the deprivation of glucose during the experiment 
depending on the activity of the cells and glucose consumption rates and hence 
“hypoglycaemic” environment. More basic research should be performed to 
assess the most optimal conditions of culture, to obtain the most accurate results 
possible.  
 
This study used primary human MAIT cells for all investigations. Murine models, 
especially genetically modified mice would help to conclusively validate our 
results. Unfortunately, mice display lower frequencies of MAIT cells than humans, 
suggesting they may not play as an essential role in their immunity as they do in 
humans (Chen et al., 2017; Kawachi et al., 2006; Rahimpour et al., 2015). 
Therefore, data obtained from mouse studies may not fully reflect the biology of 
MAIT cells in humans. In addition, mice display a homogenous population of 
subjects, which is a major difference between studies conducted on human 
samples, as each human is genetically different. This genetic variation is an 
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important factor, especially during development of drugs or treatments as well as 
the heterogenicity of the human population, may largely affect their responses. 
What’s more, mouse studies are conducted in largely controlled environments, 
whereas humans cannot be controlled in such a way. The differences in the 
lifestyles of individuals, albeit introduces variations into the data, better reflects 
the studied cohorts. Mouse studies provide a very valuable tool when 
investigating biology of MAIT cells in the whole organism, however I believe 
studying MAIT cell metabolism and function in the primary cells provides an 
advantage over mouse models in this setting.  
 
This study has advanced the knowledge of MAIT cell biology and function. Here 
we show that MAIT cell metabolism is an integral part of their activation. 
Stimulation of MAIT cells enhances their glycolytic metabolism, which is sensitive 
to amino acid influx via LAT1 amino acid transporters. Interruption of this 
metabolic pathway at any point, results in diminished IFNγ production as well as 
impaired expansion and proliferation of these cells. In this study we show that 
MAIT cells from people with obesity present with impaired glycolytic metabolism 
and effector functions, therefore we propose that a defect in glycolysis is 
responsible for the altered function of MAIT cells from obese individuals. This 
study describes a novel metabolic axis which controls MAIT cell function, which 
could be targeted in the future to restore MAIT cell function in people in obesity 
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Obesity Reduces mTORC1 Activity in Mucosal-Associated
Invariant T Cells, Driving Defective Metabolic and Functional
Responses
Aisling O’Brien,*,1 Roisin M. Loftus,†,1 Marta M. Pisarska,‡,x,1 Laura M. Tobin,*,‡
Ronan Bergin,x Nicole A. W. Wood,†,x Cathriona Foley,† Arimin Mat,* Frances C. Tinley,x
Ciaran Bannan,† Gary Sommerville,{ Natacha Veerapen,‖ Gurdyal S. Besra,‖
Linda V. Sinclair,# Paul N. Moynagh,x,** Lydia Lynch,† David K. Finlay,†,††,‡‡
Donal O’Shea,*,‡,x,2 and Andrew E. Hogan*,‡,x,2
Obesity underpins the development of numerous chronic diseases, such as type II diabetes mellitus. It is well established that
obesity negatively alters immune cell frequencies and functions. Mucosal-associated invariant T (MAIT) cells are a population of
innate T cells, which we have previously reported are dysregulated in obesity, with altered circulating and adipose tissue
frequencies and a reduction in their IFN-g production, which is a critical effector function of MAIT cells in host defense. Hence,
there is increased urgency to characterize the key molecular mechanisms that drive MAIT cell effector functions and to identify
those which are impaired in the obesity setting. In this study, we found that MAIT cells significantly upregulate their rates of
glycolysis upon activation in an mTORC1-dependent manner, and this is essential for MAIT cell IFN-g production. Furthermore,
we show that mTORC1 activation is dependent on amino acid transport via SLC7A5. In obese patients, using RNA sequencing,
Seahorse analysis, and a series of in vitro experiments, we demonstrate that MAIT cells isolated from obese adults display
defective glycolytic metabolism, mTORC1 signaling, and SLC7A5 aa transport. Collectively, our data detail the intrinsic meta-
bolic pathways controlling MAIT cell cytokine production and highlight mTORC1 as an important metabolic regulator that is
impaired in obesity, leading to altered MAIT cell responses. The Journal of Immunology, 2019, 202: 3404–3411.
O
besity is a global epidemic, impacting over 600
million adults and 150 million children (1). Obesity
is linked to numerous chronic diseases, including
type II diabetes, cardiovascular disease, and certain cancers
(2). Underpinning the obesity-driven development of chronic
disease is systemic inflammation and immune cell dysregulation
(3, 4). We have previously reported the negative impact of obesity
on several immune cell populations, including invariant NK T cells,
NK cells, dendritic cells, and mucosal-associated invariant T (MAIT)
cells (5–8).
MAIT cells are a population of non-MHC–restricted T cells that
are important in the immune defense against bacterial and viral
infections. MAIT cells are early-responding T cells that are ca-
pable of rapidly producing multiple cytokines upon activation,
such as IFN-g, TNF-a, and IL-17 (9). MAIT cells are activated
when their invariant TCR recognize bacterial derivatives presented
on the MHC-like molecule MR1 (9, 10). MAIT cells can also be
activated in a TCR-independent manner via cytokine stimula-
tion (11). Dysregulated MAIT cell cytokine profiles have been
reported in several diseases, including obesity, arthritis, and viral
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infection (8, 12–15). The pathways controlling MAIT cell cyto-
kine responses are still under investigation.
It is now well established that cellular metabolism plays a
critical role in determining immune cell responses (16). Extrinsic
and intrinsic signals result in immune cell metabolic reprogramming,
which provides both the energy and biological intermediates required
for a robust immune response. Although different lymphocyte sub-
sets can adopt distinct metabolic signatures, in general, effector
lymphocytes are characterized by elevated glucose metabolism with
high rates of glycolysis and oxidative phosphorylation (OxPhos) (16).
Currently, there is a paucity of data regarding the metabolic
profile of MAIT cells or the importance of cellular metabolism in
driving MAIT cell effector functions. In this study, we show that
MAIT cells use glycolytic metabolism upon activation. Impor-
tantly, we show the requirement of this elevated rate of MAIT
cell glycolysis for cytokine production. Using RNA sequencing
(RNA-Seq) and Seahorse analysis, we show impaired glycolytic
metabolism in MAIT cells from obese individuals. We show that
MAIT cell glycolysis is dependent on mTORC1 activation, and in
obesity mTORC1 activation is reduced. Finally, we show that
mTORC1 activation in MAIT cells is dependent on amino acid
transport via SLC7A5. Collectively, our data show for the first time,
to our knowledge, the intrinsic metabolic pathways control-
ling MAIT cell cytokine production. Furthermore, we implicate a
novel amino acid–dependent regulatory mechanism that is con-
current with impaired MAIT cell functions in obesity.
Materials and Methods
Study cohorts
A cohort of 30 obese adults (mean body mass index 45.1) was enrolled into
this study, along with an age- and sex-matched cohort of healthy lean
controls (mean body mass index 24.7) (Supplemental Table I). Exclusion
criteria included patients with comorbid inflammatory conditions outside
of type II diabetes. Patients who smoke or are on anti-inflammatory
medications, GLP-1 therapies, or sodium-glucose cotransporter 2 inhibi-
tors were also excluded.
Preparation of PBMCs and flow cytometric analysis
PBMC samples were isolated by density centrifugation from fresh venous
blood samples. MAIT cell staining (1 3 106 PBMC) was performed using
specific surface mAbs (all Miltenyi Biotec), namely, CD3, CD161, CD8,
and TCRVa7.2 (Supplemental Fig. 3). Cell populations were acquired
using a BD FACSCanto II and analyzed using FlowJo software (Tree
Star). Results are expressed as a percentage of the parent population, as
indicated, and determined using flow minus-1 (FMO) and unstained
controls.
MAIT cell RNA-Seq and analysis
Highly pure MAIT cells were isolated from peripheral blood samples using
FACS (MoFlo XDP Sorter). RNAwas extracted from cells using the RNeasy
Mini Isolation Kit (Qiagen) and analyzed for quality control and quanti-
fication purposes using the Agilent Bioanalyzer and RNA Pico assay
(Agilent Technologies). RNA-Seq libraries were prepared using the
SMART-Seq v4 Ultra Low Input RNA Kit (Clontech Laboratories), and
next-generation sequencing was carried out using Illumina NextSeq 500
Single-End 75 bp (SE75) chemistry. Single-end RNA-Seq reads were
aligned to the human hg38 reference genome using Tophat2 (17)
and Bowtie (18) and the Ensembl gene annotation downloaded from the
BioMart Web site. The Qlucore Omics Explorer 3.2 software package
was used for visualization of RNA-Seq data. Qlucore Omics software
converted imported bam files into read counts and then normalized these
across the samples using the trimmed mean of M-values method (19).
Principal component analysis was performed using the default setting:
mean = 0, variance = 1 normalization based on 503 genes that passed
filtering by variance set at the level of 0.25. Gene set enrichment analysis
ranked genes based on the correlation between their expression, and the
normalized enrichment score reflected the degree to which Hallmark gene
sets from the Molecular Signatures Database were overrepresented from
the ranked gene list (20). Differential gene expression analysis was
implemented in the Qlucore, which performed a two-group comparison
between lean and obese MAIT cells. Genes downregulated in obesity
within the glycolysis and MTORC1 gene sets with a p value ,0.05
and log2 fold change .1.5 were represented in the heat maps generated
in Qlucore. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126169.
MAIT cell cytokine production analysis
MAIT cell cytokine production was determined by intracellular flow
cytometry. Briefly, PBMC (1 3 106) were cultured in the presence of a
protein transport inhibitor in media alone (control) or stimulated with
either TCR microbeads (Miltenyi Biotec), IL-12, IL-18, IL-12/18 (all
BioLegend), or a combination of TCR microbeads and IL-12/IL-18 for
18 h at 37˚C. Additionally, metabolic inhibitors were added as indicated:
rapamycin (20 nM), 2-deoxyglucose (2DG) (10 mM), oligomycin (2 mM),
or 2-aminobicyclo- (2, 2, 1)-heptane-2-carboxylic acid (BCH) (50 mM).
For acute glucose restriction experiments, PBMC were stimulated in media
containing less than 1 mM glucose for 18 h, after which cells were in-
vestigated for intracellular cytokine production by flow cytometry, as
previously described.
MAIT cell cytokine production by ELISpot
MAIT cell cytokine production was also determined by ELISpot. Briefly,
96-well ELISpot plate(s) were precoated with mAbs to IFN-g overnight
at 4˚C. Plates were washed in PBS to remove coating Ab and incubated at
37˚C for 1 h in complete RPMI. Previously isolated MAIT cells (2 3 105)
were cultured on the precoated plates either basally or stimulated with
IL-12/IL-18 and TCR microbeads at 37˚C for 18 h. ELISpot plates were
then washed with PBS/Tween for a minimum of six washes. Following
this, 50 ml of biotinylated mouse anti-human IFN-g was added and incu-
bated at room temperature for 3 h. ELISpot plates were washed in wash
buffer, and antibiotin-labeled Ab was added to the wells and incubated at
room temperature for 2 h. Finally, prefiltered BCIP/NBT solution (50 ml)
was added to each well and incubated at room temperature for 5 min or
until distinct dark spots appeared in the positive-control wells. Plates were
rinsed with tap water and allowed to air dry overnight. Cytokine expression
was analyzed using a semiautomated ELISpot plate reader.
MAIT cell glucose consumption analysis
Fresh PBMC (1 3 106 ml) were activated as previously described for 18 h;
cells were then washed and transferred to glucose-free media in the
presence of the fluorescent glucose analogue 2NBDG (Life Technologies)
for 2 h. Additionally, glut 1 expression was examined on basal and acti-
vated MAIT cells using an mAb specific for Glut-1 (R&D Systems). FMO
and unstimulated PBMC were used as negative controls.
MAIT cell Seahorse analysis
For real-time analysis of the extracellular acidification rate (ECAR) and
oxygen consumption rate of purified MAIT cells cultured under various
conditions, a Seahorse XF-96 Analyzer (Seahorse Bioscience) was used. In
brief, 200,000 purified, expanded MAIT cells were adhered to a CellTaq
(BD Pharmingen)–coated 96-well XF Cell Culture Microplate (Seahorse
Bioscience). Sequential measurements of ECAR and oxygen consumption
rate following addition of the inhibitors (Sigma-Aldrich) oligomycin
(2 mM), FCCP (0.5 mM), rotenone (100 nM) plus antimycin A (4 mM), and
2DG, (30 mM) allowed for the calculation of basal glycolysis, glycolytic
capacity, basal OxPhos, and maximal mitochondrial capacity. Each cell
culture condition was evaluated in quadruplicate, and 14 measurements
were made per sample.
MAIT cell mTOR analysis
PBMC (1 3 106 ml) were activated as previously described for 18 h.
mTOR activity in MAIT cells and CD8+ T cells was examined via the
phosphorylation of ribosomal S6 protein (pS6) (Cell Signaling Technol-
ogy) by flow cytometry. Rapamycin treatment was used as a control for
pS6 specificity and to determine the requirement of mTORC1 for IFN-g
production. FMO and unstimulated PBMC cells were used as negative
controls.
MAIT cell amino acid uptake and BCH experiments
PBMC or MAIT cells were used to investigate kynurenine uptake as de-
scribed in (21). Briefly, after surface Ab staining of samples, cells were
resuspended in 200 ml of warmed HBSS (13 106 cells) and incubated in a
water bath at 37˚C. Kynurenine (200 mM in HBSS), BCH (20 mM in
HBSS), and HBSS were warmed to 37˚C and added as appropriate. Uptake
was stopped after 4 min by PFA (final concentration 1%) for 30 min at
room temperature in the dark. After fixation, cells were washed twice in
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PBS/0.5% BSA and resuspend in PBS/0.5% BSA prior to acquisition on
flow cytometer. The 405-nm laser and 450/50 BP filter were used for
kynurenine fluorescence detection. For SLC7A5 inhibition experiments,
the concentration of amino acids in RPMI 1640 was diluted two-fold using
HBSS (Invitrogen) in the presence or absence of BCH (50 mM; Sigma-
Aldrich).
Statistics
Statistical analysis was completed using GraphPad Prism 6 Software. Data
are expressed as SEM. We determined differences between two groups
using Student t test and Mann–Whitney U test where appropriate. Analysis
across three or more groups was performed using ANOVA. Correlations
were determined using linear regression models and expressed using
Pearson or Spearman rank correlation coefficient, as appropriate. The
p values were expressed with significance set at ,0.05.
Study approval
Ethical approval was granted by theMedical Research Ethics Committees at
St. Vincent’s University Hospital. All patients gave written informed
consent prior to partaking in the study.
Results
Increased rates of glycolysis are essential for driving
MAIT cell IFN-g production
MAIT cells are potent producers of cytokine (IFN-g and TNF-a
among the most abundant). We show that in a stimulation-
dependent manner, a large proportion of MAIT cells produce
IFN-g and TNF-a but not IL-17, with the most robust response
seen after stimulation with anti-CD3/CD28–coated beads (TCR
beads) and the cytokines IL-12/IL-18 (Fig. 1A, Supplemental
Figs. 1A, 3). The metabolic pathways used by MAIT cells during
their cytokine production are currently undefined. We show that
MAIT cells express the major glucose transporter Glut-1 and
upregulate the uptake of the fluorescent 2DG analogue 2NBDG
upon activation in a stimulus-dependent manner (Fig. 1B–D).
These data suggested that MAIT cells upregulate glucose meta-
bolism. Therefore, we next performed detailed metabolic analysis
using the Seahorse extracellular flux analyzer. Interestingly, we
found MAIT cells specifically upregulate their rates of glycolysis
(Fig. 1E, 1F), but not OxPhos (Supplemental Fig. 2B), upon ac-
tivation. In addition, the glycolytic capacity, ECAR following
oligomycin injection, of MAIT cells also increased significantly
upon stimulation, which suggests that these cells are increasing
the expression of the glycolytic machinery (Fig. 1E). Therefore,
overall there was a pronounced shift toward glycolytic meta-
bolism in activated MAIT cells. To assess if cellular glycolysis
was required for cytokine production by MAIT cells, we used low
doses of the specific glycolytic inhibitor 2DG. The data showed
that MAIT cell IFN-g production was significantly reduced when
the rate of glycolysis was limited with 2DG (Fig. 1G, 1H). In-
terestingly, 2DG treatment had no impact on TNF-a production by
MAIT cells (Fig. 1I). In contrast, inhibition of mitochondrial
respiration with the ATP synthase inhibitor oligomycin did not
reduce IFN-g production by MAIT cells (Supplemental Fig. 2D,
2E) but did reduce TNF-a (Supplemental Fig. 2F). To further test
the requirement for glucose metabolism in driving MAIT cell
cytokine responses, we cultured MAIT cells under acute glucose
restriction and showed a strong inhibition of IFN-g, further
FIGURE 1. MAIT cells use glycolytic metabolism during IFN-g production. (A) Scatter plot showing MAIT cell production of IFN-g in a cohort of lean
adults (unstimulated versus stimulated with TCR microbead/IL-12/IL-18). (B) Scatter plot showing Glut-1 expression (MFI) on either basal or stimulated
MAIT cells from lean adults (n = 10). (C and D) Representative histograms and scatter plot showing 2NBDG uptake by MAIT cells stimulated with either
TCR microbeads, IL-12, IL-18, both IL-12 and IL-18, or TCR microbeads and IL-12/IL-18 (n = 3). (E and F) Scatter plot and representative Seahorse traces
displaying MAIT cells ECAR rates in either basal (open circles) or stimulated (gray circles) MAIT cells from lean adults. Data representative of six
independent experiments. (G) Representative flow cytometry dot plots and scatter plot displaying the effect of 2DG treatment on IFN-g production by
stimulated MAIT cells (n = 10). (H) Representative ELISpot wells and scatter plot displaying the effect of 2DG treatment (bottom panel) on IFN-g production
by stimulated MAIT cells (n = 5). (I) Scatter plot displaying the effect of 2DG treatment on TNF-a production by stimulated MAIT cells (n = 10). (J) Scatter
plot showing impact of acute glucose restriction (AGR) on IFN-g production by stimulated MAIT cells from lean adults (n = 5). Data representative of five
independent experiments. Statistical comparisons using Student t test or ANOVA. Data representative of a minimum of 10 independent experiments unless
otherwise stated. Error bars represent SEM. *p , 0.05, **p # 0.01, ***p , 0.001. MFI, mean fluorescence intensity.
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supporting our findings that MAIT cell IFN-g production is de-
pendent on glycolytic metabolism (Fig. 1J).
Defective IFN-g production by MAIT cells in obesity parallels
defective cellular metabolism
We have previously reported defective MAIT cells in obese in-
dividuals, including impaired IFN-g production, which we confirm
in an expanded cohort of obese adults (Fig. 2A). Interestingly, in
our obese cohort, we did not observe defective CD8+ T cell IFN-g
production (Fig. 2B). To investigate the mechanism(s) driving de-
fective IFN-g production by MAIT cells in obesity, we performed
RNA-Seq of MAIT cells isolated from five lean and four obese
individuals. Normal enrichment score analysis highlighted a re-
duction in the glycolytic metabolism pathway (Fig. 2C). To inves-
tigate the significance of the reduced glycolytic metabolism in
obesity, Glut-1 expression and 2NBDG uptake assays were
performed. The data showed that MAIT cells from obese adults
show no significant difference in Glut-1 expression (Fig. 2D).
However, there was a significant decrease in the uptake of 2NBDG
in stimulated MAIT cells from obese individuals when compared
with healthy adults (Fig. 2E). Detailed metabolic analysis was
used to confirm the alterations in MAIT cell glycolytic meta-
bolism between healthy and obese MAIT cells. In line with the
reduced glycolytic gene expression and glucose uptake, activated
MAIT cells from obese adults do not increase their rate of gly-
colysis (Fig. 2F, 2G). Indeed, MAIT cells from obese adults show
reduced glycolytic capacity when compared with lean adults
(Fig. 2H). Furthermore, acute glucose restriction had no additional
impact/reduction on IFN-g production in MAIT cells from obese
individuals in comparison with the significant effect observed in
MAIT cells from lean individuals (Fig. 2I). These data confirm
that MAIT cells from obese adults are not performing increased
rates of glycolysis during their activation.
mTORC1 activity is essential for driving MAIT cell glycolysis
and is reduced in obesity
The signaling complex mTORC1 acts as both a nutrient sensor and
a central metabolic regulator of effector immune cells. Studies
have shown that mTORC1 is intrinsically linked with glycolytic
metabolism in effector lymphocytes (22, 23). Strikingly, our
RNA-Seq data revealed defective mTORC1 signaling. (Fig. 3A).
To investigate a role for mTORC1 in driving MAIT cell meta-
bolism, we measured mTORC1 activity in MAIT cells upon
stimulation and demonstrate a robust increase as measured via the
phosphorylation of pS6 (Fig. 3B, 3C). Importantly, these elevated
levels of pS6 were prevented by the mTORC1 inhibitor rapamycin,
demonstrating the specificity of this assay for mTORC1 signaling
(Fig. 3D). We next investigated if mTORC1 signaling is required
for increased rates of glycolysis in activated MAIT cells. Indeed,
MAIT cells stimulated in the presence of rapamycin had significantly
lower levels of glycolysis (Fig. 3E, 3F). As expected, rapamycin
treatment had no significant impact on the ECAR of MAIT cells
FIGURE 2. MAIT cells from obese adults display defective glycolytic metabolism. (A) Scatter plot displaying MAIT cell production of IFN-g in a
cohort of lean (white circles) and obese (gray circles) adult (unstimulated versus stimulated with TCR microbead/IL-12/IL-18) (n = 15). (B) Scatter plot
displaying CD8 T cell production of IFN-g in a cohort of lean (white circles) and obese (gray circles) adult (unstimulated versus stimulated with TCR
microbead/IL-12/IL-18) (n = 15). (C) Heat map depicting differentially downregulated genes (p value , 0.05) within the glycolysis gene set in MAIT cells
isolated from lean and obese donors (n = 5 and 4, respectively). (D) Scatter plot showing Glut-1 MFI on either basal or stimulated MAIT cells from lean
(white circles) or obese (gray circles) donors (n = 10). (E) Scatter plot showing 2NBDG MFI on either basal or stimulated MAIT cells from lean (white
circles) or obese (gray circles) donors. (F) Representative Seahorse trace displaying MAIT cell ECAR rates in either basal (open circles) or stimulated (gray
circles) MAIT cells from an obese adult with representative stimulated lean donor (black circles). (G and H) Scatter plot displaying glycolysis levels
(ECAR) or glycolytic capacity (ECAR post–oligomycin treatment) from lean (white circles) or obese (gray circles) donors (n = 6). (I) Scatter plot showing
impact of acute glucose restriction (AGR) on IFN-g production by stimulated MAIT cells from lean (white circles) or obese (gray circles) adults. Data
representative of a minimum of five independent experiments unless otherwise stated. Statistical comparisons using Student t test or ANOVA. Error bars
represent SEM. *p , 0.05, **p # 0.01. MFI, mean fluorescence intensity.
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from obese donors (Fig. 3G). We show that rapamycin treatment
of activated MAIT cells from lean individuals inhibits IFN-g, and
this regulation occurs at an mRNA level (Fig. 3H, 3I). Together,
these data demonstrate that mTORC1 is required for metabolic
and functional MAIT cell responses. Indeed, the data show that
activation-induced mTORC1 activity was significantly reduced in
MAIT cells from obese adults (Fig. 3J). Similar to CD8+ T cell
IFN-g production, we observed no difference in CD8+ T cell
mTORC1 activity between lean and obese donors (Fig. 3K). Collec-
tively, these data highlight an important role for mTORC1 signaling in
MAIT cell metabolism and highlight obesity-associated defects in
mTORC1 as a possible driver of defective MAIT cell function.
mTORC1 activity is dependent on amino acid flux via SLC7A5,
which is diminished in obesity
The data thus far highlight a crucial role for mTORC1 signaling in
controlling MAIT cell metabolism and function. We next inves-
tigated the upstream regulators of mTOR activity in MAIT cells in
the hopes that it may shed light on the cause behind the defective
mTORC1 signaling observed in obeseMAIT cells. Previous studies
have highlighted the importance of amino acid transport through
the system L amino acid transporter, SLC7A5, in controlling
mTOR activity in primary T cells (24). To assess whether amino
acid transport controls mTORC1 activity in MAIT cells, we first
investigated amino acid transport in MAIT cells using a recently
described flow cytometric–based assay (21). We show that MAIT
cells readily uptake exogenous amino acids (as determined by
active transport of the fluorescent system L transporter substrate
kynurenine) (Fig. 4A, 4B). Furthermore, we show that treatment
with the system L amino acid transport inhibitor BCH reduced
kynurenine uptake by MAIT cells (Fig. 4C, 4D). We next in-
vestigated if MAIT cells from obese donors had altered amino
acid uptake. Interestingly, we observed a significant decrease in
uptake through system L transport compared with MAIT cells
from lean donors (Fig. 4E, 4F). To investigate this reduction,
we measured the expression of the predominant system L
amino acid transporter expressed in T cells, SLC7A5, and show
reduced mRNA expression in obese donors (Fig. 4G). Finally,
using BCH treatment, we investigated the impact of this di-
minished amino acid uptake on mTORC1 activity and gly-
colytic metabolism in MAIT cells from healthy donors. We
observed reduced mTORC1 activation and strong abrogation of
glycolytic metabolism with BCH (Fig. 4H–K). As expected, we
observed reduced IFN-g production by MAIT cells treated with
BCH (Fig. 4L). These data implicate for the first time, to our
knowledge, a crucial role for amino acid availability in regu-
lating MAIT cell metabolism and function in obesity.
Discussion
In this study, we show definitively that MAIT cells increase their
rates of glucose uptake and glycolysis upon activation. We also
show that this increased rate ofMAIT cell glycolysis is essential for
driving IFN-g production. Furthermore, we identify mTORC1
as a key metabolic regulator that controls the rate of MAIT cell
FIGURE 3. MAIT cell glycolytic metabolism is dependent on mTORC1 activation, which displays defects in obesity. (A) Heat map depicting differ-
entially downregulated genes (p value , 0.05) within the mTORC1 gene set in MAIT cells isolated from lean and obese donors (n = 5 and 4, respectively).
(B and C) Representative histogram and scatter plot showing the activation of mTORC1 (phosphorylation of S6) in MAIT cells stimulated with either TCR
microbeads, IL-12, IL-18, both IL-12 and IL-18, or TCR microbeads, IL-12 and IL-18 (n = 3). (D) Representative histogram showing the inhibition of S6
phosphorylation by rapamycin in stimulated MAIT cells. (E) Representative Seahorse traces displaying MAIT cell ECAR rates in either basal (open
circles), stimulated (gray circles), or rapamycin-treated (open squares) in MAIT cells from lean donors. (F) Scatter plot displaying ECAR levels in
stimulated (gray circles) or rapamycin-treated (white circles) MAIT cells from lean donors. (G) Scatter plot detailing effect of rapamycin on ECAR rates in
stimulated obese MAIT cells. (H) Scatter plot detailing effect of rapamycin on IFN-g production by stimulated MAIT cells from lean donors. (I) Scatter plot
detailing effect of rapamycin on IFN-g mRNA in MAIT cells from lean donors. (J) Scatter plot showing pS6 MFI in either basal or stimulated MAIT cells
from lean (white circles) or obese (gray circles) donors. (K) Scatter plot showing pS6 MFI in either basal or stimulated CD8 T cells from lean (white circles)
or obese (gray circles) donors. Data representative of a minimum of five independent experiments unless otherwise stated. Statistical comparisons using
Student t test or ANOVA. Error bars represent SEM. *p , 0.05, **p # 0.01, ***p , 0.001.
3408 OBESITY DYSREGULATES MAIT CELL METABOLISM











metabolism and thereby effector molecule production. We show
that mTORC1 activation is under the control of amino acid uptake
by the cell and expression of the system L amino acid transporter,
SLC7A5. We previously reported that MAIT cells isolated from
obese individuals are functionally defective. To understand the
mechanisms at play, we used RNA-Seq to identify alterations in
the gene expression of MAIT cells isolated from obese individu-
als. These analyses highlighted alterations in both glycolytic and
mTORC1 pathways in MAIT cells isolated from obese individu-
als. Indeed, we confirm our sequencing data by showing reduced
rates of glycolysis and mTORC1 activity in MAIT cells from
obese adults, which parallel the loss of IFN-g production reported
in obesity (8). Finally, we provide evidence that defects in amino
acid transport contribute to the described defective MAIT cell
metabolism in obese patients.
MAIT cells are potent effector T cells, capable of rapidly
producing multiple cytokines (9). During viral infections, activa-
tion of the MAIT cell is independent of the TCR but dependent
on IL-18. Data from Slichter and colleagues (11) show that
MAIT cells respond weakly to TCR stimulation in the absence of
secondary stimulation by cytokine. Our data support this finding,
showing that MAIT cells respond most strongly when stimulated
via the TCR and cytokine receptors, specifically IL-18 and IL-12.
The pathways regulating MAIT cell cytokine production are
poorly understood; however, a recent study by Zinser and col-
leagues (25) provided evidence that MAIT cell production of
granzyme B was dependent on glycolytic metabolism. In other
effector lymphocytes, it is well established that the cytokine
profiles are regulated by intrinsic cellular metabolism (26–28).
Activated T cells have been shown to have a large glucose
requirement, especially Th 1 and 17 subsets along with CD8+
cells (27). We show that MAIT cells express the glucose
transporter Glut-1 and upon cytokine stimulation increase their
uptake of the fluorescent 2DG analogue 2NBDG. Like the
cytokine responses, MAIT cells increased 2NBDG uptake with
TCR stimulation; however, the greatest increases in glucose
uptake were observed with TCR–cytokine costimulation. This
is in keeping with the requirement for greater amounts of
energy and biological intermediates following TCR/cytokine
stimulation.
Studies in effector populations such as CD8+ T cells and NK
cells have demonstrated that the cytokine production by these cells
is dependent on glycolytic metabolism (20, 27). We investigated
the metabolic pathways used by MAIT cells using the Seahorse
extracellular flux analyzer and show that MAIT cells are glyco-
lytic cells, increasing their rates of glycolysis upon activation.
Interestingly, in contrast to NK cells, MAIT cells do not display
parallel increases in OxPhos (28). To link MAIT cell glycolytic
metabolism to cytokine production, we used the glycolytic path-
way inhibitor 2DG and show that at low doses it strongly inhibits
MAIT cell production of IFN-g. We also show that acute restriction
of glucose during MAIT cell activation significantly impacted their
activation, confirming their glycolytic requirements. Interestingly,
2DG treatment did not impact TNF-a production by MAIT cells,
whereas treatment with oligomycin reduced TNF-a production but
not IFN-g. Previous studies in macrophages have described the
differential regulation of TNF-a, showing that 2DG blocks IL-1b
but not TNF-a. This suggests differential metabolic regulation of
TNF-a production in MAIT cells.
We and others have previously reported that MAIT cells are
defective in obese adults, although the mechanism(s) underpin-
ning their dysregulation are unknown (8, 29). To elucidate the
mechanisms driving the alterations in cytokine production, we
performed RNA-Seq of MAIT cells isolated from lean and obese
adults. We observed alterations in the expression over 400 genes
between lean and obese donors, and principal component analysis
FIGURE 4. mTORC1 activation in MAIT cells is dependent on amino acid uptake via SLC7A5, which is defective in obesity. (A and B) Representative
histogram and scatter plot showing Kynurenine (Kyn) uptake by MAIT cells compared with HBSS control (no Kyn) (n = 10). (C and D) Representative
histogram and scatter plot showing the effect of BCH (50 mM) on Kyn uptake by MAIT cells (n = 10). (E and F) Representative histogram and scatter plot
showing Kyn uptake by MAIT cells from a lean (open histogram) or obese donor (gray histogram) (n = 10). (G) Scatter plot showing SLC7A5 mRNA
expression in MAIT cells from lean or obese donors (n = 5). (H and I) Representative histogram and scatter plot showing the effect of BCH (50 mM) on the
activation of mTORC1 (pS6) in TCR-/IL-12–/IL-18–activated MAIT cells (n = 4). (J and K) Representative Seahorse trace and scatter plot showing the
effect of BCH (50 mM) on the ECAR of TCR-/IL-12–/IL-18–activated MAIT cells (n = 4). (L) Scatter plot showing the effect of BCH (50 mM) on IFN-g
production by TCR-/IL-12–/IL-18–activated MAIT cells (n = 4). Data representative of a minimum of five independent experiments unless otherwise stated.
Statistical comparisons using Student t test or ANOVA. Error bars represent SEM. *p , 0.05, **p # 0.01, ***p , 0.001.
The Journal of Immunology 3409











separated MAIT cells isolated from lean donors from MAIT cells
isolated from obese donors. Pathway analysis revealed changes in
several cellular metabolism pathways, including the downregula-
tion of genes associated with glycolytic metabolism in MAIT cells
isolated from obese individuals. To confirm our sequencing data, we
performed a series of experiments, which show for the first time,
to our knowledge, that glycolytic metabolism is defective in
MAIT cells isolated from obese adults. This parallels our recent
study showing defective glycolytic metabolism in NK cells from
obese adults (30). In contrast to NK cells and the MAIT data from
obese adults presented in this study, we previously reported that in a
cohort of obese children there was altered NK cell metabolism with
elevated rates of glycolysis, which may suggest that chronic
activation of glycolytic machinery in childhood obesity results in
a failure later in life (31).
The mTOR complex is highlighted both as an important
signaling complex and regulator of metabolism in immune
populations such as CD8+ T cells and NK cells (20, 26, 32). Our
data identify mTORC1 as a key regulator of MAIT cell meta-
bolism. In this study, we show that MAIT cells increase mTORC1
activity upon activation, which is essential for the elevated levels
of MAIT cell metabolism upon activation. Finally, our sequencing
data highlighted reductions in mTORC1 signaling in MAIT cells
isolated from obese individuals. We show diminished mTORC1
activation in MAIT cells but not classical CD8+ T cells isolated
from obese individuals as compared with lean controls. Previous
studies show that inhibition of mTORC1 with rapamycin results
in reduced effector immune cell functions (20, 33). Indeed, inhi-
bition of mTORC1 activation with rapamycin inhibited IFN-g
production, which is in line with reduced rate of glycolysis ob-
served in rapamycin-treated MAIT cells and the requirement of
glycolysis for MAIT cell IFN-g production. These findings con-
tribute to our understanding as to why MAIT cell functional re-
sponses are impaired in obesity.
To investigate why mTOR activity is diminished in MAIT cells
from obese donors, we investigated the upstream regulators of
mTOR. Previous studies by our collaborators have extensively
shown that AKT is dispensable for T cell metabolism and NK cell
metabolism but highlight amino acid transport as an important
regulator of mTORC1 activity (24, 26, 34, 35). To this end,
we show that MAIT cell activation of mTORC1 and subsequent
upregulation of glycolytic metabolism and IFN-g production is
dependent on amino acid transport into the cell. We also show
that MAIT cells from obese donors have reduced expression
of the system L amino acid transporter SLC7A5 and thus re-
duced amino acid uptake. Numerous studies have highlighted the
dysregulation of obesity on amino acid metabolism, in particular
branched chained amino acids such as leucine, which is the
candidate amino acid implicated in the activation of mTOR in
T cells (36–41).
Collectively, our data show that MAIT cells use glycolytic
metabolism during their production of IFN-g and that this process
is regulated by mTORC1, which in turn is dependent on amino
acid flux into the cell. In obesity, RNA-Seq of MAIT cells
revealed downregulation of genes involved in both glycolytic
metabolism and mTORC1 signaling. We confirmed these alter-
ations using a series of in vitro experiments. These findings pro-
vide a mechanism for the reported alterations in MAIT cell IFN-g
production in obesity and may help us to understand the alter-
ations of MAIT cells in other human diseases such as hepatitis
C virus, malignant myeloma, and colorectal cancer (42–44).
Finally, understanding the metabolic pathways controlling MAIT
cell activation may highlight novel targets for controlling their
functions in disease (45).
Disclosures
The authors have no financial conflicts of interest.
References
1. Gregg, E. W., and J. E. Shaw. 2017. Global health effects of overweight and
obesity. N. Engl. J. Med. 377: 80–81.
2. Calle, E. E., C. Rodriguez, K. Walker-Thurmond, and M. J. Thun. 2003.
Overweight, obesity, and mortality from cancer in a prospectively studied cohort
of U.S. adults. N. Engl. J. Med. 348: 1625–1638.
3. Wellen, K. E., and G. S. Hotamisligil. 2005. Inflammation, stress, and diabetes.
J. Clin. Invest. 115: 1111–1119.
4. Ip, B. C., A. E. Hogan, and B. S. Nikolajczyk. 2015. Lymphocyte roles
in metabolic dysfunction: of men and mice. Trends Endocrinol. Metab. 26:
91–100.
5. Lynch, L., M. Nowak, B. Varghese, J. Clark, A. E. Hogan, V. Toxavidis,
S. P. Balk, D. O’Shea, C. O’Farrelly, and M. A. Exley. 2012. Adipose tissue
invariant NKT cells protect against diet-induced obesity and metabolic disorder
through regulatory cytokine production. Immunity 37: 574–587.
6. O’Shea, D., T. J. Cawood, C. O’Farrelly, and L. Lynch. 2010. Natural killer
cells in obesity: impaired function and increased susceptibility to the effects of
cigarette smoke. PLoS One 5: e8660.
7. O’Shea, D., M. Corrigan, M. R. Dunne, R. Jackson, C. Woods, G. Gaoatswe,
P. N. Moynagh, J. O’Connell, and A. E. Hogan. 2013. Changes in human den-
dritic cell number and function in severe obesity may contribute to increased
susceptibility to viral infection. Int. J. Obes. 37: 1510–1513.
8. Carolan, E., L. M. Tobin, B. A. Mangan, M. Corrigan, G. Gaoatswe, G. Byrne,
J. Geoghegan, D. Cody, J. O’Connell, D. C. Winter, et al. 2015. Altered distri-
bution and increased IL-17 production by mucosal-associated invariant T cells in
adult and childhood obesity. J. Immunol. 194: 5775–5780.
9. Gapin, L. 2014. Check MAIT. J. Immunol. 192: 4475–4480.
10. Kjer-Nielsen, L., O. Patel, A. J. Corbett, J. Le Nours, B. Meehan, L. Liu,
M. Bhati, Z. Chen, L. Kostenko, R. Reantragoon, et al. 2012. MR1 presents
microbial vitamin B metabolites to MAIT cells. Nature 491: 717–723.
11. Slichter, C. K., A. McDavid, H. W. Miller, G. Finak, B. J. Seymour,
J. P. McNevin, G. Diaz, J. L. Czartoski, M. J. McElrath, R. Gottardo, and
M. Prlic. 2016. Distinct activation thresholds of human conventional and
innate-like memory T cells. JCI Insight 1: e86292.
12. Chiba, A., R. Tajima, C. Tomi, Y. Miyazaki, T. Yamamura, and S. Miyake. 2012.
Mucosal-associated invariant T cells promote inflammation and exacerbate
disease in murine models of arthritis. Arthritis Rheum. 64: 153–161.
13. Cosgrove, C., J. E. Ussher, A. Rauch, K. Gärtner, A. Kurioka, M. H. Hühn,
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32. Viel, S., A. Marçais, F. S. Guimaraes, R. Loftus, J. Rabilloud, M. Grau,
S. Degouve, S. Djebali, A. Sanlaville, E. Charrier, et al. 2016. TGF-b inhibits the
activation and functions of NK cells by repressing the mTOR pathway. Sci.
Signal. 9: ra19.
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44. Sundström, P., F. Ahlmanner, P. Akéus, M. Sundquist, S. Alsén, U. Yrlid,
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Interleukin-17 producing mucosal associated invariant
T cells - emerging players in chronic inflammatory
diseases?
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Mucosal associated invariant T (MAIT) cells are a population of evolutionarily conserved
T cells, which express an invariant T cell receptor (TCR) and represent a significant sub-
set of innate-like T cells in humans, yet their role in immunity is still emerging. Unlike
conventional αβ T cells, MAIT cells are not restricted by MHC molecules, but instead
uniquely recognize microbially derived vitamin metabolites presented by the MHC-I like
molecule MR1. MAIT cells are enriched in mucosal sites and tissues including liver and
adipose tissue where they are thought to play an important role in immunosurveillance
and immunity against microbial infection. In addition to their putative role in antimicro-
bial immunity, recent research on MAIT cells, in particular IL-17 producing MAIT cells,
has demonstrated their involvement in numerous chronic inflammatory conditions. In
this review, we give an overview of the work to date on the function and subsets of MAIT
cells. We also examine the role of IL-17 producing MAIT cells in chronic inflammatory
diseases ranging from autoimmune conditions, metabolic diseases to cancer. Further-
more, we discuss the most recent findings from the clinic that might help deepen our
understanding about the biology of MAIT cells.
Keywords: chronic inflammation  IL-17  mucosal-associated invariant T cells
Mucosal-associated invariant T cells
Mucosal associated invariant T (MAIT) cells comprise a unique
population of evolutionarily conserved T cells, first described in
humans by Porcelli and colleagues in the early 1990s, what was
further confirmed by another landmark study by Tilloy et al.
in 1999 [1, 2]. These cells are characterized by expression of
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e-mail: Andrew.E.Hogan@mu.ie
the invariant TCR-α chain, Vα7.2 (TRAV1-2-TRAJ33, TRAJ20,
or TRAJ12) in human, or Vα19 (TRAV1-TRAJ33) in mice. This
TCR chain is typically associated with a limited array of TCR-β
chains, e.g., Vβ2 or Vβ13 in human, or Vβ6 and Vβ8 in mice
[3]. This constrained gene usage of the TCR suggests the ability
of these cells to target conserved antigens. MAIT cell antigen
recognition is not restricted by MHC, instead the MHC class
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I-like molecule (MR1) is recognized by the MAIT TCR [3–5].
The MR1 complex typically presents metabolites derived from
the biosynthesis of riboflavin (vitamin B2), a process mediated
by many bacterial and yeast species, but not viruses or human
cells [6]. This observation is consistent with the finding that
MAIT cells are activated by riboflavin synthesizing bacteria,
such as Salmonella and other Enterobactericaeae species [7]. In
vitro experiments have identified a number of these riboflavin
metabolites as MAIT cell antigens, including stimulatory antigens
5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU),
5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU),
6,7-dimethyl-8-D-ribityllumazine (RL-6,7-diMe), and 7-hydroxy-
6-methyl-8-D-ribityllumazine (RL-6-Me-7-OH) [8]. The potency
of these antigens varies, with a non-stimulatory MR1 ligand
6-formyl-pterin (6-FP), a natural breakdown by-product of folic
acid, also described [6]. The most potent of these stimulating
antigens are 5-OP-RU and 5-OE-RU, which are both generated
from the riboflavin precursor 5-amino-6-D-ribitylaminouracil
(5-A-RU) through non-enzymatic condensation with small
ubiquitous metabolites methylglyoxal and glyoxal, respectively
[8, 9]. Identification of these potent antigens has allowed for
development of highly specific antigen-loaded MR1 tetramers,
for improved identification of both human and mouse MAIT
cells [10–13].
In humans, MAIT cells are detectable in cord blood and fre-
quencies increase into adulthood before decreasing after the sixth
decade of life [14, 15]. MAIT cells are widely distributed through-
out the human body, comprising a substantial proportion of
T cells in blood (1–10%), intestinal tissues [16, 17], lungs [18],
skin [19], adipose tissue [20], and in particular the liver, where
MAIT cells can account for up to 50% of all T cells [21]. In a
study of human fetal tissues, MAIT cells were found to be rare in
fetal thymus, spleen, and mesenteric lymph nodes but enriched
in small intestine, liver, and lung [22]. MAIT cell development
proceeds in a step-wise process, where thymic selection precedes
peripheral expansion and is dependent on commensal microbes
and MR1 expressing B cells [23, 24]. Subsequent studies showed
that MAIT cell selecting thymocytes express MR1 and both CD4
and CD8, and that MR1 deficient mice lack MAIT cells [25]. Elab-
orate studies using MR1 loaded tetramers in mice showed that
the MAIT cell compartment is composed of three prominent pop-
ulations, defined by expression of CD24 and CD44 [26]. Of these
populations, the CD24−/CD44+ subset was the only functionally
active population and could be further subdivided into two distinct
subsets of Tbet+ and RORγt+ MAIT cells. In humans, the stages
of thymic maturation of MAIT cells were differentiated by CD27
and CD161 expression. Stage 1 was defined by lack of expression
of CD161 and CD27, at stage 2 cells remained CD161− but also
gained expression of CD27, whereas at the most mature stage
of thymic development MAIT cells were defined as CD161+ and
CD27pos-lo. In contrast to the stage 3 of murine MAIT cell matu-
ration, human MAIT cells were observed to co-express Tbet+ and
RORγt+. Upon in vitro stimulation, only a small subset of stage
3 thymic MAIT cells responded by cytokine production in com-
parison to the stage 3 MAIT cells found in blood, suggesting that
Figure 1. MAIT cell phenotype. In addition to their expression of the
invariant TCRVα7.2, MAIT cells can be defined by their expression of
several surface molecules including CD161 and CD26. MAIT cells also
express several cytokine and chemokine receptors on their surface,
including IL-18R and CCR6. Also expressed on the surface of MAIT cells
are the nutrient transporters GLUT-1 and SLC7A5, two key transporters
in MAIT cell metabolism. MAIT cells can be further characterized by
their expression of transcription factors such as PLZF, Tbet, and RORγt,
which control the production of cytokines such as IFN-γ and IL-17
during activation. Finally, MAIT cells can also express lytic molecules
including perforin and granzyme B.
further maturation of these cells takes place outside of the thymus
[24].
MAIT cell phenotype and functions
Like other so-called unconventional T cells, such as γδ T cells
and invariant NK T (iNKT) cells, MAIT cells possess attributes of
both innate and adaptive immunity, e.g., rapid effector function
upon activation by conserved ligands and recognized by a classi-
cal, albeit semi-invariant, TCR. Human MAIT cells are classically
defined by expression of an invariant Vα7.2 TCR chain and high
levels of the C-type lectin CD161 [3, 7]. MAIT cells can express
CD8, either CD8αα or CD8αβ isoforms, CD4 or can be double
negative for both CD4 and CD8, with CD8 expressing MAIT cells
representing the majority [27, 28]. The CD4−/CD8− MAIT cell
population has recently been described as a functionally distinct
MAIT cell subset, producing higher levels of IL-17 and lower levels
of IFN-γ [28]. Consistent with their presence in numerous tissue
types, MAIT cells express several tissue homing molecules, includ-
ing CCR5, CCR6, and CXCR6 [29]. MAIT cells also express mul-
tiple cytokine receptors, including IL-7R, IL-12R, and IL-18R [7,
30–32]. Several studies have outlined a requirement for cytokine
priming or stimulation for full MAIT cell activation, in particular
by cytokines IL-7, IL-12, and IL-18 [30, 33] (Fig. 1).
Similar to other unconventional T cell subsets, MAIT cells can
be activated independently of their TCR, specifically by cytokines
alone [34–36]. This means that MAIT cell activation is not solely
reliant on TCR ligation alone, which results in a relatively weak
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Figure 2. MAIT cell activation. MAIT cells can be activated in a MR1 dependent manner (1) where bacterial ligands are presented by antigen
presenting cells (APC) on MR1 and recognized by the invariant Vα7.2 TCR resulting in the production of cytokine and lytic molecules. MAIT cells
can also be activated in a MR1 independent manner (2) by inflammatory cytokine such as IL-12 and IL-18 that are produced by innate cells in the
presence of viral or bacterial infection, again resulting in the production of effector molecules.
response. Therefore, these cells can respond to a wider set of
stimuli than MR1 presented antigens alone, and in a synergistic
manner where multiple signals are present [34, 36, 37] (Fig. 2).
Upon activation, MAIT cells can produce multiple cytokines
and can be generally divided into MAIT cells that primarily pro-
duce Th1 type cytokines including IFN-γ and TNF-α (MAIT1 cells),
and MAIT cells that predominantly produce Th17 type cytokines
such as IL-17A (MAIT17 cells) [20, 29, 38, 39]. In the human
protein atlas, it was noted that MAIT cells expressed among the
highest levels of the protein coding gene RORC, which is the
transcription factor responsible for IL-17 production [40]. Sev-
eral other transcription factors have been detailed in MAIT cells
including PLZF and Tbet [41]. In addition to rapid cytokine pro-
duction, MAIT cells possess a full complement of cytolytic effector
molecules such as granzymes (granzyme A and B) and perforin,
which allow them to lyse bacteria-infected cells [42]. Upon acti-
vation, MAIT cells rapidly display this cytotoxic phenotype, which
is heightened through TCR interactions and cytokines. The cyto-
toxic ability of these cells is tightly regulated however, and is
ultimately dependent on MR1 ligation, which allows control of
bacterial infection while reducing immune-mediated pathology
[42]. Numerous recent studies have highlighted the importance
of intrinsic metabolic pathways in controlling immune cell func-
tions [43]. We have recently reported on the metabolic pathways
controlling MAIT cell cytokine production [38]. Similar to CD8+ T
cells and NK cells, MAIT cells increase their rate of glycolysis upon
activation, which provides the biological intermediates needed
for effector molecule production [38, 44]. MAIT cells express the
major glucose transporter GLUT-1 and neutral amino acid trans-
porter SLC7A5 upon stimulation increase their nutrient uptake
[38]. Inhibition of glycolysis in MAIT cells reduced the capacity
to produce IFN-γ and granzyme B, highlighting the importance of
metabolism in MAIT cell effector function [38, 44]. Mammalian
target of rapamycin (mTOR) is a well-characterized regulator of
glycolysis in effector cells such as NK cells [45]. Upon activa-
tion, MAIT cells increase signaling through mTOR and inhibition
with rapamycin results in reduced rates of glycolysis and cytokine
production, further highlighting the importance of these intrinsic
metabolic pathways in MAIT cells [38], (Fig. 3).
MAIT cells in host defense
The ability of MAIT cells to recognize bacterial metabolites via the
highly conserved MR1 molecule suggests that these cells play a
critical role in immune defense against microbial infections. MR1
KO mice show higher bacterial burden following injection with
either Escherichia coli or Mycobacterium abscessus, thus implicat-
ing MAIT cells in immunity against these pathogens [7]. Further-
more, MR1 deficient mice exposed to low dose aerosol infection
with Mycobacterium bovis demonstrated a higher bacterial bur-
den compared to MR1 sufficient mice. This effect evens out by
day 30 post-infection, however, suggesting that MAIT cells drive
early containment of mycobacterial infections in the lung [35].
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Figure 3. MAIT cell metabolism. Upon activation, MAIT cells increase their consumption of amino acids and glucose (1), which are transported
into MAIT cells via SLC7A5 and GLUT-1, respectively (2-3). Upon sensing nutrients mTORC1 activation (4) leads to increased rates of glycolytic
metabolism (5) that provides the intermediates for the production of molecules such as IFN-γ and granzyme B (6).
MAIT cells are reduced in the blood but elevated in the lungs
of humans with Mycobacterium tuberculosis (Mtb), and respond to
Mtb-infected MR1 expressing lung epithelial cells [18]. In children
with active Mtb infection, MAIT cell frequencies are decreased in
the peripheral blood but unlike in Mtb infected adults, they do
not accumulate in the lung [46]. MAIT cells have also been shown
to respond in a TCR-dependent manner to Gram-negative bacte-
ria such as Klebsiella pneumoniae, Pseudomonas aeruginosa, and
Salmonella enterica, as well as Gram-positive bacteria including
Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus
epidermidis, and Clostridioides difficile, but do not respond to Strep-
tococcus pyogenes or Enterococcus faecalis [7, 47–51]. A decrease in
circulating MAIT cells has been reported in a number of bacterial
infection settings, with lower MAIT cell presence correlating with
severity of infection. This was observed in cystic fibrosis patients
during Pseudomonas aeruginosa, active Mtb infection, in the mite-
borne disease scrub typhus, and in critically ill patients admitted
to intensive care units with sepsis, who are also more susceptible
to nosocomial infections [48, 52–55].
In addition to their broad antibacterial properties, a role for
MAIT cells in viral infection has also emerged, detailing how MAIT
cells become activated in a TCR-independent, IL-18-dependent
manner in response to human viral infections including influenza,
hepatitis C (HCV), and dengue virus [36, 56, 57]. Indeed, MAIT
cell activation and IL-18 levels correlated with disease severity
in acute dengue infection [56]. It was observed that MAIT cell
activation was further enhanced in the presence of other proin-
flammatory cytokines such as IL-12 and type I IFNs [56]. This
cytokine-driven mechanism of MAIT cell activation has also been
demonstrated in an in vitro model of Zika virus infection, and
resulted predominantly in IFN-γ production [57]. A similar IFN-γ
response was observed in HCV infection, which resulted in a reduc-
tion of in vitro HCV replication [36]. MAIT cells were also shown
to be important in the immune response against severe H1N1
influenza infection in mice, with MAIT cell deficient MR1−/− mice
showing higher mortality and greater weight loss than control
groups [58].
MAIT cells in chronic inflammatory disease
Acute inflammation is a critical process in the protection and
repair process, tightly regulated to resolve after injury or infection.
However, numerous studies have provided empirical evidence
that many diseases are caused by a systemic and non-resolving
inflammation termed chronic inflammation [59]. These diseases
are increasing in prevalence and dramatically impacting morbidity
and mortality. Chronic inflammatory diseases include rheumatoid
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Figure 4. MAIT17 cells in chronic inflammatory disease. Schematic outlining the body of works describing increased MAIT17 cells in chronic
inflammatory conditions.
arthritis, non-alcoholic fatty liver, and type II diabetes mellitus.
The role of MAIT17 cells in the development and pathogenesis of
these conditions is summarized in Figure 4 and discussed herein.
Respiratory disease
Asthma is a respiratory disease characterized by chronic airway
inflammation with increased mucus production in the bronchi-
oles, and is associated with activation of an allergen-specific T
helper type 2 (TH2) immune response [60]. Recently, IL-17 has
emerged as a pathogenic player in asthma, in particular in severe
asthma and immediate responses to bronchodilators [61]. The role
of MAIT cells in asthma is unclear with reported reduced frequen-
cies in blood, sputum, and lung biopsies of patients with asthma
[62]. In this study, the authors conclude that a loss of MAIT cells in
severe asthma might increase susceptibility to bacterial infection,
which might impact asthma pathology, suggesting a protective
role. However, in a study by Lezmi and colleagues, it was noted
that MAIT17 cells were increased in the BALF of asthma patients,
and were associated with exacerbations, suggesting a potential
pathogenic role [63]. The exact role of MAIT cells in respiratory
disease remains to be elucidated, however their relative abun-
dance in humans and association with disease severity, suggests
MAIT17 cells may be a major player in asthma pathology either
directly or indirectly.
Connective tissue disease
MAIT cells have been implicated in several rheumatoid diseases,
including rheumatoid arthritis, systemic lupus erythematosus, and
spondyloarthritis [64–68]. Rheumatoid arthritis (RA) is a chronic
inflammatory autoimmune condition which affects the joints. Sev-
eral immune cell populations have been implicated in the patho-
genesis of disease including T cells, B cells, and macrophages [69].
Studies in RA patients revealed significant decreases in peripheral
MAIT cells observed in comparison to healthy controls, and these
decreases are correlated with disease activity scores [64]. MAIT
cells have been shown to migrate into the synovial fluid in RA,
mediated by IL-1β and TNF-α driven expression of E-selectin at
that site [70]. Chiba and colleagues demonstrated an improve-
ment in disease severity in a murine model of collagen induced
arthritis in MAIT cell deficient mice, which was paired with a
reduction in IL-17 production [71]. Systemic lupus erythematosus
(SLE) is an inflammatory autoimmune condition, which impacts
several organs including skin, joints and the CNS [72]. Similar
to RA, alterations in MAIT cell frequencies were associated with
C© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2020. 50: 1098–1108 HIGHLIGHTS 1103
disease severity in patients [64]. In a murine model of SLE, IL-17
producing MAIT cells were expanded and their deletion resulted
in improved disease severity [73]. Spondyloarthritis is a group of
chronic inflammatory conditions, which can affect the joints of the
spine and pelvis. Several inflammatory cytokines have been impli-
cated in the pathogenesis of the disease including TNF-α and IL-17
[74]. Three separate studies have investigated MAIT cells in anky-
losing spondylitis (AS), with each observing reduced MAIT cell
frequencies in the circulation [65, 66, 75]. In one of the studies,
Gracey and colleagues reported an increase in MAIT cell numbers
in the synovial fluid of patients with AS [65]. All three studies
also reported that IL-17 production by MAIT cells was higher, sug-
gesting that MAIT cells play a role in pathogenesis [76]. Sjögren
syndrome (SjS) is a systemic autoimmune inflammatory disease
that primarily affects the exocrine glands resulting in the severe
dryness of mucosal surfaces, principally in the mouth and eyes
[77]. MAIT cells were found to infiltrate the salivary glands of
patients with SjS, displaying an altered phenotype and IFN-γ pro-
duction, but no difference in IL-17 was reported [78]. In a subse-
quent report, Guggino and colleagues showed increased MAIT17
cells in salivary gland tissue of patients with SjS, and provided
evidence for activation of the IL-7/IL-23 pathways in polariza-
tion of MAIT17 cells in SjS [79]. Based on the studies above, it
appears that MAIT cells play an important role in the pathogenesis
of connective tissue disease and may represent a novel therapeutic
target.
Neurological disease
Multiple sclerosis (MS) is a chronic immune-mediated condition
affecting the CNS in which T cells play a central pathogenic role
in destruction of the myelin sheath [80]. In humans, CD8 T cells
comprise the most abundant cell type in the CNS of MS patients
in contrast to animal models [71] and MAIT cells account for
approximately 5% of these CNS-infiltrating cells [81]. MAIT17
cells are increased in both the CNS and periphery of MS patients,
which indicates that MAIT cells may be driving the inflammation
associated with this autoimmune disorder [82]. A recent study by
Willing et al. has suggested a role for IL-7 in augmentation of IL-
17 production by MAIT cells in MS, where increased surface IL-7R
expression on MAIT cells correlated with their IL-17 production
[82]. Further evidence for MAIT17 cells in the pathogenesis of
MS comes from the identification of an expanded population in
MS patients of CCR6+, CD8+, CD161hi, CD3+, IL-17+ cells, which
bear all the hallmarks of MAIT cells [83]. The exact role for MAIT
cells in the pathogenesis of MS remains to be elucidated but their
increased production of IL-17 may highlight them as a potential
therapeutic target.
Inflammatory skin disease
Recent studies have begun to elucidate a role for MAIT cells in
psoriasis, one of the most common immune-mediated chronic
inflammatory skin disorders [84]. Evidence suggests that IL-17A
and TH17-related cytokines are critical in the pathogenesis of this
systemic disease [85]. A study by Teunissen et al. shows the pres-
ence of CD8+ MAIT cells in the dermis and epidermis of psoriatic
plaques as well as healthy skin, with MAIT cells accounting for a
proportion of IL-17A+ CD8+ T cells in plaques [19]. IL-17 produc-
ing MAIT cells were predominantly found in the psoriatic lesions
and were almost absent in healthy skin. These results identify an
additional source of IL-17 in psoriatic skin that may be contribut-
ing to the disease [19]. Psoriatic arthritis (PsA) is an inflamma-
tory condition, which affects the joints of up to 25% of psoriasis
patients. In the majority of cases, psoriasis precedes the onset of
PsA [86]. MAIT cells are found to be enriched in the synovial fluid
compared to blood of patients with PsA, and upon stimulation pro-
duced more IL-17 than in other rheumatoid conditions [68]. The
contribution of MAIT cells to other IL-17-driven inflammatory skin
diseases such as atopic dermatitis and hidradenitis suppurativa are
unknown to date and require further investigation.
Inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic inflammatory con-
dition of the gastrointestinal tract encompassing two separate dis-
eases: Crohn’s disease (CD) and ulcerative colitis (UC) [87]. Both
conditions are driven by over production of inflammatory medi-
ators including TNF-α, IL-23, and IL-17 [88]. Serriari and col-
leagues investigated the frequencies of MAIT cells in cohorts of
patients with either UC or CD and reported reduced frequencies
in the circulation compared to healthy controls, which was paired
with an increase of MAIT cells in the inflamed tissue [89]. In vitro,
MAIT cells from both UC and CD produced more IL-17 [89]. These
findings were supported by a subsequent study by Haga and col-
leagues, who reported reduced circulating MAIT cell frequencies
and increased IL-17 production in UC patients [90]. Furthermore,
increased MAIT cell levels in the inflamed mucosa correlated with
disease activity, suggesting a possible pathogenic role for MAIT
cells.
Metabolic disease
Obesity is emerging as the number one cause of preventable death
in the Western world, underpinning the development of many
chronic diseases, such as type 2 diabetes mellitus (T2DM), cardio-
vascular disease, and many cancers [91]. Obesity has also been
identified as a confounding factor in other chronic diseases includ-
ing psoriasis, arthritis, and cancer [92]. We and others have pre-
viously reported reduced MAIT cell frequencies in the periphery
of adults living with obesity [20]. MAIT cells isolated from the
periphery of these patients displayed a potent IL-17 phenotype,
i.e., significantly higher IL-17 production and reduced IFN-γ pro-
duction following stimulation compared to healthy controls [20,
93]. This predominant IL-17 phenotype may be contributing to
the chronic inflammation seen in obesity and insulin resistance
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[94]. MAIT cells were found at higher frequencies in adipose tis-
sue compared to blood, in both lean and obese individuals. MAIT
cells in healthy adipose tissue produce IL-10, however this pro-
duction is reduced in MAIT cells from the adipose tissue of obese
patients. [20] MAIT cells may therefore play a regulatory role
in healthy individuals and initiate a more inflammatory response
through their pro-IL-17 phenotype in obese individuals. Follow-
ing bariatric surgery (1-year post-surgery) MAIT cell levels were
increased in blood compared to presurgical levels, however the
levels detected were still lower than healthy controls [93]. The
data associated with childhood obesity is slightly different. MAIT
cell frequencies in the blood of obese children appear to be sig-
nificantly higher when compared to their lean counterparts. How-
ever, as obese children progress into adulthood, their MAIT cell
frequency declines [20]. This is not observed in the lean cohort,
suggesting that MAIT cell numbers ultimately decline with the
progression of obesity. This altered frequency is associated with
both increased fasting insulin and insulin resistance, factors driv-
ing the development of type 2 diabetes [20]. Similar to adult
obesity, increased MAIT cell IL-17 production was also seen in the
pediatric obese cohort [20]. Recently, we have demonstrated that
alterations in mitochondria ROS are linked to IL-17 production
in MAIT cells from patients with obesity. Using several mitochon-
drial antioxidants, we were able to limit the production of IL-17 by
MAIT cells from patients with obesity in vitro [95]. Non-alcoholic
fatty liver disease (NAFLD) is characterized by the excess accumu-
lation of fat in hepatocytes, which can drive fibrosis, progressing to
cirrhosis [96]. In cohorts of patients with cirrhotic NAFLD, MAIT
cell frequencies were reduced in both the periphery and the liver,
but displayed elevated MAIT17 cells compared to controls [97].
Using an in vitro system, it was demonstrated that MAIT cells could
drive a pro-inflammatory human hepatic myofibroblast phenotype
in a IL-17/TNF-a dependent manner, suggesting MAIT cells are a
pro-fibrogenic population [97]. The contribution of MAIT cells to
the progression of metabolic disease remains to be elucidated but
due to their abundance in humans, they may represent a novel
therapeutic target.
Cancer
MAIT cells have been detected within many solid tumor types,
including breast, lung, liver, thyroid, colorectal, kidney, brain,
stomach, and esophagus [98–102] and in multiple myeloma [11].
These emerging studies have demonstrated that MAIT cells are
capable of tumor cell lysis in vitro, however, the role of MAIT cells
within cancer, and in particular MAIT17 cells, remains unclear.
Ling and colleagues report elevated IL-17 production by MAIT
cells in colorectal tumors, when compared to a healthy control
group [99]. The authors also found increased IL-17 production by
MAIT cells co-cultured in vitro with colorectal cancer cell lines,
but also observed an MR1 dependent inhibition of the tumor cell
cycle in this setting, suggesting a more complex role for MAIT17
cells in cancer [99]. In contrast, a recent study by Yan and col-
leagues provided evidence for the promotion of tumor metastasis
by MAIT cells, in particular MAIT17 cells [103]. Using two murine
models, the authors showed increased tumor expression of MR1,
which promoted MAIT cell activation and production of IL-17,
which subsequently inhibited NK cell antitumor activity [103].
More work is required in order to define the role of MAIT cells
in cancer, including in infection driven cancers, and to properly
elucidate their immunotherapeutic potential.
Conclusion
MAIT cells represent a significant proportion of the human CD8+
T cell compartment, yet their place in immunity is only begin-
ning to be understood. In recent years, the volume of studies
into MAIT cell biology has exponentially increased, largely due
to greater availability of antibodies and tetramers. Many of these
studies have examined the role of MAIT cells in disease settings,
giving new insights into the role played by MAIT cells in disease.
The most striking observation common to many different disease
states, is the significant alteration in MAIT cell frequency and
cytokine profile. In particular, we have discussed the prevalence
of MAIT17 cells in chronic inflammatory diseases. Currently, we
do not fully understand the environmental signals and molecular
pathways driving this expansion of MAIT17 cells. Several studies
have implicated IL-7 as a licencing factor for MAIT17 cells [65,
79, 82], however, this was not specific to IL-17 as other studies
detailed IL-7 licencing of IFN-γ and Granzyme B [30, 104]. In
addition to IL-7 priming of MAIT17 cells, some studies detailed
additional cytokines such as IL-12 or IL-23 [79]. Further work will
be required to establish the exact cytokine signals driving MAIT
cells and if these are common or disease specific. As discussed, our
group has highlighted the importance of immunometabolism in
controlling MAIT cell cytokine responses, we highlighted altered
mitochondria as a potential driver of IL-17 in MAIT cells from
patients with obesity [38, 95]. Altered mitochondria haven been
linked to IL-17 production in conventional T cells [105–107], how-
ever additional work will again be required to determine if this
is a major mechanism driving IL-17 production in MAIT cells,
and also to elucidate the environmental signals driving mitochon-
drial dysregulation. It is clear that despite the recent surge in
MAIT cell studies, including numerous studies on MAIT17 cells,
improved insight into the pathways controlling MAIT17 cells is
required.
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